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Abstract
MicroRNAs are important regulatory factors in brain development and function. DNA variations dis-
rupting their function may contribute to neurodevelopmental disorders such as autism. Operating at
the posttranscriptional level, microRNAs regulate broad yet controlled sets of target genes typically
via interacting with target sites found in 3’ untranslated regions of mRNA transcripts. Efforts to iden-
tify microRNAs contributing to autism risk have involved examining differences in their expression
patterns, mutations that affect their function, and their interaction with autism-risk genes. However,
there have yet to be any robustly replicated candidate microRNAs supported by these functional evi-
dences. Knowing what genes a microRNA targets is a major challenge in the field, and represents an
important first step in investigating their biological role and contribution to autism.
This thesis examines the transcriptome-wide binding and interaction networks of microRNAs that
potentially contribute to dysregulation of neurological processes and development of autism spec-
trum disorder. Empirical support for autism-relevant microRNAs was generated using systems-level
approaches integrating computational predictions and biotin-tagged microRNA:mRNA capture (pull-
down) experiments quantified by RNAseq analysis. First we established a database of microRNA
target site predictions using a range of existing bioinformatics tools. An analysis of the distribution
of individual microRNA binding sites across untranslated regions for the entire genome yielded some
surprisingly distinct peaks at microRNA-specific offsets relative to the 3’ stop codon of gene tran-
scripts. The mechanistic relevance of these potential interaction peaks is yet to be elucidated, but they
may co-occur or function with other regulatory elements. The next step was to investigate regulatory
mutations within exome sequence data of an Australian autism cohort generated in our laboratory.
We identified putative regulatory site mutations, and showed that collectively, DNA variants in the af-
fected cohort were significantly more associated with known autism risk genes than controls. A rare
single nucleotide variation in the binding ‘seed’ sequence of miR-873-5p found in an autism case was
evaluated by microRNA:mRNA pulldown experiments, and we observed changes in global mRNA
targeting. The binding profile of wild-type miR-873-5p includes several autism risk-genes, and sug-
gests a potential role in potassium channel signalling of neurons. We further characterised the target
networks of other two seed-sharing microRNAs, miR-324-3p and miR-1913-3p, involved in neural
function. Results demonstrated the potential for these two related microRNAs to occupy different
regulatory niches, supporting miR-324-3p’s anti-proliferative function described in the literature, and
suggesting a further role for the previously-uncharacterised primate-specific miR-1913 in regulating
protein-synthesis and degradation pathways.
Together, these results underline the importance of taking a systems-level view when considering mi-
croRNA function, as predicted and experimentally-determined targets provide clues to pathways or
mechanisms not otherwise evident. The work establishes a workflow to take a list of variants from
an autism exome-sequenced cohort, prioritise microRNA gene variants, and apply microRNA:mRNA
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pulldown experiments to measure not only the usual binding profile, but also the difference due to a
patient-derived variant. Our microRNA-centric systems-based approaches combined computational
prediction and experimental validations to identify the underlying mechanisms of microRNA regula-
tion in fundamental neurological processes and disorders such as autism.
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1.1 Introduction
Autism Spectrum Disorder (ASD) is a highly heritable neurodevelopmental disorder characterised by
difficulties in social interactions and repetitive behaviours. It is a condition which can pose signif-
icant challenges for individuals, their families and society [1, 2]. A recent Australian study reports
an occurrence between 1.5-2.5% of individuals (among children) [3]. Although several genetic muta-
tions have been identified in protein-coding genes, autism is a genetically complex disorder and there
is a clear contribution of mutations in non-protein-coding regions such as microRNA genes, whose
functional roles are still unclear.
MicroRNAs are a class of non-coding small regulatory genes important in neural function, and are
thought to play a role in neurological conditions [4]. Implicating specific microRNAs in autism
may ultimately identify useful biomarkers or risk candidates, aid mechanistic understanding of the
underlying autism-associated pathways, and perhaps even drive the development of therapeutics.
Efforts analysing the contributions of microRNA gene disruptions to autism risk have yet to identify
any solid, cross validated candidate genes, but this is an active area of research. The broad yet
subtle multi-targeting nature of microRNA-mediated gene regulation poses some active questions
in the field - What does a given microRNA target? What is its biological purpose? And could its
disruption contribute to an autism phenotype? Determining the targeting specificity of any specific
microRNA is a particular challenge, but it is information that forms the basis of our understanding
of their function. Furthermore, the heterogeneous nature of autism genetics means that microRNAs’
putative contribution cannot be considered in isolation - they need be studied in a wider context of
DNA variations within protein coding genes and autism-risk pathways.
This review will outline current literature examining the role of microRNAs in autism, approaches
being applied to identify specific microRNAs of interest, challenges in the area - particularly regarding
the determination of microRNA targeting, and the importance of systems approaches.
1.1.1 Autism risk genes and pathways
Autism is understood to be a neurodevelopmental disorder with extreme genetic heterogeneity [5].
There have been many protein-coding risk genes identified [6], and as of March 2016 there are 806
putative autism risk genes listed in the SFARI gene database [7]. These include several strong candi-
dates such as SHANK3 [8] and ANK2 [9]. This large number of candidates is largely due to advances
in whole genome approaches, including recent sequencing studies on of clinically and behaviourally
characterised ASD individuals and their families [9–17].
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De novo and rare DNA variants are thought to form a large part of autism risk [10–12, 14]. However,
due to the nature of the disorder, the highest risk genes are the least likely to be transmitted [18],
which makes the identification of recurrent disrupted genes difficult. Many recent studies have fo-
cussed on families to better understand some of these rare or de novo variants [15, 17, 19], including
their relationship to inherited genetic risk factors, that together may contribute to complex sets of
multigenic variants underpinning autism.
This diversity of risk genes has driven a move towards pathway-focussed research [5], particularly as
an autism phenotype may be the result of multigenic variants. Accordingly, there have been numerous
pathways and/or critical brain developmental timepoints that have been proposed as central features
for autism. Indeed synapse development has been prominently identified as a risk hub for autism [20];
notably focussed on SHANK3 [8], neurexins, neuroligins and their varied molecular interactors.
1.1.2 MicroRNA biology
MicroRNA are a class of small regulatory RNAs which act through complementary binding to mes-
senger RNA, canonically resulting in a subtle downregulation of many, specific target genes. Mi-
croRNA genes often occur nested within host genes, in clusters, or encoded independently [21]. The
canonical mechanism of biogenesis and action is depicted in Figure 1.1. MicroRNA genes are ini-
tially transcribed into a pri-miRNA (or processed from the intron of a host gene), which is cleaved by
Drosha into a pre-microRNA hairpin structure [21]. This hairpin structure is then cleaved by the Dicer
complex into a duplex of the mature microRNAs [21]. The duplex associates with the RISC (RNA
induced silencing complex) complex, and one arm is lost leaving only the active mature microRNA
(which can be from either the 3’ or 5’ arms, often both can be active) [21, 22]. This single stranded
mature microRNA complex then binds to the target mRNA [21]. Typically, a target site will consist
of an exact match in the ‘seed’ region, between bases 2-7 of the microRNA, and imperfect matches
across the rest of the mature sequence [23].
By binding with a target site in the 3’ untranslated regions of (3’UTR) of gene transcripts, the mi-
croRNA facilitates degradation of the transcript or suppresses translation of the protein [24, 25]. The
binding of a microRNA-loaded RISC complex to a target mRNA can recruit the GW182 protein,
which then in turn can interact with a deadenylase complex to induce deadenylation of the mRNA
[25, 26]. This deadenylation can then lead to degradation of the transcript [25, 26]. The mechanisms
behind translational inhibition are less well understood, but is thought to involve interference with the
action of eIF4E in translation initiation [25, 26]. There is evidence that these two mechanisms can act
at different timepoints - with translational inhibition effects occurring first, followed by an induction
of deadenylation leading to mRNA degradation in a longer time-frame [25, 26]. However, this trend
is not absolute, and the processes can occur independently [26].
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The efficacy of microRNA-targeting is subject to many factors. Apart from the seed region, (canoni-
cally a perfect match), imperfect binding is expected elsewhere in the mature sequence in mammals.
While attempts have been made to define different classes of active microRNA binding sites [27, 28],
it is clear that microRNA sites cannot be simply classified by their sequence [29]. Multiple copies
of target sites, or sites from different microRNAs, can act together to have a greater influence on
transcription and gene regulation [30, 31]. The location of the sites in the 3’UTR is also relevant,
with sites near the stop codon or polyadenylation site are more common and more effective in gene
regulation [31].
There are also many and varied non-canonical methods of microRNA targeting and effects. Active
target sites may be found in the CDS [29] or 5’UTRs [29, 32], and can sometimes cause up-regulation
[32]. Indeed the effects of a single microRNA can vary, causing up or down-regulation, depending
on cellular context [33]. Additionally microRNAs may have target sites in circular RNAs working
as microRNA sponges [34]. However these non-canonical sites are difficult to interpret at a genome-
wide scale, and are not within the scope of this thesis.
Though it is possible to consider microRNAs’ actions at the individual target site level, it is their broad
but configured specific targeting that is of particular interest. Moreover they can be viewed as pathway
regulators, whose effects can manifest through different higher-order ‘systems’ of network regulation
[33, 35–37]. Most prominently, they can act as fine-tuners of gene expression across a network
of genes, perhaps for broad control over a regulatory pathway or response to cellular environment
[33, 35–37]. They can also form feedback or feed-forward loops with host or co-expressed genes
(such as other microRNAs, or transcription factors) for more coordinated or modulated effects [33].
On the other hand, they can also act on switch-like expression thresholds, where a sudden output is
trigged over a certain expression level, which may facilitated by the presence of microRNA ‘sponge’
sites in circular mRNAs or pseudogenes [36, 38, 39]. Another proposed mechanism of microRNA
function is that of buffers or dampeners to smooth out expression noise across their targets [37, 40].
They are considered important regulatory factors in the brain, where their subtle but broad regulatory
influence may help fine tune or buffer delicate balances within neural development or responses to
environmental conditions. There has been significant work into looking at associations with microR-
NAs in neurodevelopmental disorders [41], and notably miR-137 has been previously associated with
schizophrenia risk [42]. Problems in microRNA processing machinery have also been implicated in
fragile X syndrome, a disorder which often includes an autistic phenotype. The FMR1 gene silenced
in fragile X syndrome is thought to play a role in the RISC-Argonaut complex and may have a broadly
disruptive reduction in microRNA-mediated regulation [43, 44]. Whether any of the shared pheno-
types between fragile X syndrome and autism arise through more specific dysregulation of specific
microRNAs remains an open question.
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Figure 1.1: A summary of the canonical mechanisms and effects of microRNA regulation
1.1.3 The search for autism-associated microRNAs
There have been many studies looking for associations between specific microRNAs and autism and
some unbiased screens are summarised in Table 1.1. These screens fall into two main approaches,
measurements of differential expression of microRNA levels between autistic individuals and con-
trols, and looking for DNA variants in the microRNA genes.
Differential expression assays on brain tissues (Table 1.1) have the possibility of capturing biologi-
cally relevant changes, which might indicate affected pathways - irrespective of whether any changes
are causal or as a result of an autistic phenotype. For example, Ander et al. (2015) [45] used brain tis-
sue samples to identify 5 differentially expressed microRNAs (Table 1.1), and suggest an association
of their predicted targets in PI3K-Akt signalling pathways. Likewise, Mor et al. (2015) [46] observed
increased expression of miR-142 in autism samples, and correlated this change with hypomethylation
in its promoter region . However brain-tissue based studies are limited by sample size, making results
difficult to interpret. Studies which use serum or cellular samples from living individuals can facilitate
more replicates, including the use of paired sibling controls. For instance, Hicks et al. [47] used 24
saliva samples from autistic individuals and 21 matched controls to highlight differentially expressed
microRNAs (Table 1.1), which they were able to compare with behavioural metrics. But blood or
saliva is a different cellular environment than brain tissue, and may not be as relevant to the underly-
ing biology and aetiology of autism. Olfactory stem cells have been recently trialled as a compromise
between neuronal cell relevance but again has sampling constraints [48]. In one such study, Nguyen
et al. (2016) followed up one of the differentially expressed microRNAs identified, miR-146a, and
demonstrated an effect on dendrite growth in culture [48]. If successful in finding microRNAs with
changed expression profiles, these could be developed as potential biomarkers, even though circulat-
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ing microRNAs may not necessarily be causatively associated with autism. Clearly, further validation
of candidates will be necessary, as until results are replicated and studied functionally it is difficult to
interpret the significance of these molecules with autism.
A second major approach to the identification of autism-relevant microRNAs is to look for microRNA
gene disruptions (or nearby tag SNPs) in autistic individuals. Two studies have focussed on copy num-
ber variations (CNVs) affecting microRNA genes [49, 50], underlining the importance of reanalysis
in this field given that microRNAs might not have been considered in some older datasets, particu-
larly when lost in conjunction with nearby protein coding genes. Acquiring functional information
for microRNAs flagged from these studies is a particular challenge, given that they can highlight lists
of candidate genes that require follow-up work, particularly when they are microRNAs that have not
been previously studied [49, 50]. However, despite higher sample sizes, these assays are also beset
with a lack of statistical power. Although genome-wide association studies (GWAS) in schizophrenia
have managed to identify a SNP near miR-137 [42], there have not been strong, replicated results for
variants near microRNAs in autism. A GWAS study from Toma et al. [51] flagged autism-associated
SNPs near microRNAs in a discovery set of over 600 cases and controls, but their results did not
reproduce in their larger replication sample set, although they did highlight candidates in their pooled
analysis (Table 1.1) [51]. This may be due to the prevalence of rare or de novo variants, which by
definition will not occur often enough for statistical association; a challenge given the high frequency
of idiopathic autism cases. Weaker associations with lower penetrance might also play a role, but
require much larger samples sizes. Perhaps the most exciting advantage of variant-based approaches
is the ability to test them with modern genome editing techniques (e.g. CRISPR-Cas9 system) or in
vitro microRNA targeting assays.
There have also been a number of studies aimed at searching for functional significance of particular
candidate microRNAs. These generally search for a mechanistic link between the microRNA and
autism, extending beyond a simple microRNA to one target gene model. For instance, following
up work from Olde Loohuis et al. (2015) [52] a study by Kos et al. (2016) [53] characterised the
influence of miR-181 on synaptic development. Another uses the a priori knowledge of miR-137’s
association with schizophrenia [42] to investigate which known autism risk factors it may also target
[54]. Other studies have started with known risk factors and characterised microRNAs that might act
on them - such as SHANK3 targeting by miR-504, miR-34a and miR-7 [55] or miR-980 as a regulator
of potential autism-associated gene RBFOX2 (A2bp1) [56].
Though there are many proposed microRNA associations there have not yet emerged any clear ro-
bustly associated candidates. However, this may change as work begins to follow up the numerous
candidates identified in screening studies. For example there is now evidence for the association
of miR-181 from an expression assay [57] and animal model work [52, 53]. A confidently autism-
associated microRNA will require several lines of independent supporting evidence; that might be
statistical association from multiple studies, or mutational screening evidence combined with be-
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havioural models, ideally supported by mechanistic evidence involving molecular targeting. How-
ever, care should be taken not to prematurely focus on single known risk factors targeted in vitro, as
there may be a danger of missing a microRNA’s broader role and functional context.
Table 1.1: Summary of screening studies aiming to identify microRNA genes implicated in autism. Drawn
from a search of PubMed (June 2016) with following terms: (miRNA OR microRNA) AND (autism OR ASD OR
autis*). Listed microRNAs are those most prominently reported by the authors; some highlight other microRNAs
not listed, and not all reported microRNAs are statistically significant.
Type Study Method MicroRNAs
Differential
Expression
Abu-Elneel et al.
(2008) [58]
Brain tissue miRNA expression miR-484, miR-21, miR-212, miR-23a,
miR-598, miR-95, miR-129, miR-431,
miR-7, miR-15a, miR-27a, miR-15b,
miR-148b, miR-132, miR-128, miR-93,
miR-106a, miR-539, miR-652 miR-550
miR-432 miR-193b miR-181d miR-146b
miR-140 miR-381 miR-320a miR-106b
Talebizadeh et al.
(2008) [59]
Lymphoblastoid miRNA
expression
miR-23a, miR-23b, miR-132, miR-146a,
miR-146b, miR-663,miR-92, miR-320,
miR-363
Ghahramani Seno et
al. (2011) [60]
Lymphoblastoid miRNA
expression
miR-199b-5p, miR-548o, miR-577,
miR-486-3p, miR-455-3p, miR-338-3p,
miR-199a-5p, miR-650, miR-486-5p,
miR-125b, miR-10a, miR-196a
Sarachana et al.
(2010) [61]
Lymphoblastoid miRNA
expression
miR-23a, miR-106b
Mundalil Vasu et al.
(2014) [57]
Serum miRNA expression miR-151a-3p, miR-181b-5p, miR-320a,
miR-328, miR-433, miR-489, miR-572,
miR-663a, miR-101-3p, miR-106b-5p,
miR-130a-3p, miR-195-5p, miR-19b-3p
Stepniak et al.(2015)
[62]
Perhipheral blood cell miRNA
Expression
miR-181
Stamova et al.
(2015) [63]
Brain tissue miRNA expression miR-132, miR-103, miR-320 and others
Mor et al. (2015)
[46]
Brain tissue miRNA expression miR-142-5p, miR-142-3p, miR-451a,
miR-144-3p, miR-21-5p
Ander et al. (2015)
[45]
Brain tissue miRNA expression miR-4753-5p, miR-1, miR-664-3p,
miR-4709-3p, miR-4742-3p, miR-297
Huang et al. (2015b)
[64]
Perhipheral blood cell miRNA
Expression
let-7a-5p, let- 7d-5p, miR-34b-3p,
miR-103a-3p, miR-1228-3p, and others
Olde Loohuis et al.
(2015) [52]
Rat ASD model brain miRNA
expression
miR-181c, miR-30d
Hicks et al. (2016)
[47]
Salivary miRNA expression miR-628-5p, miR-127-3p, miR-27a-3p,
miR-335-3p, miR-2467-5p, miR-30e-5p,
miR-28-5p, miR-191-5p, miR-23-3p,
miR-3529-5p, miR-218-5p, miR-7-5p,
miR-32-5p, miR-140-3p
Nguyen et al. (2016)
[48]
Olfactory stem cell miRNA
expression
miR-146a, miR-221, miR-654-5p,
miR-656
Variant-
based
Vaishnavi et al.
(2013) [50]
Copy-number variants miR-590-3p, miR-944, miR-570,
miR-34a, miR-124, miR-548f, miR-429,
miR-200b, miR-195, miR-497
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Marrale et al. (2014)
[49]
Copy-number variants miR-4436b-1, miR-4436b-2, and others
Toma et al. (2015)
[51]
Association of SNPs near
miRNAs
miR-133b/miR-206 cluster,
miR-17/miR-18a/miR-19a/miR-20a/miR-
19b-1/miR92a-1
cluster
An et al. (2016) [65] Exome sequencing miR-873-5p, miR-139-3p
1.1.4 Challenges in identifying microRNA targets
A fundamental question when working with a microRNA is to know its targets. There are many tools
available for predicting microRNA target sites, which produce many different predictions - with no
single tool consistently performing better than others [66–69]. This is perhaps not surprising given
the flexible nature of the structural and thermodynamic properties that govern microRNA targeting.
Different microRNA target site prediction tools take into account different factors to improve their
prediction, much more than simple seed and mature-sequence complementarity measures (Reviewed
in [69]); such as free energy calculations [70, 71] and evolutionary conservation [72], among others. It
is common to consider sites predicted by multiple tools for a more stringent set [66, 67, 73], however
the usefulness of this approach is dependant on the choice of tools and the methods they use [67].
Addressing this problem, two recent studies have questioned which features are most predictive of
binding (through comparisons with modern CLASH microRNA-targeting datasets), which may lead
to a new wave of prediction tools [74, 75].
Even so, an individual prediction of a single microRNA target site cannot be considered completely
accurate (and may depend on cellular conditions), and calls for validation, often in the form of the
‘gold-standard’ of a luciferase reporter assay to measure its activity in vitro. However, trends within
an entire set of predictions for any given microRNA may hold a little more credence. This prin-
ciple is applied throughout this thesis - by looking at biological trends of microRNA targets at the
transcriptome-wide level we hope that observations will be robust even if not all sites are active.
Genome-wide binding assays are a useful intermediate between the limited reliability of computa-
tional predictions and the low throughput and expense of microRNA-target luciferase assays. There
are several different methods in use. In HITS-CLIP UV light is used to cross-link RNA and proteins,
and microRNA processing protein Argonaut (a member of the RISC complex) is then specifically
captured with immunoprecipitation along with the microRNA and mRNA - enabling a transcriptome
assay of microRNA binding [76]. PAR-CLIP is a similar technology, which additionally uses photo-
sensitive nucleotides to locate and improve efficiency of the UV cross-linking step [77]. These two
methods are well established, and have been employed to assay microRNA binding in many contexts;
a PubMed search for HITS-CLIP or PAR-CLIP yields 95 or 114 articles respectively (as of 4th Jan-
uary 2017). A further development is the CLASH method, which additionally includes a RNA-RNA
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linking step to capture the specific microRNA-mRNA interactions directly, which has been used to
highlight non-canonical binding patterns [29, 78]. These approaches are generally applied to look at
the entire microRNA-mRNA interactome. TAP-tar is a similar method which incorporates the capture
of mRNA with a transfected biotin tagged microRNA of interest, after Argonaut immunoprecipitation
[79]. This study focussed on specific microRNAs, electing to use a simple biotin-tagged microRNA
mRNA-pulldown assay method, without Argonaut immunoprecipitation [80–83]. This method has
the advantage of being able to be used for specific microRNAs (including custom SNP-containing
microRNAs) in an Argonaut-agnostic manner. Individual microRNAs assayed in this way have in-
cluded Drosophila microRNA gene bantam [80], human miR-182-5p [84], honeybee (A. mellifera)
miR-832 [83]. However, biotin-based approaches are limited in that they do not identify individual
microRNA target site locations (such as is possible in non-specific CLASH [78]), unless there is fur-
ther post-processing steps such as the RNase digestion performed by Tan et al. during their assay of
human miR-522 [81].
1.1.5 MicroRNAs do not work in a vacuum: Systems approaches
Once a set of target genes has been identified for a given microRNA, we can apply a systems biology
approach to help make sense of how the microRNA might be involved in regulating any one or a
number of cellular biological/molecular processes. ‘Systems biology’ is of course an extremely broad
term, but in this context might be considered simply making use of all the ’omics level data and
specific biological knowledge relevant to the problem in question. Some options are outlined in Figure
1.2. In terms of general examination of microRNA function in autism genetics, this might include its
spatio-temporal expression patters (or that of a host gene), regulatory signal from resources such as the
ENCODE project [85], and of course the microRNA’s predicted or assayed binding sites. Some recent
studies have used mRNA coexpression networks amongst protein-coding genes in conjunction with
known autism risk genes to identify regulatory networks and expression contexts relevant to autism
aetiology [86, 87]. Similarly, another study has examined microRNA expression patters across brain
tissues, and found association of autism among the targets genes of differentially expressed between
different spatio-temporal time points during neurodevelopment [88]. These approaches underline
the importance of taking a systems-level view, and may provide hints to the mechanisms by which
microRNAs identified by other methods might disrupt neurodevelopmental processes.
Additionally, microRNAs do not operate in isolation - a microRNA variant in an individual would
co-exist with other potential risk variants. MicroRNAs by their canonical broad yet subtle regulatory
nature might be expected to have less severe consequences than protein-disrupting coding mutations,
though of course exceptions may exist. Therefore it makes sense to consider any microRNA variants
in conjunction with other coding and non-coding variants.
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Figure 1.2: Applications of systems biology investigating microRNAs in autism. Data and analyses that are
useful in determining firstly the ‘usual’ function of a microRNA, then how this might be disrupted by its absence
or variation. These approaches can aid the selection of appropriate functional assays.
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1.1.6 Overview of this thesis
In recent years there has been significant progress in our understanding of microRNAs potential in-
volvement in autism. This has been largely due to gene expression studies, which have increasingly
used systems biology approaches to examine the biological relevance of microRNAs in controlling
transcription and translation. There have yet to be any strongly associated, cross-validated microR-
NAs, but recent technological development have allowed better characterisation of their targeting, and
now focussed studies into candidate microRNAs are emerging. However, there has been little direct
focus on the transcriptome-side binding profiles of potentially autism-associated microRNAs, which
is a necessary bridge when trying to link in vitro or in vivo function of candidate microRNAs. This
thesis uses several approaches to explore the roles of microRNAs in autism.
Throughout this work, microRNA target-site predictions are used as an initial step in characterising
the potential relevance of a microRNA, and these are presented in chapter 2: MicroRNA target site
prediction and 3’UTR distributions. Chapter 2 also further explores spatial distributions of predicted
microRNA target sites at the individual microRNA level, investigating whether this information could
be used to better characterise ‘biologically active’ sites in gene transcripts.
Chapter 3: An integrative approach for characterising functional regulatory DNA variations associ-
ated with ASD presents a workflow for the identification of regulatory mutations in an autism exome
sequencing dataset - highlighting DNA variants occurring within microRNA genes themselves as well
as predicted microRNA targets sites, in conjunction with other regulatory mutations. Chapter 3 also
focusses on a putative loss-of-function variant found within the seed site of miR-873-5p examining
the transcriptome-wide binding profile of this microRNA via mRNA-capture RNAseq (pulldown as-
say), and quantifying the effect of the variant on miR-873-5p binding, forming a functional hypothesis
to that lays the groundwork for future functional experiments.
Chapter 4: Effect of an ASD patient-derived miR-873-5p seed region mutation on mRNA binding
presents additional analysis of the binding profiles of miR-873-5p, exploring a potential role in potas-
sium channel regulation, and providing a general evaluation of the utility of the pulldown assay in
evaluating microRNA targeting.
Chapter 5: Differences in non-seed pairing between miR-324-3p and miR-1913-3p account for bind-
ing and functional differences follows an alternative path, taking a pathway-first approach, character-
ising the binding profiles of two similar microRNAs hypothesised to regulate members of a pathway
potentially associated with autism. The analysis further explores differences in binding and function
of these two microRNAs from an evolutionary perspective.
Ascribing function to individual microRNAs in vivo, particularly in relation to a complex neurode-
velopmental disorder like autism, is a challenging problem which requires extensive time-consuming
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experimental validation. The techniques and results discussed in this thesis aim to assist efficient
generation of testable functional hypothesis. This is achieved through examining targeting of individ-
ual microRNAs at the transcriptome-wide level in the context of binding experiments, identification
and evaluation of variants and trends in spatial distributions. Ultimately, this work will help further
understanding of the role of microRNAs in autism risk pathways.
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CHAPTER 2
MicroRNA Target Site Prediction and 3’UTR
Distributions
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Computational microRNA target site predictions are an essential first step in many microRNA analy-
ses. This chapter outlines the development of the database of microRNA 3’UTR target site predictions
used throughout this thesis. Predictions from the miRanda and RNAhybrid tools were intersected to
create a most robust prediction set. This chapter also presents a pilot exploration of unusual spa-
tial distributions of individual microRNAs’ 3’UTR target sites, which differ from global microRNA
distributions.
2.1 Introduction
MicroRNAs are a class of 21-22nt regulatory genes known for their broad yet specific targeting ca-
pabilities [21]. The most well understood role of microRNAs is that of the RNAi pathway, where
microRNAs downregulate specific target genes via imperfect sequence complementarity to binding
sites on the target gene 3’UTRs (3’ untranslated regions) [21]. Following transcription of microRNA
genes, primary microRNA transcripts (pri-miRNAs) are initially cleaved by Drosha into a hairpin pre-
cursor (pre-miRNA) before being processed into a double-stranded mature microRNA duplex with
Dicer [21]. Processed microRNA duplexes then integrate into the RISC complex and, following loss
of the anti-sense duplex strand, the complexed single-stranded mature microRNA binds to target sites
on target gene 3’UTRs [21]. Commonly in animal microRNA binding, there may be a ‘seed’ region
of 6-8 base pairs of perfect binding corresponding with the 5’ end of the microRNA (generally bases
2-7), with partial complementarity to the rest of the mature microRNA sequence [23]. MicroRNA
binding typically results in downregulation of the target mRNA protein - through a combination of
translational inhibition, and promotion of mRNA degradation through induction of deadenylation
[24–26].
Though sites on 3’UTRs are the focus of this work, it is worth noting that microRNAs can act also in
other pathways. MicroRNA target sites are not limited to the 3’UTR, as biologically active sites have
been described in the 5’UTR and coding regions of some genes [29, 32]. In some cases, target sites
in these regions have an activating [32], rather than a repressive function.
The sequence specificity of microRNA binding makes it possible to predict sites computationally,
however microRNA target site prediction is a notoriously noisy art form. There is relatively low
agreement of sites predicted with different tools [66]. However significant progress in sequencing
technologies and microRNA pulldown experiments [76–82] in recent years makes experimental de-
termination of targeting more practical.
The spatial location of microRNA target sites is a factor in how effective they are. MicroRNA binding
sites are most often found near [31] the stop codon or polyA tail of the 3’UTR, rather than the centre
[31, 89, 90], especially in longer 3’UTRs [31, 89], and are more effective in those locations [31].
However, the very start of the 3’UTR (the first 15bp after the stop codon) is an exception, and sites in
this region are fewer and less effective [31]. Groups of microRNA target sites on the 3’UTR, either
from the same or different microRNAs can also be more effective than in isolation [30, 31].
Most previous work on microRNA target site distributions has looked at patterns of microRNA bind-
ing as a whole. Gaidatzis et al. (2007) showed that the predicted independent site distributions for
several specific microRNAs were all consistent with global trends towards the ends of 3’UTRs [89].
However, there have been many more microRNAs described since that time, especially in human.
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This chapter describes the construction of a microRNA targeting database that has been used through-
out this thesis. Additionally it explores spatial distributions of individual microRNAs that differ from
the global trend.
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2.2 Methods
2.2.1 MicroRNA target site predictions
We established a database of microRNA target site predictions to be used throughout this analysis
(Figure 2.1). We used an intersection of two microRNA prediction algorithms, a common practice to
improve microRNA prediction reliability [67, 73, 91], specifically miRanda [92] which considers seed
complementarity and free energy calculations, and RNAhybrid [71] - which focuses on free energy
calculations. Despite the similar methods employed by these two tools (which can limit the utility of
an intersection approach [67]), the overlap set does limit target site predictions to workable numbers.
Additionally, neither tool has an absolute requirement for seed complementarity, which is useful for
the microRNA seed variants considered in chapters 3 and 4.
MicroRNA target sites were predicted for all miRBase v19 [93, 94] microRNAs on all 3’UTR (un-
translated regions) and 5’UTR UCSC transcript sequences (human assembly hg19, downloaded:
21/02/13). Flanking genomic sequence of 50bp was included on each UTR to capture sites that may
span the end of the coding sequence. Mature microRNA sequences, and microRNA gene locations
are from miRBase v19 [94]. In the core microRNA-target gene network a microRNA was deemed to
target a gene if there was at least one predicted site on any annotated 3’UTR.
Miranda v3.3a was run with default parameters, and filtered to a free energy less than -18. RNAhybrid
v2.1.1 was run to find target sites with parameters optimised for human 3’UTRs (options: -b 2000, -e
-18, -s 3utr human), and filtered to a free energy of -25. The set of microRNA target site predictions
used in the analysis contains only miRanda predictions that had a reciprocal 75% overlap (in terms of
individual site coordinates) with RNAhybrid site predictions.
Target sites of selected microRNAs were also predicted on the 3’UTRs of mouse (Mus musculus)
from assembly GRCm38, and chimpanzee (Pan troglodytes) using assembly CHIMP2.1.4, in the
same manner.
We also considered precomputed predictions from the TargetScan tool as a contrast to the core pre-
diction set in the microRNA target distribution analysis, due to its consideration of evolutionary con-
servation information [72]. Note that evolutionary conservation information was deliberately avoided
in the core set due to our interest in recently evolved microRNAs potentially involved in brain pro-
cesses. The TargetScan prediction set was the precomputed TargetScan6.2 human predictions [72].
These precomputed predictions from TargetScan were generated on NM RefSeq sequences, and these
results were filtered to those found in RefSeq release 71, whose annotated regions were used to gen-
erate the 3’UTR sequence lengths used in these calculations.
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Feature file and sequence processing used BEDTools (v2.17.0) [95].
Figure 2.1: Target site prediction workflow and applications.
2.2.2 MicroRNA target site spatial distributions
The spatial distributions of microRNA target sites across the 3’ and 5’ untranslated (UTR) regions
were examined via a custom library of R functions. These functions accept predicted target sites in
a gff version 3 input format, and allow for filtering by microRNA, quality scores and sequences and
enable plotting of microRNA target distributions and detection of peaks within them.
MicroRNA target distributions were examined by plotting the density of sites across 500bp regions
anchored at the 3’ or 5’ sides (Figure 2.2). Note that due to the inclusion of 50bp of genomic flanking
regions, these plots extend for 50bp beyond the anchor point to capture trends at the very ends of
the UTRs. Only those microRNAs with at least 200 sites predicted in the region were considered, as
smaller numbers make it difficult to identify trends.
To define peaks within the distributions, a stringent peak threshold was defined for each as the average
density + 3 standard deviations (as shown in Figure 2.2). Any stretches of site density over this
threshold longer than 10bp were defined as peaks.
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To ensure that target site distributions are not skewed to UCSC genes having many transcripts, and to
avoid biases due to truncated UTRs or very long UTRs, only the median length UTR sequence was
included for each gene.
Figure 2.2: Definition of peaks within microRNA target distributions.
2.2.3 MicroRNA binding motifs
The set of predicted target sites (with 10bp of flanking sequence either side) were used to generate
microRNA binding motifs. These motifs were generated using MEME (options: -dna -mod zoops
-nmotifs 1 -maxw 15 -maxsize 10000000, version 4.9.0) [96].
In certain cases where the motif was longer than the expected seed region (which forms the general
part of most of these prediction-based motifs), they were compared to public motif databases via the
TOMTOM web interface (default parameters, version 4.11.2) [97].
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2.3 Results
2.3.1 MicroRNA target site predictions
We first established a microRNA targeting database for use throughout this thesis. It has 2624853
microRNA binding sites predicted on 54832 UCSC 3’UTR transcripts of 19151 genes for the 2042
human microRNA genes in miRBase version 19. On the 5’UTRs there are 1490732 predicted target
sites.
The overall distribution of target sites on the 3’UTR in Figure 2.3a is as described in the literature
[31], with a peak shortly after the stop codon. However, the distribution is much flatter near the
3’ end of the 3’UTR (Figure 2.3b). This may be due to the inclusive and non-conserved nature of
the prediction set - as when looking at distributions for the precomputed TargetScan predictions the
conserved set show the expected biases, whereas the non-conserved set (also precomputed on the
TargetScan website) is again much flatter (Figure 2.4).
(a) (b)
Figure 2.3: Distribution of all predicted microRNA target sites relative to the end of the transcripts. Plots
show predicted target sites (overlap of RNAhybrid and miRanda) for all microRNAs, aligned relative to (a) the
stop codons, or (b) the 3’ end of mRNA transcripts. Normalised to number of sites per transcript that length
or longer. Grey lines reflect exact number of sites per sequence, black is a smoothing spline over the trends
calculated in R.
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(a) (b)
(c) (d)
Figure 2.4: Distribution of all predicted microRNA target sites from TargetScan. Relative to the end of the
transcripts. TargetScan6.2 predicted conserved target sites for all microRNAs, aligned relative to (a) the stop
codon or (b) the 3’ end of transcript. In the conserved and non-conserved set TargetScan6.2 predicted target
sites for all microRNAs, aligned relative to (c) the stop codon or (d) the 3’ end of transcript. Normalised to
number of sites per transcript that length or longer. Grey lines reflect exact number of sites per sequence, black
is a smoothing spline over the trends calculated in R.
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2.3.2 Offset peaks in microRNA target distributions
We examined the distribution of predicted microRNA target sites relative to the ends of the 3’UTRs,
and found that certain microRNAs have unusual target site distributions (Figure 2.5). Though most
follow the overall trends of all microRNA target site distributions, consistent with the literature [31,
89, 90], or are more evenly (randomly) distributed across the UTR, several show strikingly clear
spikes in density at specific offsets.
Though the effect occurs in both the 5’ and 3’ anchored alignments of both the 5’ and 3’ UTRs,
these ‘offset peaks’ are most obvious relative to the 3’ end of the 3’UTR. The offset appears at
different positions for different microRNAs, with some microRNAs having multiple offset peaks.
Some examples of the varying offset peaks observed are shown in Figure 2.5. Target sites for hsa-
miR-216a-5p have a distinct 22bp peak 58bp before the 3’ transcription end (Figure 2.5a), while sites
for hsa-miR-4772-3p have a 22bp peak at a 69bp offset from the 3’ end (Figure 2.5b). Members of the
same gene families were also found to have similar distributions, for example members of the miR-17
family, hsa-miR-17-5p and hsa-miR-93-5p both have the same pattern of two offset peaks (although
only the higher passes the stringent peak-detection thresholds) (Figures 2.5c and 2.5d).
To quantify this observation, offset microRNA peaks were determined for sites in all human microR-
NAs across all 3’UTRs and 5’UTRs. Peaks were detected in about 6%-12% of microRNAs relative to
the 3’ or 5’ ends in both UTR regions (Table 2.1). Full lists are provided in supplementary tables 2.3
and 2.4. Many of these peaks however were defined immediately at the feature to which the sequences
were anchored (i.e. near the stop codon or end of transcription in the 3’UTRs, or the transcriptional
start site (TSS) or translational start in the 5’UTR). As there would likely be other sequence factors
at play at these regions, peaks overlapping the 5’ or 3’ anchor points were excluded to focus on those
at clear offsets independent of these features. The proportion of these filtered offset peaks is almost
twice as high in the 3’UTR transcriptional stop anchored alignments than in any of the other tests
(11%, compared to 5-6%) (Table 2.1). Subsequent analyses were therefore focussed on the 3’UTR
peaks relative to the 3’ end of transcription.
Table 2.1: Counts of peaks detected in 3’UTRs aligned relative to the stop codon or transcription end (polyA)
and 5’UTRs aligned relative to the transcription start site (TSS) or start codon. Offsets are calculated relative
to the ‘anchored feature’ (e.g. stop codon)
Offset Anchor microRNAs with Peaks Not overlapping anchored feature miRNAs Tested
3’UTR Offset from stop codon 117 (8%) 78 excluding stop codon (5%) 1523
3’UTR Offset from polyA 174 (12%) 159 excluding transcript end (11%) 1497
5’UTR Offset from TSS 89 (6%) 84 excluding transcription start (6%) 1375
5’UTR Offset from start codon 167 (12%) 82 excluding start codon (6%) 1370
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(a) hsa-miR-216a-5p (b) hsa-miR-4772-3p
(c) hsa-miR-93-5p (d) hsa-miR-645
Figure 2.5: Distribution of predicted microRNA target sites for selected microRNAs, relative to the end of the
transcripts. Normalised to number of sites per transcript that length or longer. Peak region as per definition
described in methods underlined in red. Grey lines reflect exact number of sites per sequence, black is a
smoothing spline over the trends calculated in R.
2.3.3 Conservation of peaks in chimpanzee and mouse
We tested for the conservation of these peaks in chimpanzee and mouse as evidence for biological
significance.
Some of these peaks in human 3’UTRs are conserved in chimpanzee. MicroRNA target site distribu-
tion plots relative to the 3’ transcription stop were created for chimpanzee and mouse, focussing only
on those microRNAs with offset peaks in humans, and whose mature sequences are an exact match
to human homologs. These microRNAs and their peaks are listed in table 2.2.
Because only perfect microRNA homologs were considered, of the 174 microRNAs with 3’ offset
peaks (listed in supplementary table 2.4), only 8 were conserved amongst all three species. The only
two examples of these that had sufficient sites to plot (200) are shown in Figure 2.6. The peak at -263
to -242 for hsa-miR-20b-5p in conserved in chimpanzee, but absent in mouse. Hsa-miR-28-5p’s peak
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on the other hand is not seen in chimpanzee. However, for both of these conserved microRNAs in
chimpanzee and mouse, there are overall trends, which while not pronounced enough to be flagged as
peaks, do still hint at an increased site density around the peak offset.
Out of the 7 microRNAs with offset peaks conserved between human and chimpanzee, the location of
peaks was conserved in 5 of them (hsa-miR-1778-3p, hsa-miR-1303, hsa-miR-302c-3p, hsa-miR-372,
hsa-miR-645). Several examples are shown in Figure 2.7.
Locations of offset peaks were not conserved in the more evolutionary distant mouse (Table 2.2).
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Table 2.2: Peaks in microRNAs distributions in human, chimpanzee and mouse. Peak positions are relative to
the 3’UTR 3’ end. Includes only microRNAs having peaks in human, with perfect chimpanzee or mouse mature
microRNA homologs. MicroRNAs with less than 200 sites are difficult to trends for, and are marked ‘insufficient
sites’, and only those considered for either species are listed here.
microRNA Human Peak Chimpanzee
Perfect Homolog
Chimpanzee
Peak
Mouse Perfect
Homolog
Mouse Peak
hsa-miR-106b-5p -262 to -243 ptr-miR-106b Insufficiant sites mmu-miR-106b-5p No peaks
hsa-miR-181a-5p -284 to -274 ptr-miR-181a-5p Insufficiant sites mmu-miR-181a-5p No peaks
hsa-miR-20b-5p -263 to -242 ptr-miR-20b -263 to -241 mmu-miR-20b-5p No peaks
hsa-miR-216b -159 to -139 ptr-miR-216b Insufficiant sites mmu-miR-216b-5p No peaks
hsa-miR-28-5p -112 to -101 ptr-miR-28 No peaks mmu-miR-28a-5p No peaks
hsa-miR-381-3p -463 to -454 ptr-miR-381 Insufficiant sites mmu-miR-381-3p -151 to -136
hsa-miR-448 -487 to -474 ptr-miR-448 Insufficiant sites mmu-miR-448-3p No peaks
hsa-miR-9-5p -181 to -160 ptr-miR-9 Insufficiant sites mmu-miR-9-5p No peaks
hsa-miR-1178-3p -74 to -52 ptr-miR-1178 -73 to -52 none
hsa-miR-1303 -17 to 2 ptr-miR-1303 -17 to 3 none
hsa-miR-302c-3p -104 to -83 ptr-miR-302c -102 to -81 none
hsa-miR-372 -268 to -244 ptr-miR-372 -268 to -243 none
hsa-miR-6129 -336 to -327 ptr-miR-6129 No peaks none
hsa-miR-645 -41 to -24 ptr-miR-645 -39 to -23 none
hsa-miR-936 -181 to -162 ptr-miR-936 No peaks none
hsa-miR-143-3p -130 to -121 none mmu-miR-143-3p No peaks
hsa-miR-17-5p -263 to -242 none mmu-miR-17-5p No peaks
hsa-miR-183-5p -292 to -269 none mmu-miR-183-5p No peaks
hsa-miR-193b-5p -192 to -175 none mmu-miR-193b-5p No peaks
hsa-miR-20a-5p -264 to -243 none mmu-miR-20a-5p No peaks
hsa-miR-212-5p -252 to -231 none mmu-miR-212-5p No peaks
hsa-miR-216a-5p -68 to -47 none mmu-miR-216a-5p No peaks
hsa-miR-25-3p -460 to -449 none mmu-miR-25-3p No peaks
hsa-miR-30d-3p -461 to -440 none mmu-miR-30d-3p No peaks
hsa-miR-331-5p -433 to -415 none mmu-miR-331-5p No peaks
hsa-miR-361-5p -147 to -134 none mmu-miR-361-5p No peaks
hsa-miR-378a-5p -227 to -209 none mmu-miR-378a-5p No peaks
hsa-miR-574-3p -69 to -54 none mmu-miR-574-3p No peaks
hsa-miR-93-5p -263 to -243 none mmu-miR-93-5p No peaks
hsa-miR-96-5p -494 to -482 none mmu-miR-96-5p No peaks
46
(a) miR-20b-5p: human (b) miR-28-5p: human
(c) miR-20b-5p: chimpanzee (d) miR-28-5p: chimpanzee
(e) miR-20b-5p: mouse (f) mmiR-28-5p: mouse
Figure 2.6: MicroRNA distributions of conserved microRNAs between human, mouse and chimpanzee. Distri-
bution of predicted microRNA target sites for microRNAs, relative to the end of the transcripts. Normalised
to number of sites per transcript that length or longer. Peak regions as per definition described in methods
underlined in red.
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(a) miR-93-5p: human (b) hsa-miR-645: human
(c) miR-93-5p: chimpanzee (d) miR-645: chimpanzee
(e) miR-302c-3p: human (f) miR-372: human
(g) miR-302c-3p: chimpanzee (h) miR-372: chimpanzee
Figure 2.7: MicroRNA distributions of conserved microRNAs between human and chimpanzee. Distribution of
predicted microRNA target sites for microRNAs, relative to the end of the transcripts. Normalised to number of
sites per transcript that length or longer. Peak region as per definition described in methods underlined in red.
Grey lines reflect exact number of sites per sequence, black is a smoothing spline over the trends calculated in
R. 48
2.3.4 Co-occurrence with motifs
One possible reason for particular spacing of microRNA target sites relative to the transcription end
might be that their binding sites could be similar to RNA or DNA binding factors that may themselves
have spatial trends. Such a situation might arise through evolutionary convergence, or by chance.
We had generated motifs for each microRNA from its predicted target sites. In most instances this
simply returned the seed region, but in the sites of several of the microRNAs with offset peak distri-
butions there was an extended motif, with similarity to known protein binding motifs.
For instance, the seed region of hsa-miR-4772-3p shares some sequence similarity with the SOX
family of DNA binding proteins, seen in Figure 2.8a, specifically the ‘SOX8 DBD 4’ motif described
by Jolma et al. (2013) [98].
A motif generated from all hsa-miR-93-5p predicted target sites includes its seed, but also incorpo-
rates a PITX1 binding motif (PITX1 full 2 from [98]) immediately adjacent (Figure 2.8b). This is
despite a complete absence of sequence similarity between hsa-miR-93-5p’s sequence and the PITX1
binding motif at the 3’ end.
(a) hsa-miR-4227-3p and SOX8 (b) hsa-miR-93-5p and PITX1
Figure 2.8: MicroRNA binding site motifs with similarity to nucleotide binding motifs. MicroRNA binding
motifs generated from predicted target sites with MEME [96].Seed regions simply defined as bases 2-7 in the
mature microRNA. Nucleotide binding motifs found with TOMTOM [97] and both are from the Jolma 2013
database of DNA binding elements [98].
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2.4 Discussion
Understanding a microRNA’s potential target genes is an important factor in understanding its biolog-
ical function. Computational predictions are an inexpensive genome-wide starting point. This chapter
describes the construction and subsequent analysis of the microRNA target site prediction set used
throughout this thesis.
MicroRNA target site predictions are notoriously noisy, but considering a microRNA’s predictions
as a whole may uncover trends despite single target site inaccuracies. There have been many tools
developed to predict target sites, none of which performs clearly better than the others, and their
predictions often do not agree [66, 69]. A standard practice is to overlap predictions of several tools
[66], and we have chosen to use miRanda [92] and RNAhybrid [71].
The distribution of microRNA target sites on the 3’UTR as a whole was generally consistent with
what is described in the literature; increased frequency at the extremities, excluding the small region
immediately after the stop codon [31, 89, 90]. However, when the distribution of individual microR-
NAs is considered, very distinct peaks emerged for some microRNAs, offset from the 3’ transcript
ends, the distance of the offset varying between microRNAs. Although peaks were flagged on the
5’UTR and relative to the stop codon in the 3’UTR, the most striking (and most common) peaks were
found relative to the 3’ transcript ends.
Gaidatzis et al. (2007) [89] had previously explored the spatial distributions of predicted target sites
for individual microRNAs, and reported no difference to the overall microRNA site distribution. How-
ever that test used relative positions scaled along whole long (>4000bp) 3’UTRs, rather than the ab-
solute offset in the last 500bp tested here, which would have disguised these fixed nucleotide offset
peaks. Additionally none of the microRNAs reported on (let-7, miR-124, miR-16, miR-1, miR-32
and miR-9) had any offset peaks in our prediction set for their more highly expressed arms (which
were assumed to be the arms tested).
A considerable portion (6/15) of the chimpanzee-homologous microRNAs with offset site distribu-
tions maintained the location of their offset in chimpanzee 3’UTRs (Table 2.2). Mouse homologs
did not, although some hints of potential biases to the region were still seen visually (Figure 2.6).
However, although some peaks are present in both chimpanzee and human - this analysis does not
distinguish between specific conservation of the microRNA peaks themselves, or conservation due
to homology between human and chimpanzee 3’UTRs. A more complete evaluation following this
pilot analysis across all microRNAs for each species may potentially uncover the full extent of such
conservation.
The existence and conservation of these sites poses the question of their biological relevance and
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mechanisms of action. MicroRNA-mRNA target binding occurs within a rich cellular environment,
where there may be competition or cooperation with other microRNAs, RNAs or proteins. With
public databases of RNA binding proteins [99], it may be possible to look for correlation between
these unusual distributions and other RNA binding elements.
Sequence motifs were generated for every set of microRNA target site predictions to examine pat-
terns around the seed region. Most motifs correspond with the seed sequence, but some extend to
include similarity with known transcription factors (Figure 2.8). A motif for hsa-miR-93-5p, part of
the miR-17 family, retrieved a PITX1 transcription factor motif, and hsa-miR-4227-3p shares some
similarity extending from the seed region with the SOX8 transcription factor. So while co-occurrence
of sequence motifs alone is not conclusive evidence of functional linkage, it may serve to produce
some testable mechanistic or functional hypothesis to examine on a microRNA by microRNA ba-
sis. It should be noted that the transcription factors tested to date are generally DNA binding motifs,
so interactions would be unlikely to be directly mechanistic (although they could instead indicate a
expression similarity), but RNA binding motifs could be investigated in the same way.
A priority in future work will be to check for the existence of these offset peaks experimentally. This
might be done through publicly available CLASH datasets, a recently developed sequencing-based
technology that allows for the non-specific identification of cellular microRNAs and their target sites
simultaneously [78].
To further explore the potential implications of these microRNA offsets, an evolutionary analysis
across several species may be useful. By considering both the conservation of the peak location and
similarity of binding site motifs to known RNA or DNA binding factors in the context of the evolu-
tionary changes seen in both the microRNA and binding proteins - it might be possible to determine
if a microRNA has evolved to take advantage of existing spatially constrained binding motifs.
If the locations of the microRNA target site distributions do have biological significance, it may have
implications for microRNA target predictions. Some tools do favour sites in the canonical 3’UTR
positions, (for instance in TargetScan’s context score [74]), which could cause some bias against peak
sites in affected microRNAs. In microRNAs with functionally relevant peaks, it would provide a
handy way to narrow down lists of candidate target genes to those more likely active.
The focus of this thesis has been on microRNA targeting generally (as none of the microRNAs ex-
plored further had any offset peaks). The database of microRNA target site predictions has been a
useful starting point for downstream analyses.
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2.5 Supplementary Tables
Table 2.3: Peaks in microRNA target distribution in the 3’UTR relative to the stop codon. Offset refers to the
middle of the peak, and coordinates are relative to the stop codon ending at 0.
microRNA Detail Offset Size
hsa-miR-1181 407 to 417 412 11
hsa-miR-1245a 479 to 488 484 10
hsa-miR-1245b-5p -6 to 6 0 13
hsa-miR-1247-5p 9 to 18 14 10
hsa-miR-1255a 105 to 122 114 18
hsa-miR-1256 17 to 39 28 23
hsa-miR-1257 459 to 472 466 14
hsa-miR-125b-1-3p -14 to 4 -5 19
hsa-miR-1266 -8 to 1 -4 10
hsa-miR-1298 -21 to 0 -11 22
hsa-miR-1307-3p -2 to 19 9 22
hsa-miR-1322 428 to 437 433 10
hsa-miR-132-5p 0 to 12 6 13
hsa-miR-138-1-3p -13 to 0 -7 14
hsa-miR-138-2-3p 146 to 157 152 12
hsa-miR-1469 48 to 57 53 10
hsa-miR-146a-3p -2 to 11 5 14
hsa-miR-1471 123 to 140 132 18
hsa-miR-148b-3p 137 to 146 142 10
hsa-miR-152 43 to 52 48 10
hsa-miR-1538 2 to 13 8 12
hsa-miR-17-3p 3 to 22 13 20
hsa-miR-181a-2-3p 332 to 349 341 18
hsa-miR-181a-5p 470 to 490 480 21
hsa-miR-181c-5p 468 to 490 479 23
hsa-miR-183-5p 19 to 29 24 11
hsa-miR-18b-3p 481 to 491 486 11
hsa-miR-1914-5p 5 to 16 11 12
hsa-miR-196a-3p 404 to 415 410 12
hsa-miR-200c-3p 432 to 447 440 16
hsa-miR-21-3p 367 to 377 372 11
hsa-miR-221-3p -12 to 1 -6 14
hsa-miR-222-5p -21 to 0 -11 22
hsa-miR-224-5p 439 to 449 444 11
hsa-miR-22-5p 25 to 35 30 11
hsa-miR-2277-5p 1 to 19 10 19
hsa-miR-23a-3p -18 to 0 -9 19
hsa-miR-24-3p -16 to 3 -7 20
hsa-miR-27a-5p -16 to 4 -6 21
hsa-miR-27b-5p -5 to 4 -1 10
hsa-miR-300 232 to 244 238 13
hsa-miR-302c-5p 19 to 41 30 23
hsa-miR-30a-3p -13 to 2 -6 16
hsa-miR-3126-3p -5 to 13 4 19
hsa-miR-3152-3p 464 to 474 469 11
hsa-miR-3178 3 to 15 9 13
hsa-miR-3180-3p 17 to 26 22 10
hsa-miR-33a-3p 308 to 324 316 17
hsa-miR-340-3p 268 to 277 273 10
hsa-miR-3614-3p -10 to 5 -3 16
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microRNA Detail Offset Size
hsa-miR-3688-3p 132 to 153 143 22
hsa-miR-371a-5p 68 to 77 73 10
hsa-miR-383 297 to 306 302 10
hsa-miR-3922-3p -2 to 7 3 10
hsa-miR-3934-3p -13 to 2 -6 16
hsa-miR-3940-3p 4 to 14 9 11
hsa-miR-3941 217 to 226 222 10
hsa-miR-3960 6 to 19 13 14
hsa-miR-3973 457 to 468 463 12
hsa-miR-3975 405 to 414 410 10
hsa-miR-4264 -15 to 1 -7 17
hsa-miR-4281 12 to 21 17 10
hsa-miR-4283 -10 to 5 -3 16
hsa-miR-4284 -8 to 3 -3 12
hsa-miR-4301 205 to 224 215 20
hsa-miR-4312 255 to 264 260 10
hsa-miR-4315 274 to 286 280 13
hsa-miR-4321 438 to 451 445 14
hsa-miR-4329 459 to 470 465 12
hsa-miR-4437 -16 to 4 -6 21
hsa-miR-4449 4 to 19 12 16
hsa-miR-4461 488 to 497 493 10
hsa-miR-4466 4 to 19 12 16
hsa-miR-4467 1 to 11 6 11
hsa-miR-4486 5 to 19 12 15
hsa-miR-4512 -5 to 6 1 12
hsa-miR-4518 -12 to 1 -6 14
hsa-miR-4520b-3p 435 to 444 440 10
hsa-miR-452-5p 208 to 221 215 14
hsa-miR-4665-3p 8 to 25 17 18
hsa-miR-4677-3p 101 to 126 114 26
hsa-miR-4766-5p 303 to 314 309 12
hsa-miR-4767 -1 to 16 8 18
hsa-miR-4774-5p 373 to 386 380 14
hsa-miR-4780 322 to 333 328 12
hsa-miR-4797-3p -16 to 1 -8 18
hsa-miR-485-3p -11 to 0 -6 12
hsa-miR-487a -20 to 1 -10 22
hsa-miR-489 283 to 294 289 12
hsa-miR-499a-3p 458 to 473 466 16
hsa-miR-5003-5p 199 to 219 209 21
hsa-miR-505-3p 50 to 59 55 10
hsa-miR-5088 -6 to 5 -1 12
hsa-miR-516a-5p 61 to 75 68 15
hsa-miR-518e-3p 0 to 12 6 13
hsa-miR-542-5p -8 to 7 -1 16
hsa-miR-548s 260 to 274 267 15
hsa-miR-550b-3p -11 to 1 -5 13
hsa-miR-554 -9 to 0 -5 10
hsa-miR-5571-5p 455 to 476 466 22
hsa-miR-5586-5p -3 to 10 4 14
hsa-miR-5588-3p 487 to 498 493 12
hsa-miR-573 12 to 21 17 10
hsa-miR-578 400 to 409 405 10
hsa-miR-601 -9 to 3 -3 13
hsa-miR-615-5p 4 to 15 10 12
hsa-miR-629-5p -11 to 4 -4 16
hsa-miR-6499-5p -1 to 13 6 15
hsa-miR-6505-5p 487 to 499 493 13
53
microRNA Detail Offset Size
hsa-miR-660-5p 81 to 95 88 15
hsa-miR-668 -17 to 1 -8 19
hsa-miR-675-5p 4 to 14 9 11
hsa-miR-744-5p 3 to 13 8 11
hsa-miR-875-5p -7 to 5 -1 13
hsa-miR-887 68 to 79 74 12
hsa-miR-96-5p 418 to 433 426 16
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Table 2.4: Peaks in microRNA target distribution in the 3’UTR relative to the end of transcription (i.e. polyA
site). Offset refers to the middle of the peak, and coordinates are relative to the end of the 3’UTR at 0.
microRNA Detail Offset Size
hsa-miR-106a-5p -263 to -242 -253 22
hsa-miR-106b-5p -262 to -243 -253 20
hsa-miR-1178-3p -74 to -52 -63 23
hsa-miR-1208 -381 to -372 -377 10
hsa-miR-1224-5p -369 to -360 -365 10
hsa-miR-1227-3p -147 to -131 -139 17
hsa-miR-1245a -234 to -216 -225 19
hsa-miR-1245b-3p -499 to -489 -494 11
hsa-miR-1253 -282 to -260 -271 23
hsa-miR-1256 -293 to -271 -282 23
hsa-miR-1263 -306 to -291 -299 16
hsa-miR-1273f -18 to -4 -11 15
hsa-miR-1273g-3p -73 to -59 -66 15
hsa-miR-1285-5p -29 to -10 -20 20
hsa-miR-1303 -17 to 2 -8 20
hsa-miR-1304-3p -74 to -54 -64 21
hsa-miR-1307-3p -312 to -291 -302 22
hsa-miR-1322 -490 to -481 -486 10
hsa-miR-1323 -2 to 8 3 11
hsa-miR-139-3p -191 to -180 -186 12
hsa-miR-143-3p -130 to -121 -126 10
hsa-miR-143-5p -55 to -34 -45 22
hsa-miR-151b -110 to -99 -105 12
hsa-miR-16-1-3p -168 to -159 -164 10
hsa-miR-17-5p -263 to -242 -253 22
hsa-miR-181a-5p -284 to -274 -279 11
hsa-miR-183-5p -292 to -269 -281 24
hsa-miR-18b-3p -459 to -442 -451 18
hsa-miR-193b-5p -192 to -175 -184 18
hsa-miR-195-3p -177 to -166 -172 12
hsa-miR-200c-3p -499 to -490 -495 10
hsa-miR-20a-5p -264 to -243 -254 22
hsa-miR-20b-5p -263 to -242 -253 22
hsa-miR-212-5p -252 to -231 -242 22
hsa-miR-21-3p -5 to 8 2 14
hsa-miR-216a-5p -68 to -47 -58 22
hsa-miR-216b -159 to -139 -149 21
hsa-miR-2276 -319 to -310 -315 10
hsa-miR-25-3p -460 to -449 -455 12
hsa-miR-2681-5p -303 to -294 -299 10
hsa-miR-26a-5p -234 to -220, -71 to -57 -227, -64 15,15
hsa-miR-28-5p -112 to -101 -107 12
hsa-miR-29b-2-5p -194 to -173 -184 22
hsa-miR-302b-3p -94 to -83 -89 12
hsa-miR-302c-3p -104 to -83 -94 22
hsa-miR-30d-3p -461 to -440 -451 22
hsa-miR-3122 -132 to -119 -126 14
hsa-miR-3130-5p -38 to -29 -34 10
hsa-miR-3135a -41 to -22 -32 20
hsa-miR-3135b -46 to -29 -38 18
hsa-miR-3150a-5p -231 to -214 -223 18
hsa-miR-3150b-5p -231 to -212 -222 20
hsa-miR-3159 -270 to -251 -261 20
hsa-miR-3167 -117 to -96 -107 22
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microRNA Detail Offset Size
hsa-miR-3184-3p -28 to -7 -18 22
hsa-miR-3186-5p -143 to -124 -134 20
hsa-miR-325 -450 to -439 -445 12
hsa-miR-331-5p -433 to -415 -424 19
hsa-miR-3615 -65 to -47 -56 19
hsa-miR-361-5p -147 to -134 -141 14
hsa-miR-3617-3p -455 to -446 -451 10
hsa-miR-3622a-3p -216 to -206 -211 11
hsa-miR-3652 -44 to -27 -36 18
hsa-miR-3666 -399 to -379 -389 21
hsa-miR-3676-5p -382 to -371 -377 12
hsa-miR-371a-5p -242 to -219 -231 24
hsa-miR-372 -268 to -244 -256 25
hsa-miR-373-3p -265 to -244 -255 22
hsa-miR-378a-5p -227 to -209 -218 19
hsa-miR-378f -217 to -207 -212 11
hsa-miR-381-3p -463 to -454 -459 10
hsa-miR-383 -4 to 10 3 15
hsa-miR-3908 -183 to -162 -173 22
hsa-miR-3913-5p -19 to 1 -9 21
hsa-miR-3975 -409 to -394 -402 16
hsa-miR-425-3p -213 to -198 -206 16
hsa-miR-4258 -145 to -129 -137 17
hsa-miR-4259 -132 to -116 -124 17
hsa-miR-4267 -222 to -207 -215 16
hsa-miR-4273 -395 to -379 -387 17
hsa-miR-4278 -229 to -215 -222 15
hsa-miR-4284 -67 to -58 -63 10
hsa-miR-4301 -105 to -86 -96 20
hsa-miR-4418 -71 to -60 -66 12
hsa-miR-4425 -268 to -250 -259 19
hsa-miR-4430 -44 to -27 -36 18
hsa-miR-4440 -296 to -285 -291 12
hsa-miR-4442 -499 to -490 -495 10
hsa-miR-4452 -223 to -202 -213 22
hsa-miR-4465 -122 to -106 -114 17
hsa-miR-4471 -318 to -300 -309 19
hsa-miR-4475 -395 to -377 -386 19
hsa-miR-448 -487 to -474 -481 14
hsa-miR-4484 -394 to -384 -389 11
hsa-miR-4524a-3p -16 to -1 -9 16
hsa-miR-4524b-3p -19 to -2 -11 18
hsa-miR-454-3p -68 to -57 -63 12
hsa-miR-4633-5p -155 to -137 -146 19
hsa-miR-4652-3p -495 to -481 -488 15
hsa-miR-4661-3p -176 to -161 -169 16
hsa-miR-4680-5p -221 to -208 -215 14
hsa-miR-4681 -331 to -321 -326 11
hsa-miR-4695-3p -68 to -50 -59 19
hsa-miR-4696 -2 to 17 8 20
hsa-miR-4704-5p -8 to 13 3 22
hsa-miR-4737 -405 to -390 -398 16
hsa-miR-4761-5p -477 to -468 -473 10
hsa-miR-4763-5p -109 to -96 -103 14
hsa-miR-4766-5p -7 to 16 5 24
hsa-miR-4772-3p -79 to -58 -69 22
hsa-miR-4772-5p -1 to 13 6 15
hsa-miR-4774-3p -282 to -271 -277 12
hsa-miR-4777-3p -252 to -231 -242 22
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microRNA Detail Offset Size
hsa-miR-4783-5p -140 to -129 -135 12
hsa-miR-4787-3p -148 to -127 -138 22
hsa-miR-4788 -9 to 0 -5 10
hsa-miR-4789-3p -5 to 6 1 12
hsa-miR-4792 -360 to -349 -355 12
hsa-miR-4800-3p -239 to -222 -231 18
hsa-miR-4801 -411 to -401 -406 11
hsa-miR-4804-5p -154 to -140 -147 15
hsa-miR-499b-5p -348 to -339 -344 10
hsa-miR-5003-5p -110 to -91 -101 20
hsa-miR-507 -433 to -423 -428 11
hsa-miR-5091 -5 to 13 4 19
hsa-miR-509-3-5p -133 to -119 -126 15
hsa-miR-509-3p -419 to -402 -411 18
hsa-miR-5095 -274 to -256 -265 19
hsa-miR-5096 -195 to -176 -186 20
hsa-miR-512-5p -116 to -98 -107 19
hsa-miR-517-5p -488 to -477 -483 12
hsa-miR-5187-3p -252 to -233 -243 20
hsa-miR-518a-3p -8 to 3 -3 12
hsa-miR-518e-3p -265 to -254 -260 12
hsa-miR-5197-3p -5 to 15 5 21
hsa-miR-519e-3p -480 to -470 -475 11
hsa-miR-519e-5p -416 to -407 -412 10
hsa-miR-539-5p -442 to -429 -436 14
hsa-miR-541-5p -107 to -93 -100 15
hsa-miR-548b-3p -106 to -87 -97 20
hsa-miR-550a-3p -32 to -9 -21 24
hsa-miR-5571-5p -106 to -86 -96 21
hsa-miR-5582-5p -2 to 15 7 18
hsa-miR-5585-3p -127 to -107 -117 21
hsa-miR-5694 -388 to -379 -384 10
hsa-miR-5706 -477 to -456 -467 22
hsa-miR-5708 -282 to -264 -273 19
hsa-miR-574-3p -69 to -54 -62 16
hsa-miR-600 -275 to -257 -266 19
hsa-miR-602 -6 to 8 1 15
hsa-miR-6078 -325 to -312 -319 14
hsa-miR-610 -467 to -457 -462 11
hsa-miR-6129 -336 to -327 -332 10
hsa-miR-614 -412 to -401 -407 12
hsa-miR-627 -381 to -365 -373 17
hsa-miR-640 -239 to -219 -229 21
hsa-miR-642a-3p -65 to -54 -60 12
hsa-miR-643 -499 to -480 -490 20
hsa-miR-645 -41 to -24 -33 18
hsa-miR-6499-5p -339 to -327 -333 13
hsa-miR-6505-3p -433 to -413 -423 21
hsa-miR-6514-5p -280 to -259 -270 22
hsa-miR-660-3p -121 to -103 -112 19
hsa-miR-6715a-3p -157 to -136 -147 22
hsa-miR-6715b-3p -418 to -406 -412 13
hsa-miR-6719-3p -230 to -211 -221 20
hsa-miR-6722-5p -496 to -478 -487 19
hsa-miR-758-5p -350 to -340 -345 11
hsa-miR-890 -479 to -462 -471 18
hsa-miR-924 -24 to -7 -16 18
hsa-miR-93-5p -263 to -243 -253 21
hsa-miR-936 -181 to -162 -172 20
57
microRNA Detail Offset Size
hsa-miR-9-5p -181 to -160 -171 22
hsa-miR-96-5p -494 to -482 -488 13
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CHAPTER 3
An integrative approach for characterisation of
functional regulatory DNA variations associated
with ASD
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Many genetic studies have identified association of rare coding variants with ASD, a neurodevelop-
mental disorder with heterogeneous genetic risks. In contrast, the contribution of functional, regula-
tory genetic variations in noncoding regions remains less well understood. Here we investigate the
potential contribution of regulatory variants to autism risk in a previously sequenced cohort of 48
ASD family exomes. We filtered rare SNVs having regulatory signal using several established tools
to determine functionality and conservation of these sequences. Using publicly available datasets and
computational predictions, we identified those SNVs within putative regulatory regions in promoters,
transcription factor binding sites and microRNA genes and their targets. Overall, we found regulatory
variants were enriched in autism risk genes and among genes involved in fetal neurodevelopment. As
with previously reported coding mutations, we found an enrichment of regulatory variants associated
with dysregulation of L1CAM interaction and synaptic signalling pathways. The significance of a
novel loss-of-function SNV found in the seed region of miR-873-5p was functionally determined.
We compared transcriptome-wide binding affinity interactions of wild-type and mutant miR-873-5p
molecules and determined a shift in binding affinity among key autism-risk genes including NRXN2.
We conclude mutant miR-873-5p may additively impact on synaptic function when combined with a
loss-of-function coding variation found in NRXN1, in this idiopathic case. In this regard, our anal-
ysis pipeline provides a template for identifying potential loss-of-function noncoding regulatory and
coding variations from next generation sequencing of ASD families.
3.1 Introduction
Autism (or autism spectrum disorder - ASD) is a neurodevelopmental disorder with heterogeneous
genetic origins. Recent exome sequencing studies have identified many risk genes from protein-
coding variants, which has driven a move towards analysis of convergent risk pathways [5, 14, 86,
87]. However, less is known about the contribution to risk by variants in non-coding regulatory
regions, which hold the potential to disrupt the finely tuned biological pathways involved in brain
development.
Our previous exome sequence study showed many DNA variations occur in non-coding regions [16].
The functional significance of these variants has been difficult to interpret due to the lack of specific
knowledge concerning their contribution to non-coding regulatory regions that control and modulate
gene transcription. Even in cases where a variant in a non-coding region is found to be associated
with a disorder through linkage analyses, it is a challenge to assess if they have regulatory function, or
if the risk lies elsewhere in a linkage region [100]. The problem is compounded in de novo mutations,
which are unlikely to be in public databases, despite their significant contribution to ASD [11, 17,
101]. Much of this inertia arises from the lack of data integration and functional sequence analysis
surrounding transcription control, the molecular interactions and transactions of which are poorly
understood when compared to the dynamics of protein coding and protein function. In this regard
the identification and contribution of noncoding regulatory variants in autism-associated biological
pathways remains less known.
The availability of large, genome-wide regulatory resources such as FANTOM5 [102], ENCODE [85]
and the BrainSpan developmental brain tissue expression datasets [103], have been instrumental in
driving modern systems biology approaches to evaluating regulatory mutations in human disorders.
These encompass predictions of a variant’s ability to disrupt microRNA regulatory pathways [104]
to region-based evaluations based on integrated sequence-level ENCODE data [100], and systems
approaches linking transcription factor binding information to network contexts [105].
In the autism field, there have been focused efforts on the UTRs (untranslated regions) of known
autism associated genes [106], and the risk of brain specific enhancer regions in autism [107]. Re-
cently, Turner et al. (2016) have used DNAase hypersensitivity sites to prioritise regulatory mutations
in autism exome data [108]. Together these data provide a vision how we might assess the potential
impact of noncoding regulatory DNA variations associated with autism.
In this study we analysed regulatory variants from our previously published exome sequencing study
of autism families [16]. Single nucleotide variants (SNVs) in regulatory regions were filtered by
rarity, and functional scores from several tools that rank the functional significance of non-coding
regions. We compiled a resource of regulatory regions from public databases covering promoters,
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microRNA genes and their predicted targets, and predicted transcription factor binding sites. We
were able to evaluate the relationship of these regulatory SNVs to autism associated pathways such
as L1CAM pathways previously highlighted in this cohort [16], and characterise these regulatory
mutations within autism-associated databases, functional networks and neurodevelopment. We also
provide proof of principle concerning the functional significance of a SNV found in miR-873-5p on
transcriptome binding and regulation of key autism-risk genes via a mRNA-pulldown sequencing
analysis.
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3.2 Methods
3.2.1 Autism and control exome variants and filtering
The whole exome sequencing data used in this study was from our previous study of 40 Australian
ASD families (n=128; 48 ASD cases and 80 parents) [16], and we considered single nucleotide vari-
ants (SNVs) for this analysis. Similar to our previous analysis of coding variants in the same autism
cohort [16], we used a two-stage filtering process to identify the most interesting SNVs. First a ‘MAF’
(Minor Allele Frequency) filter was applied to select rare variants, which are thought to have a larger
effect in complex disorders such as ASD [16, 17, 109], then a ‘functional’ filter integrating several
established databases of non-coding functional signals [110–112]. Though by no means an exact in-
dication of biological impact or relevance to autism, these filters aim to enrich for potentially relevant
variants, especially important as we consider the combined effects of multiple variants. Annotations
were made using the ANNOVAR package (version: 2015Jun16) [113].
The MAF filter excluded SNVs having MAFs > 1% from any of several databases; the 1000 Genomes
Project (October 2014 release for European and Asian populations, matched to individual’s eth-
nicity), (1000g2014oct eas/1000g2014oct eur annovar database), [114], the NHLBI-6500 Exomes,
(esp6500si all annovar database) (NHLBI GO Exome Sequencing Project (ESP)) and the Exome
Aggregation Consortium (ExAC), (exac01 annovar database), [115].
The functional filtering step selected SNVs meeting thresholds across any of several databases; Com-
bined AnnotationDependant Depletion (version 1.0, phred-scaled score> 20), (cadd annovar database),
which integrates multiple lines of genome-wide annotation and regulatory signal [110], Genomic
Evolutionary Rate Profiling (GERP++) score > 2, (gerp++gt2 annovar database) which measures
selective constraint, [116], and PhyloP conservation score > 0.4 (ljb23 phylop annovar database), a
measure of sequence conservation.
Coding variants additionally underwent the same SIFT [111] (ljb23 sift annovar database) and PolyPhen2
[112] (ljb23 pp2hdiv annovar database) functional filtering pipeline described in [16]. Coding vari-
ants were classified according to RefSeq annotations via ANNOVAR [113], and synonymous SNVs
were excluded.
The control dataset (‘1kgenome controls’) used in enrichment calculations was constructed from
European-ancestry individuals (n=379, as per predominate ethnicity of cases) from 1000 genome
analysis phase 1 analysis results [114]. Because the 1000 genomes data originates from whole-exome
sequencing, only SNVs from coverage-matched regions (defined as having >= 20 reads in 90% of
ASD cohort samples) were included.
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3.2.2 Definition of regulatory regions from public data and predictions
We defined the regulatory SNV set as those situated in promoters, enhancers, microRNA genes, pu-
tative microRNA binding sites on the 3’UTRs and putative transcription factor binding sites (TFBS)
on the 5’UTRs and 3’UTRs.
Promoter regions were defined using FANTOM5 phase 1 TSS (transcription start site) CAGE data
(Cap Analysis of Gene Expression) as regions 1000bp upstream and 300bp downstream of the an-
notated CAGE peaks for HGNC gene records [102]. Enhancer region coordinates were downloaded
from the FANTOM5 phase 1 database [117]. Genomic annotations of non-coding regions are from the
UCSC ‘knownGene’ annotation (downloaded 21 February 2013) on hg19 human reference genome,
including all transcript variants.
For TFBS prediction, we built a database of 1289 DNA motifs collected from different studies: the
FANTOM5 project [102], JASPAR [118], Cristino et al. (2013) [119] and Jolma et al. (2013) [98],
as well as data from several stem-cell-focused transcription factor studies [120–128]. We searched
for instances of these DNA motifs (70% similarity) on the 3’UTRs, 5’UTRs and promoter regions of
genes, using the TAMO package [129].
We predicted microRNA regulatory element (MRE) sites across 3’UTRs for all human microRNAs
(miRBase version 19) [94]. MicroRNA target sites predicted by miRanda (default parameters, free en-
ergy <= -18) [92], having a 75% overlap with RNAhybrid were used (-b 2000, -e -18, -s 3utr human,
then filtered free energy <= -25) [71].
We also searched for SNVs falling within microRNA precursor gene regions themselves. These
variants were filtered by population frequency only, and SNVs interpreted on the basis of the mature
sequence (as annotated in miRbase19) and seed regions. To identify conserved microRNA match
motifs as a proxy for seed regions, we ran MEME (v4.9.0, options: -mod zoops -nmotifs 1 -maxw
15 -maxsize 10000000) over each microRNA’s predicted MREs [96]. Regions of motifs with low
information density were filtered out with TAMO (trimming threshold 0.2) (Version updated 21st
Mar 2012) [129]. To estimate effects of microRNA gene variants in terms of loss or gain of targets,
we ran target site predictions with microRNA sequences incorporating those variants.
3.2.3 Enrichment analyses
To test for a general association of the regulatory SNVs with autism, enrichment was calculated
against several autism-associated gene sets of diverse origins; curated autism SFARI database, (De-
cember 2015 update, Scores indicating any support: S,1-4), [7], AXAS-ASD, our previously devel-
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oped ASD protein-protein interaction network, which uses ‘seed’ genes from public resources and
their first-degree neighbours [119] and Module 13 (M13-Li2014) a module of protein-protein con-
structed by Li et al. (2014) [130] which is associated with autism risk. Additionally one unrelated
control dataset was included - the CADgene V2 database of heart-disease associated genes [131].
Genes with regulatory SNVs from the ASD dataset were contrasted with controls (‘1kgenome con-
trols’) from the 1000 genomes project data [114]. To mitigate biases to mutation finding in certain
genes that might overinflate enrichment if SNVs are assumed to occur randomly, p-values to test for
enrichment of ASD case variants in a given dataset were calculated on a binomial distribution where
variants are assumed to occur within the dataset at the rate seen in the 1kgenome controls.
We calculated enrichment of regulatory SNVs (via hypergeometric distribution 1-tailed test in R) in
co-expression modules constructed and characterised by Parikshak et al. (2013) [86]. Also, using the
methods and resources described in [86], we looked for specific higher or lower expression levels of
our gene list in different cortical layers, based on fetal tissue expression data from BrainSpan [132]
and adult primate cortical layers [133].
3.2.4 Biotin-tagged microRNA mRNA-pulldown assay
Biotin tagged mRNA-microRNA pulldown (pulldown) experiments were used to identify bound
mRNA transcripts of miR-873-5p wild-type (WT) and SNV-containing (Mut) microRNAs. Briefly,
biotin-tagged microRNAs were transfected into undifferentiated SH-SY5Y cells (a neuroblastoma
cell line), and then captured from the transfected cell lysates along with their targeted transcripts to
magnetic streptavidin beads.
The pulldown protocol was primarily drawn from [82], as well as [83], with the following modifica-
tions. Samples were transfected in a 75cm2 flask with 560 pmol of biotinylated microRNA with lipo-
fectamine 2000 (Thermo Fisher), and grown for 24 hrs before pulldown. Four biological replicates,
from four independent transfection and pulldown experiments, were made for each microRNA (WT
and Mut). RNA was purified with RNAeasy columns (QiAGEN), and sequencing libraries prepared
from 100 ng input RNA with Illumina TruSeq Stranded mRNA kit. Libraries were sequenced across
two lanes using v4 SBS chemistry on an Illumina HiSeq2000. Cells were grown in DMEM F12 with
HEPES media with penicillin/streptomycin at 37o with 5% CO2. The synthetic microRNA duplexes
with biotin tags on the 3’ end of the mature microRNA were ordered from IDT (Supplementary Table
3.2).
Sequence data quality was examined with FastQC (v0.11.3). Illumina adaptor sequences were re-
moved and reads quality trimmed with Trimmomatic [134]. Sequences were aligned to the human
GRCh38 Ensembl release 83 transcriptome with TopHat2 [135]. Gene-level counts were generated
from paired reads in HTseq-count (Parameters: -s reverse -m union). Differential expression analysis
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to evaluate the enrichment of targets in pulldown samples (paired comparisons) compared to matched
whole-transcriptome transfection controls were done using DEseq2 [136].
3.2.5 Data tools
Manipulation of sequence, annotation and SNV files was undertaken using VCFtools (v0.1.12a)
[137], tabix (v0.2.6) [138], ANNOVAR (version: 2015Jun16) [113], SAMtools (v0.1.18) [139] and
bedtools (v2.17.0) [95]. Cytoscape v3 was used visualising for network analyses [140], and the
ClueGO plugin for GO enrichment [141].
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3.3 Results
3.3.1 Annotation of variants in regulatory regions
In this study, we have used previously published whole exome sequencing (WES) data [16] to inves-
tigate putative regulatory genetic variation in 128 individual genomes from in an Australian autism
cohort (48 affected cases and 80 parents) [16]. To examine the captured non-coding regions we devel-
oped a computational pipeline to systematically analyse WES data in non-coding regulatory contexts:
transcription factor binding sites (TFBS), microRNA regulatory elements (MRE), promoter regions
and microRNA genes (Figure 3.1).
We generated overlapping predictions of TFBSs (4.8 million 5’UTR / 22.4 million 3’UTR from 1289
motifs) and MREs (2.6 million from 2042 mature microRNAs) across 59133 untranslated regions of
19414 genes, and used public databases of microRNA genes (miRbase v19) [94], promoters (FAN-
TOM5) [102] and enhancers (FANTOM5)[117] (Table 3.1).
Then, we assessed sequencing coverage across different regulatory regions (Table 3.1 and Supple-
mentary Figure 3.5). Despite this being exome sequencing data, there was still sufficient read depth
to call variants across 20-24% of TFBS and MREs in untranslated regions (Table 3.1), with coverage
skewed to the potentially more interesting sites proximal to the captured genes (Supplementary Fig-
ure 3.5). MicroRNA genes were well covered at 48% coverage (Table 3.1), considering that there are
many microRNAs in miRBase with limited evidence (especially newer ones), which may not have
been considered during the development of the exome capture design. Although promoters had less
callable coverage (13%) they still yielded valuable data (Table 3.1). Enhancers had very low callable-
coverage (1%) due to their distance from the captured coding regions, and were omitted from this
analysis (Table 3.1).
A list of the definitions of the regulatory regions, and TFBS PWM (Position Weight Matrix) defini-
tions in TAMO format [129] are available at figshare:
(https://dx.doi.org/10.6084/m9.figshare.3581781.v1)
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Figure 3.1: Identification of regulatory regions. An overview of the computational pipeline and databases used
to identify regulatory regions to check for variants in (1) promoters, (2) Transcription factor binding sites
(TFBS) (3) microRNA binding sites and (4) microRNA genes
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Table 3.1: Summary of regulatory region predictions, exome sequencing coverage and SNVs in regulatory regions. Note that feature counts include redundant features
(e.g. target sites of similar microRNAs) and overlapping regions (e.g. promoters from alternate transcriptional start sites). Feature sizes and coverage are calculated
using non-redundant genomic regions. SNV-callable coverage is defined as genomic regions with 20X read depth (sufficient for SNV-calling) in at least 90% of samples.
Raw variants are all quality-passed SNV calls, and filtered variants are those having passed the MAF and functional filtering described in the methods.
Regulatory Region Number of
Individual
Features
Cumulative
Region Size
SNV-Callable Size
(Percent of total)
Average Raw
Variants Per
Individual
Average Filtered
Variants Per
Individual
Promoters 235917 74.57 Mb 9.7 Mb (13%) 3119 49
Transcription factor binding sites - 5’UTRs 4770730 7.67 Mb 1.9 Mb (24%) 619 12
Transcription factor binding sites - 3’UTRs 22447998 22.75 Mb 4.8 Mb (21%) 1350 25
MicroRNA target sites 3’UTRs 2624853 18.08 Mb 3.5 Mb (20%) 2037 43
MicroRNA precursors 1600 0.13 Mb 0.06 Mb (48%) 50 0.3
Mature microRNAs 2042 0.05 Mb 0.02 Mb (48%) 12 0.1
Enhancers 43011 12.39 Mb 0.06 Mb (0.5%) 16 0.1
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3.3.2 Filtering genetic variations with putative regulatory function
To prioritise putative regulatory variants, variants were filtered for population frequency and function-
ality predictions (with SIFT [111] and CADD [110]) as previously described [16]. Then we searched
for their occurrence in the putative regulatory regions around coding genes and within microRNA
genes.
After filtering regulatory variants for rare population frequency (MAF <= 1%) and functional anno-
tation, each individual had an average of 106 regulatory variations (Figure 3.2a). Greater numbers of
SNVs were identified in the promoter regions, followed by 3’UTR MREs and TFBSs, reflecting the
relative sizes of these regions (Table 3.1).
We identified a total of 14 microRNAs with rare (heterozygous) SNVs within their mature sequences,
which could globally disrupt their mRNA binding specificity (Supplementary Table 3.3). Of these,
two variants were in conserved ‘seed’ regions of the microRNAs, where there is greater potential for
disruption due to the exact target complementarity required in canonical microRNA-mRNA binding
(Supplementary Table 3.3). MiR-873-5p had a SNV in a conserved region within the seed and lost
predicted target sites in 85% of the genes with predicted wild-type target sites in our RNAhybrid and
miRANDA-based prediction database (which can include non-perfect seed matches), the greatest of
any of the microRNAs (Supplementary Table 3.3). However these seed-region variants might also
be considered a total loss of targeting potential in a canonical exact-seed-match binding model. In
contrast, a more subtle impact is expected if the variants at less conserved positions (e.g. miR-139-3p,
56% predicted target loss), or outside the seed regions (e.g. miR-668, 29% predicted target loss).
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(a)
(b) (c)
(d) (e)
Figure 3.2: (a) Filtering process for regulatory variants showing average counts of SNVs per individual at each
stage. The regulatory variants are defined as those within promoters, predicted TFBSs or predicted MREs. (b)-
(e) Enrichment of filtered regulatory variants from cases and 1kgenome controls in different reference datasets
described in the methods, specifically (b) AXAS-ASD (n=2664), a resource of autism-associated genes and
interactors [119], (c) SFARI curated autism gene database (n=397), [7], (d) M13 - Li 2014 (n=115), an
autism-associated protein-protein interaction module from the work of Li et al. (2014) analysis [130] (e) An
unrelated heart-disease control dataset, CADgene V2 (n=581) [131]. P-values for differences between cases
and 1kgenome controls were calculated on the full gene lists (not subsamples) using a binomial distribution
assuming that SNVs occur within the tested databases at the same rate as the 1kgenome control SNV set,
as described in methods. To visualise contrasts despite differences between gene numbers, boxplots display
resampled counts of database hits from subsets of regulatory variant containing genes (1000 replicates of 400-
gene subsets). Only genes from the background of genes annotated in UCSC and RefSeq were considered.
Control samples (1kgenome controls) are from the European population of 1000 genome project [114].
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3.3.3 Association of regulatory variants with autism risk genes
We used enrichment tests to assess if genes with rare regulatory variants (in TFBSs, MREs and pro-
moters) found in ASD individuals were over-represented in ASD associated genes. Strikingly, we
saw significant enrichment of genes with regulatory mutations in cases compared to the rate of the
1kgenome control dataset [114] in gene lists from three distinct autism associated resources, SFARI,
AXAS-ASD and M13-Li2014 (Figures 3.2b, 3.2c and 3.2d), but not in ‘CADgene V2’, the heart-
disease associated control database (Figure 3.2e), [7, 119, 130, 131]. Though the contribution of
different classes of regulatory mutations may differ, there was no obvious domination of a single
feature type (Supplementary Figure 3.6).
Having seen an overall association, we then wanted to examine if regulatory mutations were overrep-
resented in particular pathways or regions during neurodevelopment. Parikshak et al. (2013) have
previously constructed and characterised a set of co-expressed gene modules with respect to autism
[86]. We saw significant (p<0.05) enrichment of genes having regulatory mutations in cases against
one only module, M16 (Supplementary Table 3.4); which is associated with early synaptic develop-
ment, at late fetal and early postnatal timescales [86].
The genes affected by these variants were more specifically expressed in the intermediate cortical
layer in fetal development, in both PCW (post-conception weeks) 15-16 and PCW 21 datasets, in
contrast to the adult layers where no significant differences were observed (Supplementary Table
3.5).
3.3.4 Convergence of microRNA and regulatory variants in a synaptic
pathway
Our previous analysis of the protein coding mutations within these samples uncovered convergence
of mutations in L1CAM pathways [16]. We focussed on finding further regulatory variants concen-
trating on L1CAM interactions (Reactome: R-HSA-373760.1) [142], and saw several variants within
ankyrins and spectrins in the ‘Interactions between L1 and Ankyrins’ sub-pathway (R-HSA-445095),
which is noteworthy as ankyrins ANK2 and ANK3 have been previously associated with autism
[9, 143].
For instance, one individual (30.s1) had a SNP in the coding region of spectrin SPTA1, but examina-
tion of regulatory variants revealed a further maternally inherited change in autism-associated ANK2
promoter region, and a paternally inherited variant in the 5’UTR of SPTAN1 (Figure 3.3a). The SP-
TAN1 5’UTR mutation (chr9:131317629, C=>T) is within predicted binding sites of ZNF354C from
the JASPAR database [118] and a novel motif64 from FANTOM database [117]. There is also reg-
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ulatory signal from ENCODE CHIP-seq peaks of several other transcription factors [144], including
JUND and FOSL2 which are involved in the AP-1 transcription initiation complex [145].
We also chose to follow up on the effect of the SNV within miR-873-5p due to its location in the
seed region (Figure 3.4a), the microRNA’s robustly expressed profiles across all regions of the human
brain (Supplementary Figure 3.7), and functional enrichment analysis of its predicted target genes
pointing towards a role in the regulation of nervous system development (Fisher’s exact test with
Bonferroni step down corrected P-value = 0.002) and signalling (Fisher’s exact test with Bonferroni
step down corrected P = 0.0003) [141]. The existence of this inherited SNP in the filtered variant set is
no guarantee of its functional relevance, so we aimed to experimentally gather a transcriptome-wide
view of how can affect miR-873-5p binding, in order to evaluate its potential relevance to autism.
Biotinylated microRNA mRNA pulldown (pulldown) experiments of the wild-type miR-873-5p iden-
tified a transcriptome-wide binding profile, with 3226 genes significantly enriched (and putatively
targeted). These putative targets include many of the potentially autism-associated genes documented
in the SFARI database [7]. By contrasting the relative pulldown assay enrichment of the wild-type
and mutant miR-873-5p, we identified genes that may suffer from loss or gain of mRNA targeting
through the existence of this variant (Figure 3.4b). This includes a loss of binding in NRXN2, a
member of the neurexin family of synaptic genes prominently implicated in autism risk [20].
However, the miR-873-5p SNV is heterozygous and inherited from an unaffected father, so while
though clearly not causative on its own, we hypothesized that it could contribute additively through
interactions with other mutations. Notably, in the affected proband there is a putative maternally
inherited loss of function coding variant in NRXN1 (G=>A mutation at chr2:50847195), resulting in
a proline to serine structural change adjacent to a disulphide bridge and calcium binding site in LNS
domain 2. This could act in concert with the loss of binding in NRXN2 by the miR-873-5p paternally
inherited SNV, illustrated in Figure 3.4b. Furthermore, the wild-type miR-873-5p appears to have
the capability to bind further synaptic autism risk genes among the local protein-protein interaction
network of neurexins, neuroligins, DLG and DLGAP genes and all three SHANK family members
(Figure 3.3b).
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(a)
(b)
Figure 3.3: Networks of variants examples. Grey lines indicate protein interactions from bioGRID version
3.2 [146]. (a) Mutations marked for individual 30.s1 in ankyrin and spectrin genes (a subset of Interaction
between L1 and ankyrin (Reactome: R-HSA-445095.1)). (b) Network of regulatory variants in individual 34.s1
(as described in [16]) across several synaptic gene families, highlighting the convergence of the maternally
inherited NRXN1 coding variant, and the paternally inherited miR-873-5p variant. Putative target genes of
miR-873-5p (significantly enriched in the wild-type pulldown assay) are shown in red outlines. The paternally
highlighted red fill of NRXN2 indicates the loss of binding measured in the pulldown assay with the mutant
miR-873-5p, compared to the wild-type. This was defined as a loss of 0.5 log 2 fold-change as described in
Figure 3.4b.
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(a)
(b)
Figure 3.4: MicroRNA miR-873-5p variant. (a) Mature sequence of miR-873-5p showing the variant relative
to the conserved motif. The motif is a representation of the seed region generated from predicted miR-873-5p
target sites with MEME [96]. (b) Genes with gained or loss of binding from the introduction of the miR-873-5p
variant according to pulldown results. Plot contrasts log2 fold-changes of mRNA enrichment of the wild-
type (WT) and mutant (Mut) microRNAs pulldown experiments for autism-associated SFARI genes (having
SFARI score 1-4, S) [7]. Colour of circles represents whether each gene was significantly enriched in the WT
pulldown only (red), Mut pulldown only (blue), both (purple) or neither (grey). Size of circles is proportional
to the difference in log2 fold-change between assays, and those genes with a difference more than 0.5 log2
fold-change are labelled.
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3.4 Discussion
Our study provides a comprehensive identification and characterization of putative regulatory varia-
tions in an exome-sequenced cohort. We combined our variant data with recent regulatory element
resources and computational TFBS and MRE predictions.
The overall cohort-level enrichment of regulatory variants within autism-associated genes derived
from several diverse studies (Figures 3.2b, 3.2c and 3.2d) [7, 119, 130] supports the involvement of
regulatory variants in autism risk.
There have been several studies aimed at identifying functional modules that capture processes dis-
rupted in autism, showing convergence of autism risk variants [86, 87, 147]. Only one of the genome-
scale co-expression modules constructed by Parikshak et al. (2013) was enriched in our regulatory
variant set; the same one (M16) that they had highlighted for potential involvement in autism [86].
It is enriched for autism relevant GO terms such as ‘synaptic transmission’ and ‘homophilic cellular
adhesion’ and more specifically expressed in later fetal development and early infancy [86]. Notably,
Parikshak et al. (2013) had suggested that M16 might be targeted by lower-risk inherited variants, in
contrast to other modules involved in more fundamental early developmental processes, something
that is supported by enrichment of our dataset of regulatory, and perhaps subtle, largely inherited
mutations.
There has been some work inspecting convergence of autism risk genes in specific cortical layers
during neurodevelopment [86, 87]. The enrichment of regulatory variants seen in the intermediate
layer during fetal development (Supplementary Table 3.5) is broadly consistent with association of
autism risk genes in fetal neurodevelopment within the deeper cortical layers although Parikshak et
al. (2013), whose processed BrainSpan data we used, observe this in the intermediate layer [86],
whereas Willsey et al. (2013) report on layers L5 and L6 [87]. Taken together, our analysis supports
the idea that early neurodevelopment of the brain is a critical period affected by regulatory variations
in ASD.
Autism has complex and heterogeneous genetic causes, and may arise from combinations of cod-
ing, regulatory, inherited and de novo variants [5]. Consequently, to investigate a possible additive
contribution of regulatory SNVs, it makes sense to focus attention on clusters of variants, both reg-
ulatory and coding, that are in the networked neighbourhood of known autism-associated genes and
pathways.
Several members of the L1 family of synaptic cellular adhesion molecules have been implicated in
autism [148–150], and the previous analysis of coding variants in this dataset revealed changes in the
L1 pathway [16]. Looking for further regulatory mutations in this context revealed several regulatory
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SNVs among L1 interacting ankyrins and spectrins, including a regulatory SNV in a promoter region
of ANK2, a gene previously associated with autism [9]. Also notably, this approach identified a SNV
in the 5’UTR of SPTAN1, in a putative TFBS (for ZNF354C from the JASPAR database [118] or
‘motif64’ descried in FANTOM [117]). This is also a region with experimental CHIP-seq associa-
tions with members of AP-1 transcriptional initiation complex JUND and FOSL2, which outlines a
possibility of the SNV interfering with transcriptional initiation and thus downstream protein levels.
While we cannot state from our prediction-based annotations if such mutations can genuinely dysreg-
ulate expression levels of L1 molecules or associated pathway members, it is an intriguing possibility,
particularly given that recent work by Sauce et al. (2015) in a heterozygous mouse knockout suggests
L1CAM dosage sensitivity [149].
Our study described variants within microRNA genes, and we used computational analyses to predict
their potential to disrupt microRNA function. We identified rare variations in the seed region (the
major factor in binding specificity) of two microRNAs; miR-139-3p and miR-873-5p, and followed
up the miR-873-5p variant due to its greater predicted loss of target sites (Table 3.3) and genomic
location. The miR873 gene is located within LINGO2, a neural gene which has been investigated
with respect to essential tremor and Parkinson’s disease [151], and had seen recorded deletions in
some autism cases [152], albeit away from miR873. The binding profile of miR-873-5p measured
by pulldown assay includes several autism risk genes at the synapse including all 3 members of the
SHANK family (SHANK1, SHANK2, SHANK3), as well as several neuroligins (NLGN2, NLGN3
and NLGN4X), and NRXN2. This targeting information, combined with the neural expression of
miR-873-5p and its host gene LINGO2 suggest a potential regulatory role in the synaptic context.
Despite this mutation being inherited from an unaffected parent, the measurable loss of binding po-
tential in several putative autism risk genes has lead us to hypothesise that it could contribute addi-
tively to autism risk. Consistent with this idea is the convergence of mutations seen in the neurexins
in this individual from the observed drop in NRXN2 binding potential from the paternally inherited
miR-873-5p mutation combined with the maternally inherited NRXN1 coding variant. Further exper-
imental assays are underway to evaluate the potential of this microRNA mutation to disrupt function
in vivo.
This work has allowed consideration of regulatory mutations in a biological network context. How-
ever, the application of domain-specific expert knowledge to such networks remains essential to their
utility. With microRNA and TFBS targeting information based on predictions, individual variants do
require validation. The principle aim of identifying these putative disrupted networks is to enable
the generation of these testable molecular hypotheses, particularly in the case of de novo mutations,
which contribute significantly to autism risk [101].
Public genomic resources are constantly improving, larger populations of SNVs will aid identification
of rare variants and projects like psychENCODE [153], aimed at generating detailed datasets of regu-
lation in the brain, can only improve interpretations of variants in regulatory regions. The approaches
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described here will be equally applicable to whole-genome sequencing datasets, and the evaluation
of variants identified in genome-wide association studies. Combined, more autism sequence data
and more genomic resources, and integrated approaches that examine regulatory variants in autism-
associated genes and pathways as identified in this study should further improve understanding of
how regulatory variants may contribute additively to autism risk.
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3.5 Supplementary
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Table 3.2: Biotinylated microRNA duplexes used in experiments. These are based on the hairpin predictions annotated by miRBase, with minor modifications (Added 3’
A on miR-873-5p WT bi and miR-873-5p Mut bi ) to bring overhangs closer to recommendations in [82]
miRNA 3p Biotinylated strand Sequence 3p Non-biotinylated strand Sequence 5p
hsa-miR-873 WT miR873-5p WT GCAGGAACUUGUGAGUCUCCUA miR873-3p GGAGACUGAUGAGUUCCCGGGA
hsa-miR-873 Mut miR873-5p Mut GCUGGAACUUGUGAGUCUCCUA miR873-3p GGAGACUGAUGAGUUCCCGGGA
cel-miR-67 celmir67-3p UCACAACCUCCUAGAAAGAGUAGA celmir67-5p CGCUCAUUCUGCCGGUUGUUAUG
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Figure 3.5: Proportions of 5’UTR, 3’UTR, coding, promoter and enhancer regions that have sufficient read
depth to detect SNVs (SNV-callable regions defined as having >= 20 reads in 90% samples), with distribu-
tions displayed relative to the start and end of the coding regions. Coverage was calculated across all UCSC
transcripts on hg19. Introns were omitted from the calculations and are not shown on this diagram.
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Figure 3.6: Enrichment of regulatory variants found in different feature classes across from cases and 1kgenome controls (from 1000 genomes) in AXAS-ASD set of
autism-associated genes from the literature and their protein-protein interactors [119]. To account for differences between sample numbers and numbers of effected
genes, boxplots show counts of regulatory-mutation hosting genes (200 genes) that fall within the gene set of interest, across randomly selected subsets of regulatory
mutations (n =1000), considering only genes annotated in UCSC and RefSeq. MicroRNA target sites are 3’UTR only as used in analysis. Control samples are from
European population of 1000 genome project [114]
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Figure 3.7: Raw counts of miR-873-5p expression across different brain tissue types as described in BrainSpan
database [103]. Error bars reflect 95% confidence interval. Tissue codes are as per BrainSpan designations,
specifically; DFC: Dorsolateral prefrontal cortex, VFC: Ventrolateral prefrontal cortex, MFC: Anterior (ros-
tral) cingulate (medial prefrontal) cortex, OFC: Orbital frontal cortex, M1C: Primary motor cortex, S1C: Pri-
mary somatosensory cortex, IPC: Posteroinferior (ventral) parietal cortex, A1C: Primary auditory cortex, STC:
Posterior (caudal) superior temporal cortex, ITC: Inferolateral temporal cortex, V1C: Primary visual cortex,
HIP: Hippocampus, AMY: Amygdaloid complex, STR: Striatum, MD: Mediodorsal nucleus of thalamus, CBC:
Cerebellar cortex.
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Table 3.3: Table of rare variants in mature microRNAs. Including only those microRNAs having SNVs in cases, observed in fewer than 5 families. The variant within
the mature microRNA is shown in red, with the 2-7bp canonical seed region in bold. The ‘predicted target loss’ shows the proportion of predicted genes that genes that
were not predicted to be targeted by the mutant allele. Because these SNVs fall within mature microRNA regions already, these have not undergone the full MAF (Minor
Allele Frequency) and functional filtering step described in the supplementary methods. Only the 1kgenome MAF frequency (as listed in table) was considered.
microRNA Chr Position MAF Effect on Mature microRNA Predicted
Targets
Predicted
Variant
Targets
Predicted
Target Loss
miR-139-3p chr11 72326125 - UGGAGAC[G=>A]CGGCCCUGUUGGAGU 1451 2411 56%
miR-2110 chr10 115933921 - UUGGGGAAAC[G=>C]GCCGCUGAGUG 2402 1855 43%
miR-296-3p chr20 57392686 0.50% GAGGGUUGGGUGGAGG[C=>U]UCUCC 3326 3139 27%
miR-3162-5p chr11 59362602 0.06% UUAGGGAGUAGAAGGGUGGG[G=>A]AG 4070 4183 18%
miR-3190-5p chr19 47730221 - UCUGGCCAG[C=>U]UACGUCCCCA 1792 1689 28%
miR-3191-3p chr19 47730221 - UGGGGACGUA[G=>A]CUGGCCAGACAG 1667 1277 37%
miR-411-5p chr14 101489692 - UAGUAGACCGUAUAG[C=>U]GUACG 66 76 64%
miR-449b-3p chr5 54466508 - CAGCCACA[A=>G]CUACCCUGCCACU 1272 1930 19%
miR-4657 chr7 44921387 0.46% AAUGUGGAAGUG[G=>U]UCUGAGGCAU 1965 1580 51%
miR-4673 chr9 139414065 0.04% UCCAGGCAGGAG[C=>U]CGGACUGGA 3727 3958 19%
miR-4690-5p chr11 65403798 0.10% GAGCAGGCGAGGCUGGG[C=>U]UGAA 3283 3285 22%
miR-668 chr14 101521654 - UGUCACUCGGCUCGGCC[C=>U]ACUAC 1333 1384 29%
miR-873-5p chr9 28888941 - GC[A=>U]GGAACUUGUGAGUCUCCU 961 910 89%
miR-936 chr10 105807909 0.38% ACAGUAGAGGGAGGAAUCGCA[G=>A] 1486 1466 7%
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Table 3.4: Enrichment of genes having regulatory SNVs in co-expression modules described in [86]. P-values
were calculated with hypergeometric distribution in R, with BH multiple hypothesis correction [154]. Only
those genes included in both the Parikshak et al. (2013), analysis and in our combination UCSC and RefSeq
background were used in calculations, resulting in smaller module sizes.
Parikshak
2013 Module
Num Hits Query Size Module Size Background
Size
p-value BH p-value
M1 84 2141 556 13971 0.529 1
M2 108 2141 626 13971 0.078 0.27
M3 134 2141 759 13971 0.031 0.24
M4 37 2141 304 13971 0.931 1
M5 112 2141 659 13971 0.102 0.29
M6 29 2141 256 13971 0.960 1
M8 35 2141 185 13971 0.074 0.27
M9 12 2141 194 13971 1.000 1
M10 0 2141 26 13971 0.987 1
M11 59 2141 430 13971 0.807 1
M12 34 2141 288 13971 0.948 1
M13 84 2141 645 13971 0.948 1
M14 60 2141 429 13971 0.760 1
M15 32 2141 260 13971 0.902 1
M16 86 2141 416 13971 0.001 0.02
M17 116 2141 724 13971 0.276 0.67
M18 126 2141 718 13971 0.042 0.24
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Table 3.5: Cortical layer specificity of genes having regulatory mutations. Using the approach and tissue-
specificity data supplied by Parikshak et al. (2013) [86], enrichment was calculated for genes having regulatory
mutations in ASD cases in human fetal and adult primate cortical layers. The original source data (prior to
t-value calculations of [86]) was fetal layer expression from BrainSpan and adult Rhesus macaque cortical
layer data from [133]. Z-scores calculated and thresholded at 2.7 (FDR 0.01) as per [86].
Layer Mean t-value Population
Mean t-value
z-score Geneset
Expression
Fetal Layers (PCW 15-16) MZ 0.37 0.14 2.42 -
BrainSpan CPo 0.72 0.58 0.94 -
CPi 0.07 -0.03 0.74 -
SP 0.60 0.24 2.58 -
IZ 0.74 0.42 3.50 up
SZo -0.60 -0.17 -3.26 down
SZi -0.30 -0.19 -0.84 -
VZ -1.58 -0.96 -2.61 -
Fetal Layers (PCW 21) MZ -0.14 -0.29 1.14 -
BrainSpan CPo -0.07 0.14 -1.01 -
CPi 0.67 0.46 0.98 -
SP 0.61 0.36 1.84 -
IZ 0.33 -0.08 4.56 up
SZo 0.01 0.26 -1.85 -
SZi -0.73 -0.42 -2.09 -
VZ -0.43 -0.29 -0.73 -
Adult Primate L2 -0.20 -0.21 0.13 -
(Bernard et al. 2012) L3 -0.11 0.04 -2.52 -
L4 -0.01 -0.13 1.39 -
L5 0.12 0.19 -1.09 -
L6 0.19 0.11 1.01 -
86
CHAPTER 4
Effect of an ASD patient-derived miR-873-5p
seed region mutation on mRNA binding
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MicroRNAs are regulatory factors with broad yet specific targeting, which may play a role in neu-
rodevelopmental disorders such as autism. Recent years have seen a wave of autism sequencing
studies suggesting potential risk variants, but the interpretation of their biological relevance remains
challenging, particularly for non-coding variants such as those in microRNA genes. Our lab has
previously identified a rare inherited variant within the seed of microRNA miR-873-5p, and we hy-
pothesised that this mutation, while not causative, could contribute to an autism phenotype. We used
a biotinylated-microRNA mRNA pulldown assay to capture a transcriptome-wide binding profile of
both the wild-type and mutant miR-873-5p, followed by RNAseq. As previous analysis in chapter
3 had suggested targeting of several synaptic genes implicated in autism risk, this work focussed on
more general miR-873-5p associations and flagged a potential role in neuronal voltage-gated potas-
sium channels. The presence of the variant does appear to have a broad yet subtle dampening of
transcriptome-wide targeting trends. This analysis has aided the design of pertinent assays of biolog-
ical function.
4.1 Introduction
Autism (or Autism Spectrum Disorder; ASD) is a highly heritable neurodevelopmental disorder, and
despite a few proposed single gene candidates, recent exome sequencing studies have made it clear
that it is a disorder with diverse and multigenic genetic causes and risk factors. MicroRNAs are a
large class of regulatory genes whose function are thought to be important in neurological disorders
[41]. Though there have yet to be any single microRNA strongly linked to autism across multiple
studies, this is an active area of research [48, 51, 57, 106], encouraged by the example of miR-137 in
schizophrenia risk [42].
A previous study in our lab had detected a SNP (Single Nucleotide Polymorphism) in the seed re-
gion of the microRNA of miR-873-5p in an autistic individual [16, 65]. In the canonical model of
microRNA regulation, the seed region must be a perfect match to its target site in order to bind its
mRNA target, thus this mutation has the potential for significant disruption. This is a heterozygous
mutation, inherited from an unaffected parent, but not seen in public databases. So, although this SNP
is clearly not causative, as is to be expected for a complex disorder like autism, we hypothesised that
SNPs such as this one could subtly alter function and contribute to an autism phenotype.
The work described in chapter 3 [65] has already explored the potential effects of this miR-873-5p
variant in binding affinity among synaptic autism risk genes and how this combines with the network
of variants seen in the affected individual. Therefore, this chapter focusses on a more general putative
functionality of miR-873-5p, outside of the specific family context. It also examines the utility of
the biotinylated-microRNA mRNA pulldown (pulldown) assay in assessing microRNA targeting and
putative functionality.
MicroRNA miR-873 is located within the neuronally expressed LINGO2 gene, nearby another mi-
croRNA, miR-876, and the three genes have correlated expression [155]. MiR-873 has been studied
or found dysregulated in a number of diverse contexts, including cancers [156–159], immune system
[160, 161], and pregnancy [162–164]. There is also evidence for a neuronal function, as a heterozy-
gous deletion of this region has been observed in an individual with craniofacial abnormalities and
learning difficulties [155]. MiR-873 has also been detected differentially expressed in a memory-
impaired epileptic rat model [165].
Variants in miR-873 host gene LINGO2 (and its paralog LINGO1) have been suggested to play a
role in the neurological condition of essential tremor [151]. Deletions within the LINGO2 gene have
been detected in autistic individuals [152], but these do not include the miR-873 gene region. How-
ever, in mouse, LINGO2 (which also hosts mouse miR-873) is seen expressed in the central nervous
system during development [166], further underlining a potentially relevant expression context of
miR-873.
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To date, there have been no genome-scale studies of miR-873-5p targeting, so this study will use
microRNA pulldowns to examine which genes and pathways may be in vivo targets, and to evaluate
the effect of the detected SNP on binding at a global level. While effects of microRNA gene SNPs
can be predicted computationally [167], experimental validation is still required due to the high er-
ror rates inherent in any microRNA target prediction. Luciferase-based assays may be considered
the ‘gold-standard’ in microRNA-target validation, and can easily be used to quantify the effects
variants in a low-throughput, gene-by-gene manner. The overall targeting profile of a microRNA
may be assessed directly through biochemical pulldown techniques [80–83], or indirectly through
over-expression or silencing assays. However, there is currently little literature evaluating the global
effects of a microRNA gene SNP in vitro with such techniques. This work demonstrates the utility of
pulldown-assays approach in testing other potentially deleterious SNPs found in microRNA genes.
This work uses microRNA pulldown experiments to investigate the effect of a patient-derived miR-
873-5p mutation on its transcriptome-wide binding profile. Our results previously presented in chap-
ter 3 suggest it target sites include several autism risk genes at the synapse, which may combine with
another protein coding mutation in NRXN1 [16, 65]. In this chapter, we additionally flag signifi-
cant targeting of voltage-gated potassium channel genes. Overall, we outline a workflow suitable for
downstream analysis of SNPs occurring within microRNA genes, which aids the efficient design of
relevant downstream biological function assays.
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4.2 Methods
4.2.1 MicroRNA target site predictions
MicroRNA target site predictions were made as described in Chapter 2. Briefly, we used the inter-
section of sites predicted by RNAhybrid [71] and miRanda [92] for all microRNAs listed in miRBase
(v19) [94] across all human 3’UTRs the hg19 UCSC knownGene annotation. With the noisiness of
microRNA target site prediction tools, it is often useful to use an overlapped set [66, 69], so we chose
these two programs for their different approaches - miRanda’s general model of seed binding and en-
ergy [92], and RNAhybrids free-energy focus [71]. A given gene was considered a predicted target of
a microRNA if it had at least one target site prediction on any of its transcripts, and UCSC identifiers
were mapped to gene symbols for downstream analysis.
For this analysis, microRNA target sites were also predicted for miR-873-5p across 5’UTRs and
coding regions in the same manner.
4.2.2 Biotin-tagged microRNA mRNA-pulldown assay
Biotin tagged microRNA pulldown experiments were used to identify bound mRNA transcripts of
the miR-873 wild-type (WT) and SNP-containing (Mut) microRNAs. The full dataset and method
has already been presented in [65] (Chapter 3), and the method was originally adapted from [82, 83].
Briefly, biotin-tagged microRNAs were transfected into SH-SY5Y cells (a neuroblastoma cell line),
and then after cell-lysis, were captured along with their targeted transcripts to magnetic streptavidin
beads.
In addition to the four replicates of paired whole-transcriptome (Control samples - Con) and post-
pulldown (Pulldown - PD) samples described in [65], there were there were also four mock-transfected
SH-SY5Y libraries (Untransfected), which were shared with [168] (run concurrently), making a total
of 20 libraries. These samples allowed us to measure the effect of the microRNA transfection itself
in an exogenous overexpression experiment.
As per [65], RNA libraries were purified with RNAeasy columns (QiAGEN), and sequencing libraries
were prepared from 100ng input RNA with Illumina TruSeq Stranded mRNA kit. Libraries were
sequenced across two lanes using v4 SBS chemistry on an Illumina HiSeq2000.
During the pilot phase prior to sequencing, we tested for the enrichment of three predicted target genes
in the pulldown assay (BUD31, NEUROD1 and SEPT4), against a control of EMC7, HPRT1 and
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PSMB4 combined. RT-qPCR primers are listed in Supplementary Table 4.2. RT-qPCR experiments
were performed and analysed as described in Chapter 5 [168].
4.2.3 Staining
To check if biotinylated microRNAs were efficiently transfected into cells we stained for the biotin
tag after transfection with biotinylated microRNA duplexes. Transfection was performed as per pull-
down, but scaled to 24 well plates. Then cells were fixed in 4% PFA, rinsed with PBS, and blocked
with 2% BSA in .3% Triton X-100 (TX) for 30 min at room temp for 2 hours. Cells were incubated
with Alexa Flour 594 streptavidin (Illumina) in BSA/PBS/TX mix for 1 hour at room temperature on
rotation, followed by 10 minutes of DAPI incubation.
4.2.4 Sequence analysis and enrichment calculations
Sequence analysis was performed as described in [65], aligning to the to the human GRCh38 En-
sembl release 83 transcriptome with TopHat2 (v2.1.0, options: -p 8 –library-type fr-firststrand –no-
novel-juncs) [135], getting gene counts with HTseq (HTSeq-0.6.1p1, options: –order=name -f bam
-s reverse -i gene name -m union) [169], and using DEseq2 (v1.8.2) [136] to calculate enrichment in
paired pulldown samples, or differential expression changes after transfection (to measure the effect
of exogenous overexpression). Additionally, in order to examine patterns of splice variants, DEXseq
(v1.14.2, options: dexseq count.py -p yes -s reverse -f bam -r name) was used to calculated differen-
tial expression at the exon level [170].
Again, as per [168] we used the GSEA (Gene Set Enrichment Analysis) (v2-2.1.0) (pre-ranked anal-
ysis, weighted method) to evaluate functional associations from fold-change ranked pulldown data
[171]. Enrichment profiles were compared with public databases Reactome [142], KEGG [172], and
Gene Ontology (GO) (Biological Process (BP) and GO Cellular Component (CC)). FDR and nominal
pVal statistics were interpreted according to recommendations in GSEA documentation [171].
4.2.5 Annotations databases and tools
The pulldown analysis used human genome version GRCh38 and Ensembl gene annotation (En-
sembl v83). The predicted target sites on the hg19 UCSC genome annotation were translated via
official gene symbols. The differential expression analyses and plotting were performed in R (version
3.2.2).
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4.3 Results
4.3.1 MicroRNA miR-873-5p binding measured by pulldown assays
We used a biotin-tagged microRNA pulldown assay to measure the transcriptome-wide mRNA bind-
ing profiles of the wild-type and mutant miR-873-5p.
The validity of the pulldown was checked prior to RNAseq. Staining of transfected cells demonstrated
that the microRNAs were persistent in the cells at the timepoint (24hrs) used for the pulldowns (Sup-
plementary Figure 4.9). Pilot RT-qPCR assays against several predicted target genes indicated that
NEUROD1 and SEPT4 were enriched in the pulldown samples but BUD31 was not (Supplemen-
tary Figure 4.10a), and all levels were unchanged in the transfection contrast (Supplementary Figure
4.10b). However, the enrichment of these genes was not seen in the subsequent pulldown results.
There were 3226 genes significantly enriched in the wild type miR-873-5p pulldown sample com-
pared to the corresponding whole transcriptome, and 3249 genes for miR-873-5p with the variant.
There were no significantly differentially expressed genes following transfection of the miR-873
mimics into the cells. The MA-plots highlight the widespread difference seen in the pulldown contrast
compared to simple transfection of the microRNAs (Figure 4.1).
Results of the enrichment calculation output from DEseq2 are available from figshare:
(https://dx.doi.org/10.6084/m9.figshare.3581781.v1).
Two genes have previously been identified in the literature as target genes of miR-873-5p by way of
luciferase assays. Of these, SRCIN1 [173] was detected in our pulldown assay (p=1.63×10−18, as
calculated by corrected DEseq2 enrichment) but BCL2 [174] was not (p=1).
Similarly no differentially expressed exons were detected from DEXseq analysis in the transfection
experiments. In the WT or Mut pulldowns there were respectively 1835 or 2393 gene groups (proxi-
mal groups analysed as a unit by DEXseq) having differentially enriched exons reported. The overall
distributions of log2 enrichment levels was similar across 5’UTRs, 3’UTRs and coding regions (Fig-
ure 4.2).
A PCA (Principal Component Analysis) of the sequenced libraries shows obvious separation between
the pulldown and whole lysate samples in PC1. There is clear separation within the pulldown samples
of miR-873-5p WT versus Mut across PC3, compared with no separation of the transfected and
untransfected full cell transcriptomes (Figure 4.3). Some batch effect is evident between the replicates
in PC2 (Figure 4.3), but this is not of concern since the analyses are balanced across replicates.
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Figure 4.1: MA plots for differential expression and enrichment contrasts. Genes that are significantly enriched
are marked in red. Plots created with in R with DEseq2 [136].
There is a slight negative correlation (r=-0.15) between the pulldown enrichment and the transcriptome-
wide non-significant expression changes in the transfection assays for the miR-873-5p WT (Figure
4.4). This is consistent with the expected action of a microRNA, with captured mRNAs slightly more
downregulated. Notably, the effect is almost absent in the mutant (r=-0.065), potentially indicating a
less consistent trend in any biological response.
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Figure 4.2: Distributions of enrichment changes across exons from different gene regions. Each boxplot plots
the log2 fold changes calculated by DEXseq for all exons (or more specifically, contiguous sequences that
DEXseq constructs during its analysis) that are mostly (75%) within 3’UTR, 5’UTR or coding regions. Exons
that do not meet those conditions are not plotted. Boxplots of log2 fold-change generated in R for miR-873 WT
results. Outliers with log2 FC more than 3 not included.
(a) PC1 vs PC2 (b) PC1 vs PC3
Figure 4.3: PCA (Principal component analysis) plot showing relationship of the sample transcriptomes. Gen-
erated in R with DEseq2 [136].
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(a) miR-873 WT (b) miR-873 Mut
Figure 4.4: Pulldown results vs transfection results for (a) miR-873-5p WT and (b) miR-873-5p Mut. These plots
show the slight negative correlation between enrichment of a gene in the pulldown results and downregulation
in the transfection (Exogenous overexpression), by plotting the log2 fold-changes of both DESeq2 contrasts.
Displayed ‘r’ is the Pearson product-moment correlation calculated in R. Only genes measured in both assays
are included.
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4.3.2 MicroRNA target predictions versus pulldown assay
We tested the correlation of predicted miR-873-5p target sites with observed enrichment in the pull-
down assay. There was a significant enrichment of predicted miR-873-5p target genes within the en-
riched genes of both the WT and Mut pulldowns (p=1.17×10−12 in WT pulldown, p=3.88×10−13 in
Mut) (Figure 4.5a-4.5b). However enrichment was also seen in the predicted target sites of unrelated
let-7a, but the p-values are much less significant (p=4.30×10−4 in WT pulldown, p=1.36×10−2
in Mut). This may indicate the contribution other confounding factors such as sequence length or
expression levels, but the overall enrichment is more than this background.
There was significant enrichment of genes enriched in the WT pulldown among those genes having
predicted targets sites on the 5’UTR (p=1.32×10−3) and coding regions (p=1.88×10−6), though the
proportion of pulldown genes and significance is lesser than for the 3’UTR (Table 4.1). However, this
trend does not hold in the mutant microRNA pulldown, where proportions may be more even (Table
4.1).
Among the predicted target sites, there was slight correlation of the free energy (strength of binding)
with the extent of enrichment in the pulldown (Figures 4.5c and 4.5d).
Table 4.1: Pulldown results compared to predictions across 3’UTRs, 5’UTRs and coding regions. P values
reflect the hypergeometric probability of at least this number of significantly enriched genes in the pulldown
assays, from those predicted in the specific gene region. There is no multiple hypothesis correction. The
‘Total Population’ background set includes only those genes having 3’UTRs, 5’UTRs and coding regions (CDS)
annotated, intersected with the assayed genes in each pulldown. PD indicates ‘pulldown’ (note that these
counts differ slightly from Figure 4.5 due to the need to include 5’UTR and CDS annotations in the background
of these calculations).
microRNA Region Predicted and PD % of Predicted Predicted PD Total Population pval
WT 3UTR 233 33% 701 2719 12379 9.27E-13
WT 5UTR 103 29% 358 2719 12379 1.32E-03
WT CDS 321 27% 1169 2719 12379 1.88E-06
Mut 3UTR 235 34% 695 2757 12241 1.54E-12
Mut 5UTR 119 34% 354 2757 12241 8.30E-07
Mut CDS 357 31% 1154 2757 12241 2.25E-12
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(a) WT PD vs miR-873-5p predictions (b) Mut PD vs miR-873-5p predictions
(c) WT PD vs Free energy (d) Mut PD vs Free energy
Figure 4.5: Correlation of predicted targets with observed enrichment in pulldown assay. Venn diagrams show
the overlap of miR-873-5p predicted target genes with genes significantly enriched in the (a) miR-873-5p WT
and (b) miR-873-5p Mut pulldown assays. P-values calculated for on a hypergeometric distribution against the
common background of genes used in predictions that were measurable in assay. Correlation plots for (c) WT
and (d) Mut contrast the shrunken fold-change calculations calculated for the pulldown assays with DEseq2
[136] with the sum of free-energy calculations for the RNAhybrid for the best miR-873-5p target sites predicted,
for all genes having predicted target sites [71], genes outside the main cluster likely having multiple sites. Note
that this is only those genes with predicted target sites (on hg19) and differential expression measured (GRCh38
annotations), matched via gene symbol. To avoid biases due to very long 3’UTRs, a single transcript was used
to represent each gene, selecting one having a median length 3’UTR. The solid horizontal line indicates the
average log2FC for the plotted predicted target genes, and the dotted line for all genes. Blue linear fit line and
95% grey confidence interval calculated in R stat smooth function. R correlation and p-values calculated with
Pearson’s product-moment method implemented in R.
4.3.3 Effect of SNP on targeting
Through pulldown experiments on both the wild-type and mutant miR-873-5p, we aimed to test the
relative effect of this SNP on target binding. Notably the presence of the SNP does not completely
change the binding profile of the microRNA in this pulldown assay. There is still similarity between
the WT and Mut microRNA pulldown binding profiles (Figure 4.6b), and even some correlation
between the non-significant fold changes seen in the exogenous overexpression assay (Figure 4.6a).
However, when enrichment is considered at the individual replicate level (a simple log2 fold-change of
a single pulldown sample and its matched control), there is still more correlation between replicates
of the same condition (ie. wild-type or mutant microRNA) than between conditions (Figure 4.7).
Pearson’s correlation between pairs of replicates of either microRNA, as shown on Figure 4.7, were
significantly higher than those between wild-type and mutant pairs (p = 0.0007, unpaired t-test).
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The difference in enrichment of each gene between the wild-type and mutant pulldown experiments is
plotted in Figure 4.6b. Among the genes enriched in both pulldowns (top right quadrant), the overall
angle of the loess fit indicates a greater proportion of genes with stronger binding in the wild-type
than in the mutant, compared to the reverse. In contrast, among the non-enriched genes (bottom left
quadrant) there is a more even relationship. This supports the influence of the SNP on mRNA-binding
in this assay, as the difference is seen specifically in the enriched genes that are being considered as
microRNA targets, but not the rest of the transcriptome.
(a) Transfection differential expression (b) Pulldown enrichment
Figure 4.6: Relationship of wild-type and mutant exogenous overexpression and pulldown results. (a) Plots
the fold-change seen in the transfected cells versus the untransfected controls. Note that for these transfection
assay no individual gene is significantly differentially expressed for either microRNA. Linear fit (calculated
with lm method in R) shown in blue. (b) Plots the fold-change (where positive values indicate to enrichment)
for each gene of the wild-type miR-873-5p pulldown, versus the mutant pulldown. A loess curve is fitted to the
values in red. Correlation r values are calculated with Pearson’s product-moment method implemented in R.
Fold-change values are shrunken-fold changes calculated by DEseq2.
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Figure 4.7: This matrix of plots shows the correlation between each individual pulldown replicate (matched
pulldown and control samples. Shows correlation within wild-type (within blue box) and mutant (within green
box) groups, as well as between the two groups (outside boxes). Plots show genes with at least 10 reads across
all sequence libraries, and having at least one read in each. Pearson’s correlations between each pair of
samples shown in the top right panels.
4.3.4 MiR-873-5p targeting in voltage-gated potassium channels
Because microRNAs are capable of acting broadly but subtly across many targets [175], we ap-
plied a GSEA analysis to our full genelist to evaluate functional associations of the microRNA
targets (Supplementary Table 4.3). The results suggest an association of miR-873-5p WT with
potassium ion transport, with top enriched terms ‘Potassium Channels’ (p=1.54×10−3) and ‘volt-
age gated potassium channels’ (p=1.17×10−3) in the Reactome database, and ‘Potassium ion trans-
port’ (p=3.89×10−3) in GO BP and ‘Voltage gated potassium channel complex’ (p=3.39×10−3) in
GO CC (Supplementary Table 4.3). Similar but less focussed and weaker trends were observed for
the miR-873-5p Mutant pulldown, which had top terms of ‘RORA Activates circadian expression’
(p=2.47×10−3) in Reactome, ‘Positive regulation of transcription’ (p=9.70×10−4) in GO BP and
‘Voltage gated potassium channel complex’ (p=1.30×10−2) in GO CC (Supplementary Table 4.3).
The leading edge subset of genes reported by GSEA are those that contribute to the maximal enrich-
ment score, and because it is ranking based, can also include those not significantly enriched. In the
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the miR-873 WT pulldown results against the Reactome pathway ‘Voltage gated Potassium channels’
(REACT 75770), ranked in descending order of contribution these are: KCNC4, KCNC3, KCNC1,
KCNG1, KCNH2, KCNQ1, KCNF1, KCNH4, KCNH3, KCNB1, KCNAB2, KCNQ4, KCND1,
KCNQ3, KCNQ2, KCNH6, KCNH1 and KCNAB3. Overall enrichment of voltage-gated potassium
channel genes is visualised in Figure 4.8, using the families described in [176].
These include several members Kv7 potassium channel gene family; KCNQ1, KCNQ2 and KCNQ3,
where both KCNQ1 and KCNQ2 are significantly enriched (Figure 4.8), and KCNQ2 and KCNQ3
have been associated with autism [177, 178].
In addition to the putative targeting of miR-873 to Kv7 channel genes, the individual from which the
tested SNP is derived also has a paternally inherited coding sequence mutation in KCNQ5 at position
(chr6:73332249). This results in a valine to glycine amino acid change within the S2 transmembrane
domain [179]. This position does vary in the other human KCNQ proteins, though it is occupied by a
hydrophobic amino acid in all five (specifically valine, leucine or isoleucine) [179].
Similarly, there is also significant enrichment of 3 of the 4 Kv3 channels - KCNC1, KCNC3 and
KCNC4, though KCNC2 could not be assayed. Other voltage-gated channel genes enriched for in the
miR-873-5p pulldown experiment were KCNB1, KCND1, KCNG1 and KCNH2 and KCNH4.
Figure 4.8: MiR-873-5p targeting of voltage-gated potassium channel genes. Gene families are as described in
[176]. Genes significantly enriched in the miR-873 WT pulldown assay are coloured blue, non-enriched genes
shown in grey, and those that were not measured (usually due to low expression levels) are white. Red text and
outline indicates a protein-coding mutation described in [16, 65].
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4.4 Discussion
In previous work we highlighted a variant within the seed region of miR-873-5p in an autistic indi-
vidual, and investigated its potential implications in regulation of synaptic risk factor genes [16, 65].
This chapter furthers that analysis, aiming to characterise the general binding profile of miR-873-5p
for insight into its biological function, and to evaluate the pulldown assay as a tool for assaying the
effects of microRNA SNPs. To this end we continued analysis of the microRNA pulldown assays
used to quantify the biochemical binding affinity of both the wild-type and mutant miR-873-5p. A
functional association analysis highlighted miR-873-5p targeting of several voltage-gated potassium
channel genes, potentially serving a role in their neuronal regulation. The pulldown results indicate
that the miR-873-5p SNP may cause a subtle but broad loss in binding affinity.
Previous studies concerning miR-873-5p function have been quite broad, from cancers [156–159] to
immunity [160, 161], and pregnancy [162–164]. However, the overall pattern of enrichment of the
miR-873-5p WT pulldown experiment measured with GSEA suggested an association with potassium
channel signalling (Supplemtary Table 4.3), which has not been previously suggested. This associa-
tion was consistent between both the Reactome and Gene Ontology databases. There has been some
work proposing a role for potassium channels in autism risk [178, 180], although most research in
these ion channels concerns epilepsy risk and long QT syndromes. However, there has been some
exploration into miR-873’s role in memory using a memory-impaired epileptic rat model [165], pos-
sibly indicating a potential biological relevance, especially given the degree of co-morbidity between
autism and epilepsy [181].
Although potassium channels are important in many non-neuronal tissues, we would expect that miR-
873-5p effects are more relevant in their neuronal context, due to its neuronal expression, correlated
with host gene LINGO2 [155]. This is further supported by the primary expression pattern of the
mouse homolog of LINGO2 (which also hosts miR-873) in the central nervous system during early
embryogenesis (E10) [155, 166].
More specifically, miR-873-5p appears to target several members of the Kv7 channel family. Ion
channels formed from these genes contributed to the ‘M-current’ signal [182, 183], which plays a
role in controlling excitability in neurons [184]. Protein-coding mutations in these genes have been
associated with several different disorders, primarily epilepsy, long QT syndrome and deafness [183].
However, more subtle effects might be expected in microRNA mistargeting.
Both KCNQ2, and KCNQ3 have been suggested to play a role in autism risk [177, 178]. The KCNQ3
association arises from an observed translocation mutation, and a potential association of a rare SNP
(rs74582884) [178]. That SNP was shown to have a functional impact on potassium channel electrical
signalling, specifically when it complexed with Kv7.5 (KCNQ5) [178]. However, rs74582884 on its
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own is a rare SNP that does occur in unaffected individuals [178], including within the 1000 genomes
project [114], as well as inherited in another autism family in the study used to identify this variant
[16, 65]. Although KCNQ1 was also enriched in the pulldown assay, it is not of interest in this work,
as it is more associated with cardiac expression and functions [176, 183, 185].
MiR-873-5p pulldown also significantly enriched for KCNH2 (Kv11.1), for which a transcript variant
has been associated to schizophrenia [186]. Recent work has suggested that the electrophysiological
behaviour of the encoded channel gene can be altered by risperidone treatment [187], a drug some-
times used in autism therapy [188].
On the whole, our results have suggested that the SNP in miR-873-5p may subtly reduce its usual
binding affinity. The results of miR-873-5p wild-type and SNP in both the pulldown assay enrichment
and in the exogenous overexpression (Figure 4.6) are broadly correlated. However, among those genes
that are enriched in the pulldown there is a broad reduction in enrichment among the SNP pulldown
(Refer to fit line in Figure 4.6a), which is not mirrored in the depleted genes, consistent with a loss
of affinity among the captured mRNAs. Also, despite having a similar count of significantly enriched
genes, the wild-type microRNA pulldown has slightly more significant agreement with predicted
target sites (Figure 4.5c-4.5d), slightly less correlation between pulldown and overexpression results
(Figure 4.4), and slightly less significant scores in the GSEA functional associations (Figure 4.3).
Additionally, the higher agreement of pulldown results with predicted target site on the 3’UTR seen
in the wild-type is not clear in the mutant (Table 4.1), potentially indicating that this variant targets
more randomly and may not fit neatly into its usual mechanisms and pathways. However, it should be
remembered that these results are based on artificial levels of miR-873-5p expression, and the SNP
may behave differently at physiologically-relevant levels in vivo [82].
This work also sought to evaluate the use of this microRNA pulldown assay in examining the effect
of microRNA SNPs. This is important because many mutations are de novo or rare [9, 11] and we
need efficient work-flows to evaluate these in future. Analysis of the resulting sequence indicates
no particular biases to sequence regions (Figure 4.2), meaning that it can be analysed simply with
standard RNAseq approaches, making the pulldown assay a fairly straightforward approach to get a
broad unbiased view of a microRNA’s binding profile.
However the pulldown assay is an assay contrasting the biochemical ‘pulldown’ treatment to a cell,
and the spread of enrichments is quite broad when considered versus the context of a typical cellular
condition versus control assay (Figure 4.1). Essentially this is an assay of biochemical affinity within
a over-expressing cellular model, which provides a guide to what a microRNA is capable of binding,
rather than what is actually happening in the cell typically. These pulldown assays are well com-
plemented by a contrast of exogenous overexpression with untransfected cells. Even though in this
miR-873-5p study we saw little differential expression, other microRNAs may behave differently, and
our experiment benefited from the increased statistical power of pairing libraries of pulldown samples
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with their matched whole transcriptome.
The next step in this work is to validate the potential effects of such a mutation in a cellular model. In
ongoing work, dendrite outgrowth assays in mouse explant neurons are being employed to evaluate
the effects of miR-873-5p and its SNP in a biologically relevant cellular context. Luciferase assays are
planned to quantify the impact of the miR-873-5p SNP on several target sites of interest in NLGN2,
SHANK3, SYNGAP1, and ARID1B. Finally a CRISPR knock-out mouse model will be created and
used to assess any behavioural effects.
In conclusion, this chapter proposes that miR-873 could play a role in the regulation of potassium
channels in the brain. This supports our hypothesis that a variant that interferes with its usual binding
profile might, in conjunction with other variants, potentially contribute to an autism phenotype. Fur-
thermore we have established a workflow that enables going from a sequence variant through to this
transcriptome-wide assay, which in turn is enabling the informed design of relevant functional assays
currently under way - further narrowing the gap from genomic variation to function.
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4.5 Supplementary
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Table 4.2: Primer sequences used in RT-qPCR of predicted miR-873 target genes
Target Class Forward primer Forward Sequence Reverse Primer Reverse Sequence
EMC7 control EMC7-F1 CAGTTGTTCCAGGGGTGAAG EMC7-R1 GAACCACAAAACTCCCATCTG
HPRT1 control HPRT1-F1 TGCTGAGGATTTGGAAAGG HPRT1-R1 GCACACAGAGGGCTACAATG
PSMB4 control PSBM4-F1 GTGGACATGCTTGGTGTAGC PSBM4-R1 CTCGGTCTGGCTTAGCACTG
BUD31 test BUD31-F1 ATGGCTGGGAGTTGATTGAG BUD31-F1 AAGATGGGCCACAGAGATTC
NEUROD test NEUROD-F1 AGGCCCCAGGGTTATGAG NEUROD-F1 CTCTCGCTGTACGATTTGGTC
SEPT4 test SEPT4-F1 CTCACCATTGTGGACACACC SEPT4-F1 GTATTCTGCCACAGGCTTCC
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(a) miR-873-5p WT (b) miR-873-5p Mut
(c) cel-miR-67 (d) Mock-transfected
Figure 4.9: Staining shows small distinct clusters of streptavidin-594 staining in SH-SY5Y cells transfected
with biotinylated synthetic microRNAs miR-873, WT and Mutant, and cel-miR-67, but no such signal is seen
in mock-transfected control cells. Images were made by merging light images, with DAPI (blue) channel and
Alexa Flour 594 Streptavidin (red). Images were coloured in FIJI imageJ and of the red channel was increased
consistently across all images via Adobe Photoshop levels tool.
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(a) Pulldown (b) Transfection
Figure 4.10: RT-qPCR results for a) pulldown and b) overexpression of microRNA miR-873 wild-type (WT)
and Mutant (Mut) and control cel-miR-67. Error bars reflect 95% confidence interval. Significance tested with
students t-test, paired in (a), and unpaired in (b), * indicates significance (p-value <0.05), and + indicates
marginal significance (p-value <0.1). Relative expression is 2-∆∆CT.
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Table 4.3: MicroRNA miR-873 pulldown GSEA vs public databases. A summary of GSEA (Gene Set Enrichment Analysis) [171] looking at the global expression
or enrichment changes in pulldown and transfection experiments against several public databases; Reactome [142], KEGG [189], Gene Ontology (GO) Biological
Process (BP) and GO Cellular component (CC) . GSEA input was a ‘pre-ranked’ list of all tested genes sorted by DESEQ2 log2FC values (where higher values
mean greater enrichment) with ‘weighted’ scoring. Normalised Enrichment score and Nominal p-value are described in the GSEA documentation.
MicroRNA Database Annotation Size Normalised
Enrichment
Score
Nominal pVal FDR qVal
miR-873-5p WT GO BP POTASSIUM ION TRANSPORT 31 2.14 0.00E+00 3.89E-03
POSITIVE REGULATION OF CELLULAR
METABOLIC PROCESS
162 1.99 0.00E+00 1.71E-02
SYNAPTIC TRANSMISSION 103 1.99 0.00E+00 1.17E-02
POSITIVE REGULATION OF TRANSCRIPTION 118 1.99 0.00E+00 9.28E-03
G PROTEIN COUPLED RECEPTOR PROTEIN
SIGNALING PATHWAY
141 1.98 0.00E+00 9.00E-03
TRANSMISSION OF NERVE IMPULSE 113 1.98 0.00E+00 7.50E-03
POSITIVE REGULATION OF CELLULAR PROTEIN
METABOLIC PROCESS
34 1.97 1.49E-03 6.71E-03
NERVOUS SYSTEM DEVELOPMENT 283 1.96 0.00E+00 7.24E-03
CELL CELL SIGNALING 193 1.95 0.00E+00 7.73E-03
MONOVALENT INORGANIC CATION TRANSPORT 55 1.95 0.00E+00 7.15E-03
POSITIVE REGULATION OF METABOLIC
PROCESS
167 1.93 0.00E+00 8.00E-03
POSITIVE REGULATION OF CELLULAR
COMPONENT ORGANIZATION AND BIOGENESIS
27 1.92 0.00E+00 8.23E-03
POSITIVE REGULATION OF
NUCLEOBASENUCLEOSIDENUCLEOTIDE AND
NUCLEIC ACID METABOLIC PROCESS
125 1.91 0.00E+00 8.79E-03
POSITIVE REGULATION OF PROTEIN
METABOLIC PROCESS
36 1.91 1.48E-03 8.30E-03
G PROTEIN SIGNALING COUPLED TO CYCLIC
NUCLEOTIDE SECOND MESSENGER
44 1.88 0.00E+00 1.19E-02
METAL ION TRANSPORT 65 1.84 0.00E+00 1.77E-02
CATION TRANSPORT 83 1.81 0.00E+00 2.51E-02
CYCLIC NUCLEOTIDE MEDIATED SIGNALING 46 1.8 2.90E-03 2.84E-02
TRANSMEMBRANE RECEPTOR PROTEIN
TYROSINE KINASE SIGNALING PATHWAY
59 1.79 0.00E+00 2.90E-02
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MicroRNA Database Annotation Size Normalised
Enrichment
Score
Nominal pVal FDR qVal
SMALL GTPASE MEDIATED SIGNAL
TRANSDUCTION
71 1.78 0.00E+00 3.03E-02
miR-873-5p WT GO CC VOLTAGE GATED POTASSIUM CHANNEL
COMPLEX
23 2.06 0.00E+00 3.39E-03
INTRINSIC TO PLASMA MEMBRANE 481 1.81 0.00E+00 4.23E-02
INTEGRAL TO PLASMA MEMBRANE 469 1.79 0.00E+00 3.48E-02
CELL JUNCTION 50 1.75 2.80E-03 3.70E-02
INTERCELLULAR JUNCTION 35 1.74 0.00E+00 3.43E-02
ADHERENS JUNCTION 17 1.67 1.77E-02 6.18E-02
EXTRACELLULAR SPACE 78 1.5 1.19E-02 2.25E-01
APICOLATERAL PLASMA MEMBRANE 17 1.48 5.56E-02 2.25E-01
miR-873-5p WT KEGG KEGG NEUROACTIVE LIGAND RECEPTOR
INTERACTION
88 2.19 0.00E+00 0.00E+00
KEGG NOTCH SIGNALING PATHWAY 39 1.97 0.00E+00 5.44E-03
KEGG AXON GUIDANCE 109 1.89 0.00E+00 1.31E-02
KEGG ACUTE MYELOID LEUKEMIA 51 1.87 0.00E+00 1.34E-02
KEGG BASAL CELL CARCINOMA 39 1.83 0.00E+00 1.98E-02
KEGG ALDOSTERONE REGULATED SODIUM
REABSORPTION
25 1.75 4.69E-03 4.03E-02
KEGG VEGF SIGNALING PATHWAY 51 1.75 2.91E-03 3.58E-02
KEGG MELANOGENESIS 74 1.66 1.38E-03 7.92E-02
KEGG THYROID CANCER 26 1.66 7.78E-03 7.16E-02
KEGG GLYCOSAMINOGLYCAN BIOSYNTHESIS
CHONDROITIN SULFATE
19 1.62 1.21E-02 8.74E-02
KEGG HEDGEHOG SIGNALING PATHWAY 34 1.61 8.84E-03 9.01E-02
KEGG ENDOCYTOSIS 149 1.6 1.20E-03 8.94E-02
KEGG PROSTATE CANCER 77 1.58 9.19E-03 9.79E-02
KEGG WNT SIGNALING PATHWAY 122 1.58 1.24E-03 9.83E-02
KEGG BLADDER CANCER 34 1.57 2.11E-02 1.01E-01
KEGG CHEMOKINE SIGNALING PATHWAY 113 1.56 2.50E-03 9.74E-02
KEGG CYTOKINE CYTOKINE RECEPTOR
INTERACTION
82 1.56 6.60E-03 9.26E-02
KEGG PANCREATIC CANCER 63 1.56 8.25E-03 9.31E-02
KEGG ADHERENS JUNCTION 68 1.56 6.55E-03 8.82E-02
KEGG TYPE II DIABETES MELLITUS 33 1.54 3.03E-02 9.85E-02
miR-873-5p WT Reactome REACTOME POTASSIUM CHANNELS 55 2.2 0.00E+00 1.54E-03
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MicroRNA Database Annotation Size Normalised
Enrichment
Score
Nominal pVal FDR qVal
REACTOME VOLTAGE GATED POTASSIUM
CHANNELS
22 2.12 0.00E+00 1.17E-03
REACTOME NEURONAL SYSTEM 185 1.98 0.00E+00 1.15E-02
REACTOME GPCR LIGAND BINDING 122 1.94 0.00E+00 1.83E-02
REACTOME INHIBITION OF INSULIN SECRETION
BY ADRENALINE NORADRENALINE
22 1.85 1.61E-03 4.88E-02
REACTOME CHONDROITIN SULFATE DERMATAN
SULFATE METABOLISM
42 1.81 1.43E-03 5.94E-02
REACTOME GLYCOSAMINOGLYCAN
METABOLISM
84 1.78 0.00E+00 7.32E-02
REACTOME CLASS B 2 SECRETIN FAMILY
RECEPTORS
50 1.75 1.46E-03 8.83E-02
REACTOME G ALPHA I SIGNALLING EVENTS 70 1.75 1.36E-03 8.53E-02
REACTOME GABA RECEPTOR ACTIVATION 30 1.71 2.99E-03 1.09E-01
REACTOME G ALPHA Z SIGNALLING EVENTS 38 1.7 4.39E-03 1.05E-01
REACTOME TRANSMISSION ACROSS CHEMICAL
SYNAPSES
130 1.69 1.19E-03 1.06E-01
REACTOME AXON GUIDANCE 207 1.68 0.00E+00 1.09E-01
REACTOME CLASS A1 RHODOPSIN LIKE
RECEPTORS
68 1.68 1.35E-03 1.02E-01
REACTOME SIGNALING BY GPCR 278 1.67 0.00E+00 1.10E-01
REACTOME N GLYCAN ANTENNAE
ELONGATION IN THE MEDIAL TRANS GOLGI
16 1.66 1.61E-02 1.05E-01
REACTOME SEMAPHORIN INTERACTIONS 57 1.66 5.35E-03 1.04E-01
REACTOME THROMBIN SIGNALLING THROUGH
PROTEINASE ACTIVATED RECEPTORS PARS
25 1.66 1.18E-02 9.97E-02
REACTOME GPCR DOWNSTREAM SIGNALING 212 1.65 0.00E+00 1.03E-01
REACTOME DEVELOPMENTAL BIOLOGY 304 1.64 0.00E+00 1.03E-01
miR-873-5p Mut GO BP POSITIVE REGULATION OF TRANSCRIPTION 119 2.22 0.00E+00 9.70E-04
TRANSMEMBRANE RECEPTOR PROTEIN
TYROSINE KINASE SIGNALING PATHWAY
59 2.14 0.00E+00 9.62E-04
POSITIVE REGULATION OF
NUCLEOBASENUCLEOSIDENUCLEOTIDE AND
NUCLEIC ACID METABOLIC PROCESS
126 2.08 0.00E+00 2.61E-03
POSITIVE REGULATION OF
TRANSCRIPTIONDNA DEPENDENT
97 1.99 0.00E+00 9.10E-03
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MicroRNA Database Annotation Size Normalised
Enrichment
Score
Nominal pVal FDR qVal
POSITIVE REGULATION OF RNA METABOLIC
PROCESS
99 1.97 0.00E+00 1.22E-02
POSITIVE REGULATION OF CELLULAR
METABOLIC PROCESS
164 1.96 0.00E+00 1.05E-02
INSULIN RECEPTOR SIGNALING PATHWAY 16 1.96 0.00E+00 9.99E-03
POSITIVE REGULATION OF METABOLIC
PROCESS
169 1.92 0.00E+00 1.29E-02
POTASSIUM ION TRANSPORT 32 1.91 3.26E-03 1.42E-02
POSITIVE REGULATION OF TRANSCRIPTION
FROM RNA POLYMERASE II PROMOTER
56 1.84 0.00E+00 2.87E-02
ORGAN MORPHOGENESIS 90 1.84 0.00E+00 2.83E-02
ENZYME LINKED RECEPTOR PROTEIN
SIGNALING PATHWAY
102 1.78 0.00E+00 5.24E-02
IMMUNE EFFECTOR PROCESS 15 1.76 0.00E+00 5.89E-02
HEART DEVELOPMENT 23 1.75 5.32E-03 5.71E-02
ACTIN FILAMENT ORGANIZATION 20 1.73 9.19E-03 6.72E-02
ECTODERM DEVELOPMENT 37 1.72 1.67E-03 6.88E-02
NERVOUS SYSTEM DEVELOPMENT 286 1.72 0.00E+00 6.79E-02
TRANSCRIPTION FROM RNA POLYMERASE II
PROMOTER
378 1.68 0.00E+00 9.44E-02
ORGAN DEVELOPMENT 326 1.68 0.00E+00 9.13E-02
SYNAPTIC TRANSMISSION 103 1.66 1.55E-03 1.00E-01
miR-873-5p Mut GO CC VOLTAGE GATED POTASSIUM CHANNEL
COMPLEX
23 1.97 0.00E+00 1.30E-02
CELL JUNCTION 51 1.66 9.85E-03 2.13E-01
ADHERENS JUNCTION 17 1.56 2.99E-02 2.41E-01
miR-873-5p Mut KEGG KEGG BASAL CELL CARCINOMA 40 1.83 0.00E+00 9.69E-02
KEGG PROSTATE CANCER 77 1.79 1.63E-03 7.76E-02
KEGG ACUTE MYELOID LEUKEMIA 51 1.77 1.66E-03 5.96E-02
KEGG NEUROACTIVE LIGAND RECEPTOR
INTERACTION
89 1.76 0.00E+00 4.69E-02
KEGG THYROID CANCER 26 1.71 5.23E-03 6.47E-02
KEGG AXON GUIDANCE 111 1.67 1.50E-03 8.21E-02
KEGG MELANOMA 50 1.65 4.90E-03 8.45E-02
KEGG HEDGEHOG SIGNALING PATHWAY 35 1.64 6.87E-03 8.09E-02
KEGG ADHERENS JUNCTION 68 1.64 3.16E-03 7.45E-02
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MicroRNA Database Annotation Size Normalised
Enrichment
Score
Nominal pVal FDR qVal
KEGG NOTCH SIGNALING PATHWAY 41 1.63 1.70E-02 6.72E-02
KEGG PHOSPHATIDYLINOSITOL SIGNALING
SYSTEM
62 1.55 1.89E-02 1.22E-01
KEGG NEUROTROPHIN SIGNALING PATHWAY 113 1.55 3.05E-03 1.13E-01
KEGG ENDOMETRIAL CANCER 47 1.53 2.00E-02 1.23E-01
KEGG MELANOGENESIS 75 1.53 7.70E-03 1.15E-01
KEGG GAP JUNCTION 67 1.53 1.76E-02 1.11E-01
KEGG ENDOCYTOSIS 149 1.5 2.89E-03 1.23E-01
KEGG COLORECTAL CANCER 59 1.49 2.17E-02 1.26E-01
KEGG GLYCOSAMINOGLYCAN BIOSYNTHESIS
HEPARAN SULFATE
23 1.48 3.60E-02 1.36E-01
KEGG VEGF SIGNALING PATHWAY 51 1.46 3.29E-02 1.40E-01
KEGG WNT SIGNALING PATHWAY 122 1.46 7.68E-03 1.42E-01
miR-873-5p Mut Reactome REACTOME RORA ACTIVATES CIRCADIAN
EXPRESSION
23 2.2 0.00E+00 2.47E-03
REACTOME CIRCADIAN REPRESSION OF
EXPRESSION BY REV ERBA
22 2.07 0.00E+00 8.10E-03
REACTOME YAP1 AND WWTR1 TAZ
STIMULATED GENE EXPRESSION
19 2.04 0.00E+00 7.01E-03
REACTOME BMAL1 CLOCK NPAS2 ACTIVATES
CIRCADIAN EXPRESSION
33 2.03 0.00E+00 5.65E-03
REACTOME NUCLEAR RECEPTOR
TRANSCRIPTION PATHWAY
30 1.98 0.00E+00 7.48E-03
REACTOME POTASSIUM CHANNELS 55 1.96 0.00E+00 8.99E-03
REACTOME CIRCADIAN CLOCK 49 1.96 0.00E+00 7.70E-03
REACTOME PRE NOTCH EXPRESSION AND
PROCESSING
41 1.95 0.00E+00 8.37E-03
REACTOME PRE NOTCH TRANSCRIPTION AND
TRANSLATION
27 1.95 0.00E+00 7.81E-03
REACTOME NEURONAL SYSTEM 187 1.88 0.00E+00 1.62E-02
REACTOME VOLTAGE GATED POTASSIUM
CHANNELS
23 1.85 1.77E-03 2.18E-02
REACTOME NRAGE SIGNALS DEATH THROUGH
JNK
39 1.84 0.00E+00 2.29E-02
REACTOME P75 NTR RECEPTOR MEDIATED
SIGNALLING
72 1.71 3.29E-03 8.39E-02
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MicroRNA Database Annotation Size Normalised
Enrichment
Score
Nominal pVal FDR qVal
REACTOME SIGNALING BY ROBO RECEPTOR 29 1.67 1.73E-03 1.18E-01
REACTOME DEVELOPMENTAL BIOLOGY 305 1.66 0.00E+00 1.21E-01
REACTOME SIGNALLING BY NGF 195 1.61 0.00E+00 1.65E-01
REACTOME G ALPHA1213 SIGNALLING EVENTS 64 1.59 9.52E-03 1.92E-01
REACTOME PI3K AKT ACTIVATION 36 1.59 2.16E-02 1.85E-01
REACTOME CELL DEATH SIGNALLING VIA
NRAGE NRIF AND NADE
54 1.59 8.10E-03 1.76E-01
REACTOME GAB1 SIGNALOSOME 35 1.59 1.82E-02 1.68E-01
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CHAPTER 5
Differences in non-seed pairing between
miR-324-3p and miR-1913-3p account for
binding and functional differences
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The binding of microRNAs to target sites on the 3’ untranslated regions (UTRs) of target genes is af-
fected by many factors. The presence of an exact ‘seed’ complementary match from bases 2-7 is often
very important, but complementarity in other regions of the mature microRNA sequence also plays a
role. MicroRNAs miR-324-3p and miR-1913-3p are mature microRNAs that share a seed sequence,
but have different mature sequences overall. While miR-1913 has evolved recently within primates,
miR-324 is more broadly conserved. We were interested in the degree of similarity between the bind-
ing patterns of these microRNAs, and if differences in targeting could indicate functional divergence.
We used biotin-tagged microRNA mRNA-pulldown assays to measure the binding profiles of those
microRNAs, and also measured the effect of exogenous overexpression (via transfection) of these
microRNAs in the cells. The results indicate a general association of miR-324-3p and miR-1913-3p
with cellular differentiation, consistent with their expression changes seen during differentiation of
SH-SY5Y human neuronal derived cell line, lending further support to an anti-proliferative effect
described for miR-324 in the literature. To examine the difference between miR-324-3p and miR-
1913-3p targeting, we examined their relative bias to communities in a mRNA coexpression network
and protein-protein interactions networks. This revealed a miR-1913-3p-specific association with
translational processes and the proteasome, in contrast to the more proliferation and cancer related
pathways most prominent for miR-324-3p. More generally, these results provide some characterisa-
tion of the targeting and function for these two microRNAs, particularly miR-1913 for which there is
little information available, and indicate a possible importance in neuronal function.
5.1 Introduction
MicroRNAs are 21-22bp regulatory RNA molecules, most well known for their ability to subtly
downregulate multiple specific genes through interaction with binding sites on the 3’UTRs, resulting
in downregulation of the gene through mRNA degradation or translational suppression [24]. Though
it is possible for single microRNA to single gene targeting to have a dramatic switch-like effects [38],
it is generally their subtle but broad and configurable targeting nature that underlies their regulatory
potential; sometimes serving buffering or stabilising effects in a system [40, 190]. This configura-
bility may allow microRNAs to occupy specific regulatory niches, such as within certain tissues,
cellular context or developmental timepoints [191–193]. So, while some microRNAs are highly con-
served across species, other functional microRNAs are not [193], and may show pronounced tissue-
specificity [193, 194].
Our previous work had highlighted a potential involvement of L1 adhesion molecule L1CAM path-
ways in autism [16]. As microRNAs are an important class of regulators in the brain [191, 195], we
sought to identify potential microRNA regulators of these pathways. To this end we chose to focus on
microRNAs miR-324-3p and miR-1913-3p, due to their neuronal context and predicted target genes.
The two of them were considered in parallel, as they have identical ‘seed’ regions. Seed regions
are a major factor in microRNA targeting specificity, as they canonically form a perfect complemen-
tary match to the microRNA binding sites, supported by imperfect matching across the rest of the
microRNA [24].
MicroRNA miR-324 is a conserved microRNA present in many mammal species, including human,
first identified in rat cortical tissue [196]. It lies within a small (5.5kb) gap between genes DLG4 and
DVL2 in the sense orientation, within an antisense intron of ACADVL. Several studies into miR-324
function point towards an anti-proliferative role, coupled with increased expression in differentiated
cell types [197, 198]. Human miR-324 (hsa-miR-324) has been observed to promote neural differen-
tiation in human neuroepithelial-like stem cells neurons [198]. A mechanism for its anti-proliferative
effects has been proposed through repression of members of the hedgehog signalling pathway GLI1
[197, 199], and smoothed [197].
MiR-1913 (hsa-miR-1913) was first described in 2008 by a microRNA identification study in hu-
man embryonic stem cells, where it was flagged for its shared seed (on the 3’ arm of the precursor
microRNA hairpin) with miR-324-3p [200]. This 3’ arm of miR-1913 is discussed throughout (miR-
1913-3p, named miR-1913 in miRBase), as there is currently no annotated mature 5’ arm microRNA
for the gene in miRBase [94]. However, there has yet to be any specific characterisation of miR-1913.
It is a primate-specific gene, embedded within an intron of host gene RPS6KA2 (RSK3), and currently
in miRBase is only annotated in human and orangutan [94]. Such ‘seed-paralog’ microRNA genes
are quite widespread within less described microRNAs, and are generally expected to have similar
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functions as their more well-studied counterparts due to the importance of the seed region [193].
Efforts have been made to understand and to some extent define types of microRNA binding, for
instance, different sized seeds [201], nucleation-bulges [202] and non-seed binding [28]. However
it is a problem that evades simple classification, complicated by many other factors outside of the
target site sequence. The efficacy and frequency of microRNA sites on the 3’UTRs is higher near the
extremities (near the polyA or stop codon) [31, 90], and they can be more effective when in clusters
[31, 203] with optimal spacing [30, 31]. Additionally, functional sites are not limited to the 3’UTR;
binding has been described in 5’UTRs [32, 204, 205], coding regions [206] and circular RNAs [207],
and these modes of binding can have different functional implications.
With the extent of variance possible in binding sites, it is difficult to know exactly what genes a
specific microRNA can target. There are many computational tools for binding sites prediction, and
while useful at a broad level, they have notoriously high error rates and a low agreement between
tools [66, 69]. Generally tools use multiple lines of evidence to predict target sites, which are re-
viewed extensively in [69]. Generally, most check for the presence of an exact or near exact seed
match complemented by other factors such as sequence homology between different species (e.g.
TargetScan, miRWalk [66, 175] ), site accessibility (e.g. PITA [208]) and free energy calculations
(e.g. RNAhybrid [71]). With the degree of difference between different tools, it can be useful to
combine predictions from multiple tools [66, 69]. However, cell-based assays still provide a more
reliable, biologically relevant dataset for individual microRNAs of interest.
To identify targets of miR-324-3p and miR-1913-3p, this study employs a synthetic biotinylated mi-
croRNA pulldown method in SH-SY5Y (a neuroblastoma cell line) to capture bound mRNA at the
genomic scale [80, 82]. The RNA products of these experiments can be assayed with microarray
[80, 82], but more recent studies have used RNAseq [81, 82]. By sequencing the pulldown mRNA,
and the transcriptomes of both transfected and untransfected cells, we are able to assay both the effect
of exogenous microRNA overexpression on the cellular transcriptome, as well as its direct targeting
via the enrichment in the pulldown sample. We take a systems biology approach to characterising
the identified targets, by analysing their relative influence to gene communities from networks at the
protein interaction [146] or mRNA expression levels [86].
This work characterises the in vitro transcriptome-wide binding profiles of miR-1913-3p and miR-
324-3p, and suggests that despite their identical seed sequences, other differences in the mature mi-
croRNA sequences are sufficient to cause a measurable difference in binding, resulting in different
functional profiles for these two microRNAs. While we found no evidence to support their hypothe-
sised role in L1 pathway regulation, this analysis presents further support for the role of miR-324-3p
(and miR-1913-3p) in cellular differentiation, and also flags a potential miR-1913-3p-specific associ-
ation in protein synthesis and degradation in primates.
118
5.2 Methods
5.2.1 MicroRNA phylogeny and expression
Cross-species microRNA homologs were searched for with MapMi (online tool v1.5.9-b31) [209]
and blast [210], and Sintra (online tool v1.5.9-b31) was used to explore synteny of the surrounding
environment [211].
Expression levels of both microRNAs were examined in the BrainSpan dataset [132]. Due to low
expression in the the BrainSpan dataset, neuronal expression of miR-1913-3p was evaluated by look-
ing at several unrelated datasets; microRNA sequence libraries from cerebral neocortex of individuals
with and without Alzheimer’s and dementia (neural conditions not expected to interfere with the abil-
ity to detect miR-1913-3p) (Accession: GSE46131) [212], and across a number of human tissues
(Accession: ERP000773) [194].
MiR-1913-3p expression was further examined in the context of its host gene RPS6KA2. The local
sequence environment around was examined through the UCSC genome browser for indication of
regulation and active promoters, principally considering the histone modification and DNase accessi-
bility information for cell lines SK-N-SH, H1 and HeLa from the ENCODE project [85]. Transcrip-
tional start sites from CAGE experiments by the FANTOM5 project were examined via the ZENBU
browser [117].
5.2.2 MicroRNA target site prediction
Putative microRNA target sites were identified as described in [65]. Specifically, microRNA tar-
get sites were predicted for all miRBase v19 [93, 94] microRNAs on all 3’UTR UCSC transcript
sequences (reference genome hg19, downloaded: 21/02/13). Mature microRNA sequences, and mi-
croRNA gene locations are from miRBase v19 [94]. To reduce variability in target site predictions
made by different prediction utilities, two tools with slightly different approaches were used; mi-
Randa [92] - which considers seed complementarity and free energy calculations, and RNAhybrid
[71] - which focuses on free energy calculations. Genomic flanking sequence of 50bp was included
to capture sites spanning the extremities of the 3’UTRs.
Miranda v3.3a was run with default parameters. RNAhybrid v2.1.1 was run to find target sites with a
minimum free energy less than -18 with parameters optimised for human 3’UTRs (options: -b 2000, -e
-18, -s 3utr human). The predicted sites were then further filtered to a free energy of -18 for miRanda
and-25 for RNAhybrid. The set of microRNA target site predictions used in the analysis contains only
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miRanda site predictions that had a reciprocal 75% overlap (by coordinates) with RNAhybrid sites.
The same method was used to predict sites in the 3’UTRs of other species obtained from Ensembl
(release 84); chimpanzee (Pan troglodytes) assembly CHIMP2.1.4, gibbon (Nomascus leucogenys)
assembly Nleu1.0, macaque (Macaca mulatta) assembly MMUL 1.84, marmoset (Callithrix jacchus)
assembly C jacchus3.2.1, and mouse (Mus musculus) assembly GRCm38. Due to the fragmented na-
ture of some of the assemblies, 3’UTR flanking regions were not included in this analysis. The human
sequences used for the evolutionary contrasts were repeated with the GRCh38 assembly (Ensembl re-
lease 83) with these conditions. MicroRNA site occurrences were contrasted within orthologs of each
species having one-to-one homology with human, as downloaded from Ensembl BioMart (Release
84).
5.2.3 MicroRNA:mRNA pulldown assay
Binding profiles of miR-324-3p and miR-1913-3p were generated with pulldown experiments, pulling
down a cellular transcriptome (from transfected cell lysate) with synthetic biotinylated microRNAs,
as illustrated in Figure 5.1. We sequenced four replicates for each microRNA, with paired whole-
lysate Control (Con) and pulldown (PD) for each sample, as well as four mock-transfected samples
(Untransfected).
We used undifferentiated SH-SY5Y cells (a neuroblastoma cell line) to capture a neural transcriptome.
Cells were grown in DMEM:F12 with HEPES media with penicillin/streptomycin at 37◦ with 5%
CO2.
The pulldown protocol is described in [82, 83], with the following modifications. Sequenced samples
were transfected in a 75cm2 flask with 560pmol of biotinylated microRNA with lipofectamine 2000
(Thermo Fisher), and grown for 24hrs before pulldown. Four biological replicates, from four inde-
pendent experiments, were made for each transfection. RNA was purified with RNAeasy columns
(QiAGEN), and sequencing libraries prepared from 100ng input RNA with Illumina TruSeq Stranded
mRNA kit. Libraries were sequenced across two lanes using v4 SBS chemistry on an Illumina
HiSeq2000.
The synthetic microRNA duplexes with biotin tags on the 3’ end of the mature microRNA were
ordered from IDT (www.idtdna.com), their sequences are listed in Supplementary Table 5.7.
To check if biotinylated microRNAs were effectively transfected into cells we transfected cells with
the biotinylated microRNA duplexes as per pulldown in 24 well plates. Then they were fixed in 4%
PFA, rinsed with PBS, and blocked with 2% BSA in .3% Triton X-100 (TX) for 30 min at room temp
for 2 hours. Cells were incubated with Alexa Flour 594 streptavidin (Illumina) in BSA/PBS/TX mix
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for 1 hour at room temperature on rotation, followed by 10 minutes of DAPI incubation.
Figure 5.1: Pulldown experimental design. Synthetic biotinylated microRNA duplexes for human miR-324-3p or
miR-1913-3p were transfected into SH-SY5Y cells. Most of the lysed transfected cells was used for the pulldown
assay, with small amount kept aside to enable paired contrasts of pulldown treatment versus transfected cell
lysate.
5.2.4 RT-qPCR of microRNA targets in microRNA:mRNA pulldown
During the pilot phase, we tested for enrichment of three predicted target genes (DPYSL4, L1CAM
and NUMB). The cDNA was generated for pulldown and transfection control samples using the super-
script III reverse transcriptase kit (Life Technologies) and oligo dT primers. The qPCR reactions were
setup using Invitrogen SYBR green master mix, with 3 technical replicates for each assay. Primers
were all designed across intron boundaries, resulting in RNA amplicons of approximately 100bp listed
in Supplementary Table 5.8. The cDNA for the RT-qPCR experiments was produced from a scaled
down transfection and pulldown experiment, with 3 wells of a 24 well plates per condition performed
simultaneously.
Technical outliers 0.5CTs away from average were removed, and replicates with high technical vari-
ance (remaining 2 technical replicates still differ by 0.5CTs) were removed entirely. Enrichment of
predicted targets was assessed with ∆∆CT method, using three genes (EMC7, HPRT1 and PSMB4)
averaged together as the reference [213]. Where one control gene could not be included on one side
of the comparison, it was omitted from both for the given replicate to keep controls balanced within
contrasts.
Each pulldown sample was paired with its corresponding control transfected-lysate sample. Signifi-
cance was tested with student t-test of ∆∆CT of the microRNA pulldown versus cel-miR-67 treated
controls. The microRNA overexpression tests of transfected sample versus mock-transfected SH-
SY5Y cells were not paired, as they were from different cellular populations.
121
5.2.5 MicroRNA:mRNA pulldown analysis and functional associations
Sequence data quality was examined with FastQC (v0.11.3). Illumina adaptor sequences were re-
moved and reads quality trimmed with Trimmomatic (v0.33) [134]. Sequences were aligned to the
human GRCh38 Ensembl release 83 transcriptome with TopHat2 (v2.1.0, parameters: –library-type
fr-firststrand –no-novel-juncs) [135] with method described in [214]. Gene-level counts were gen-
erated from paired reads in HTseq-count (HTSeq-0.6.1p1, parameters: -s reverse -m union) [169].
Differential expression analysis to evaluate the enrichment of targets in pulldown samples (paired
comparisons) or expression changes during transfection was done using DEseq2 (v1.8.2) [136].
We ran the GSEA (Gene Set Enrichment Analysis) (v2-2.1.0) package to evaluate functional associa-
tions with the pulldown enrichment and microRNA transfection data, as pre-ranked analyses with de-
fault parameters and ‘weighted’ method [171]. Complete genesets were ranked by the ‘shrunken’ log2
fold-change generated by DEseq2 (enrichment/upregulation high, depletion/downregulation low), a
metric which is suggested to be more appropriate than the p-values (or un-shrunken fold-changes)
[136]. Genesets were compared with several predefined reference datasets (Reactome, KEGG, Gene
Ontology (GO) Biological Process (BP) and GO Cellular Component (CC), and custom sets (genes
differentially expressed during induced SH-SY5Y differentiation from [215] as described in section
‘Analysis of SH-SY5Y differentiation microarray data’).
For network analyses, human protein-protein interactions (PPI) were obtained from bioGRID (ver-
sion 3.4.134) [146]. A merged miR-324-3p and miR-1913-3p target PPI network was constructed
using the significantly enriched genes from the pulldown assays for either microRNA (the ‘merged
target’ PPI network). Broad communities were detected via the ‘cluster fast greedy’ method imple-
mented in igraph (version python-igraph 0.7.0) [216, 217]. Gene ontology (GO) term associations
for the created communities were calculated using the fisher exact test via the TopGO package [218].
CFinder (version 2.0.5–1440) was used to identify smaller overlapping PPI clusters (k-cliques), po-
tentially representing protein complexes or other small units in the merged target network [219], and
functional annotation enrichment calculated with ClueGO [141]. To examine regulatory linkages in
a neurodevelopmental mRNA context, we also examined enrichment of the microRNA targets within
modules of a human brain developmental co-expression network published by Parikshak et al. [86].
If miR-324-3p and miR-1913-3p have biologically relevant differences in their targeting networks, we
might expect that they could differentially target different parts of the overall targeting networks. So
we calculated enrichment of miR-324-3p and miR-1913-3p targeted genes in these network communi-
ties (hypergeometric p-values), as well as genesets shared by both, or specific to either microRNA.
The igraph R package (version R/igraph 0.7.1) [216], and Cytoscape [220] were used for network
manipulation and visualisation
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5.2.6 RT-qPCR of mature microRNA expression during SH-SY5Y
differentiation
Forty cycles of real-time PCR was performed as previously described [215]. Briefly, specific microRNA-
primed reverse transcription was carried out on 500ng DNase-treated (Invitrogen) total RNA using
Superscript II reverse transcriptase (Invitrogen) in a final volume of 20µl. Real-time PCR was per-
formed in triplicate 12.5µl reactions on diluted cDNA with Power SYBR Green master mix (Applied
Biosystems) using an ABI Prism 7500 sequence detection system (Applied Biosystems). Relative
expression was calculated via ∆∆CT, using U6 as the calibration control.
5.2.7 Analysis of SH-SY5Y differentiation microarray data
We used the Affymetrix Exon v1.0 arrays previously generated from a study into transcriptome
changes during different methods of SH-SY5Y induced differentiation [215]. The cells differenti-
ated by the combined ATRA and BDNF differentiation protocol were contrasted with undifferentiated
cells to identify genes altered during the differentiation process.
Arrays were RMA normalised using the oligo package in R [221, 222]. Differential expression was
calculated with limma [223] at the transcript level, for those transcripts annotated at the Affymetrix
‘extended’ evidence level, which includes RefSeq genes and other transcripts having evidence of
expression. Differentially expressed genes were defined as those with a corrected p-value < 0.01
(using BH method).
5.2.8 Validation of microRNA binding sites via luciferase assay
Putative target sites for human microRNA miR-1913-3p were cloned into psiCHECK2 plasmids
(Promega) for use in luciferase assays using the dual-luciferase reporter assay kit from Promega,
following procedure described in [83].
A luciferase assay was used to assess the effect of microRNA miR-1913-3p on the tested target sites,
using a method adapted from [83]. MiR-1913 and negative control microRNA cel-miR-67 were tested
against a predicted hsa-miR-1913 target site, a positive control with exact complementarity to miR-
1913 and a negative control (native psiCHECK2), with 6 biological replicates for each condition.
This assay used cos7 cells, maintained at 37◦, 5% CO2 in DMEM 10% FBS with streptomycin and
penicillin.
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Synthetic microRNA ‘MIRIDIAN’ mimic microRNA molecules for miR-1913 and negative control
microRNA cel-miR-67 (CN-001000-01 Negative Control #1) were ordered from Thermo Scientific.
Sequences of microRNA mimics and target sites are listed in Supplementary Table 5.9.
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5.3 Results
5.3.1 Sequence similarity of miR-324 and primate-specific miR-1913
We examined the sequence similarity and conservation of miR-324 and miR-1913 to determine their
evolutionary relationship
The miR-324 gene is well conserved across mammals including mouse (Figure 5.2). However miR-
1913 currently only has miRBase annotations for human and orangutan (Pongo pygmaeus). The
MapMi microRNA homolog tool detected several primate miR-1913 homologs including within
chimpanzee (Pan troglodytes) and gibbon (Nomascus leucogenys), using permissive parameters [209].
There is further sequence-level homology amongst some other primates, including Macaque (Macaca
mulatta), but not all, for instance it is absent in marmoset (Callithrix jacchus) as well as mouse (Mus
musculus) (Figure 5.2). This suggests that miR-1913 has originated somewhere in the simiiforme
linage [224].
Human microRNAs miR-324-3p and miR-1913-3p share a seed region and some additional similarity
at the 5’ end of the mature sequence (Figure 5.3a), but little similarity within the hairpin sequence
(Figure 5.3b).
The synteny for both genes is consistent across species (Figure 5.2). Human miR-324 is consistently
wedged in sense orientation within the small gap between DLG4 and DVL2 (which is only 5.5kb
in human), although at the same time it is also within the anti-sense orientation in an intron of gene
ACADVL. MiR-1913 lies within an intron of the RPS6KA2 gene, a member of the RSK ribosomal
protein kinase family which itself is conserved in mouse.
The presence of predicted target sites for miR-1913-3p and miR-324-3p amongst one-to-one homolog
target genes occurs at a similar rate across different species, irrespective of the presence of the miR-
1913 gene in that species (Figure 5.2). This may be in part due to the sequence similarity of the two
microRNAs. MiR-1913 orthologs were similar or identical across species, and since some miR-1913
genes are based on homology only, the calculations use the human versions.
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Figure 5.2: Synteny and target conservation of miR-324 and miR-1913 across species. Diagram showing
synteny of miR-324 and miR-1913 across human (Homo sapiens), chimpanzee (Pan troglodytes), Gibbon (No-
mascus leucogenys), Macaque (Macaca mulatta), marmoset (Callithrix jacchus) and mouse (Mus musculus).
MicroRNA homologs and synteny determined with MapMi [209] and Ensembl genome browser. Conserved
sites reflect the percentage of one-to-one homologs of human genes predicted to be targeted by the microRNA
that also have target sites predicted in the other species.
(a) Mature
(b) Precursor
Figure 5.3: (a) Sequence similarity of mature human microRNAs miR-324-3p and miR-1913-3p. Seed sequences
highlighed in red. (b) Sequence similarity of miR-324 and miR-1913 microRNA genes. Alignment created with
muscle v3.8 [225]. Mature microRNAs miR-324-5p and miR-1913-5p highlighted in red.
5.3.2 Expression and regulation of miR-324 and miR-1913
Though not brain-specific, miR-324 (both 5’ and 3’ arms) are expressed at their highest levels within
the brain compared to other tissues [226] (Supplementary Figure 5.11), and is robustly expressed
across different parts of the brain described in the BrainSpan dataset [103].
On the other hand, miR-1913-3p has much lower expression, too low to obtain relative tissue expres-
sion from public databases. Given the lack of previous work on miR-1913-3p, we checked for its
existence within the raw or processed datasets from several independent studies. Mature miR-1913-
3p transcripts were detected in 115 of the of 216 BrainSpan microRNA sequence libraries from 17
different brain regions, (an average of 1.1 reads detected per library) [103]. It was seen in low levels
(at least one read per library ) in 4 of 18 libraries of an unrelated human brain transcriptome study
[212]. A third microRNA expression study detected just one copy of miR-1913-3p in one of five
brain samples, and none in other tissues (heart, liver and testis) [194]. This suggests that the expres-
sion of miR-1913-3p in brain is low, perhaps at limits of detection with standard sequencing depth,
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but genuinely present.
MicroRNAs located in introns may be co-expressed with their host genes, but can also be expressed
independently of the host gene [227]. The pattern of histone marks and DNase accessibility from EN-
CODE data [85] in the vicinity of the miR-1913 gene are not suggestive of an independent promoter
region, nor is there evidence of miR-1913 transcription start sites in the FANTOM project data [117]
(Table 5.1).
Therefore it is useful to consider the expression of host gene RPS6KA2 as a proxy for miR-1913
expression. The RefSeq annotation currently describes two protein-coding isoforms of RPS6KA2; a
longer form (NM 001006932.1) and a shorter one (NM 021135.4), both of which carry miR-1913.
The short isoform has a prominent promoter, and appears to be expressed in a diverse range of cell
types (Table 5.1). The longer isoform has a less obvious promoter region, and appears to be more
specialised to brain tissues the FANTOM data shows of the 28 libraries with more than 20 CAGE tags
- all of which were brain derived, compared to the 8% (n=263) libraries of the short isoform.
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Table 5.1: MicroRNA regulatory context. Table showing summary of epigenetic feature signatures from ENCODE project, and the transcription start sites from CAGE
from the FANTOM5 project (Specifically track: FANTOM5 Phase 1 CTSS human tracks pooled filtered with 3 or more tags per library and RLE (Relative Log Expression)
normalised). The histone makes considered were H3K4Me1, H3K27Ac and H3K4Me3. CAGE Samples with at least 20 tags were included in the percentage of brain
derived tissues/samples/cell-lines calculations.
miR-1913 RPS6KA2 Short Isoform RPS6KA2 Long Isoform
Histone marks No clear peaks Yes. Typical promoter signature. Weak peaks around start of transcript.
DNase clusters No Yes Yes
CpG Islands No Yes Yes
CAGE TSS peaks No chr6:167040542-167040898 (-) chr6:167275699-167276865 (-)
Top 10 CAGE Tissues n/a neutrophil PMN caudate nucleus
Endothelial Cells - Microvascular putamen
Lymphatic Endothelial cells response to VEGFC hippocampus
Fibroblast - Lymphatic amygdala
Mesenchymal stem cells - hepatic caudate nucleus - adult
Melanocyte - light parietal lobe
Amniotic Epithelial Cells thalamus
Mesenchymal Stem Cells - hepatic occipital cortex
Fibroblast - Cardiac medial frontal gyrus
Hair Follicle Outer Root Sheath Cells medial temporal gyrus
Brain CAGE Tissues n/a 8% (n=263) 100% (n=28)
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5.3.3 MiR-324-3p and miR-1913-3p binding profiles
We used a biotin-tagged microRNA, mRNA pulldown assay to measure transcriptome-wide binding
profiles of miR-324-3p and miR-1913-3p. This identified 1396 genes significantly enriched in the
miR-324-3p pulldown, and 2068 genes significantly enriched in the miR-1913-3p pulldown (Wald
test, in DEseq2), 647 of which overlap (Figure 5.4a). The full results of the pulldown assay contrasts
calculated in DEseq2 is available at figshare (https://dx.doi.org/10.6084/m9.figshare.3581781.v1).
The validity of this pulldown assay is supported by several lines of evidence. Firstly, staining of biotin
revealed the persistence of biotinylated microRNA in the transfected cells at the 24 hour mark that was
used for the pulldown (Supplementary Figure 5.12). We saw significant enrichment of predicted target
sites with their captured mRNAs in the pulldown assays (miR-324-3p p=4.94×10−6, miR-1913-3p
p=7.20×10−11). There was also a significant enrichment with the 5p arm of miR-324 in the miR-324-
3p samples, but to a lesser degree (p=2.03×10−3). Notably the miR-324-3p pulldown assay supports
three genes previously shown to be targeted by miR-324-3p via luciferase assay; CREBBP, DVL2
[228] and SMAD7 [229], which were all significantly enriched (Table 5.2). The other two genes for
which luciferase assay data has been published, WNT2B [230] and WNT9B[228] had expression too
low to be examined in our data.
We also checked the pulldown results for evidence of pulldown of GLI1 and Smoothened (SMO), as
these genes have been proposed as possible target genes of the 5’ arm microRNA of miR-324, through
which it acts on the hedgehog signally pathway [197, 199]. SMO was not significantly enriched in
the pulldown results, and GLI1 was not detected at high enough levels to measure.
RT-qPCR measurements on pilot pulldown samples (Supplementary Figure 5.13a) indicated capture
of predicted targets L1CAM and NUMB in a miR-324-3p pulldown (p <0.05), and marginal signifi-
cance (p <0.1) against SZT2, as well as hsa-miR-1913-3p capture of DPYSL4, L1CAM and NUMB.
However, these results were not replicated in the pulldown results, which detected only marginally
significant enrichment (p = 0.046) of L1CAM within the miR-324-3p pulldown. The full pulldown
experiment may be more robust against false positives, as the replicates were generated in a balanced
design across several weeks, rather than in parallel like the pilot.
To check for overall effect of miR-324-3p or miR-1913-3p over-expression we also contrasted the
whole-transcriptome transfected samples with mock-transfected controls, and found no differential
expression (Supplementary Figure 5.14). Likewise, the pilot RT-qPCR measurements for the same
genes tested in the pulldowns samples showed no difference in expression levels (Supplementary
Figure 5.13b).
To aid in analyses of the similarities and differences of miR-324-3p and miR-1913-3p, genes signif-
icantly enriched in the pulldown experiments were classified as common to both or specific to either
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microRNA. To distinguish between a microRNA significantly enriched in one pulldown but not the
other, from those where only the first reached statistical significance and the other is borderline, we
calculated a difference in p-values as (1- miR-324-3p pulldown enrichment p-value ) - (1- miR-1913-
3p pulldown enrichment p-value), and classified those > 0.9 as miR-324-3p only, and those < -0.9 as
miR-1913-3p only. These categories are visualised in Figure 5.4b.
(a)
(b)
Figure 5.4: (a) Venn diagram showing the overlap of miR-324-3p and miR-1913-3p binding. (b) This plot
visualises the classification of targets into categories ‘miR-324 only’ (Only324), ‘miR-1913 only’ (Only1913),
‘both’ and borderline cases of more miR-324-3p than miR-1913-3p (Borderline324) or more miR-1913-3p than
miR-324-3p (Borderline1913). The borderline cases were kept out of the unique sets to avoid genes that do not
have significant enrichment due to lack of statistical power. Note that instances of fuzzy overlaps between
these categories are due to the classification being performed on p-values, and this plot is showing log2FC
enrichments calculated by DEseq2.
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Table 5.2: Enrichment of miR-324-3p gene targets previously shown via luciferase assays. A number of studies
have previously shown action of miR-324-3p arms, against genes of interest: Li et al. (2013) [230], Ragan et
al. (2009) [228] and Xu et al. (2015) [229]. This table shows their enrichment in the pulldown assay (log2
fold-change calculated DEseq2) and corresponding corrected p-values. Values of ‘na’ indicate that DESeq2
was unable to calculate an enrichment for these samples due to low expression levels.
Target Gene Source Pulldown Enrichment P-value
CREBBP Ragan et al. 2009 0.93 1.39E-07
DVL2 Ragan et al. 2009 0.80 5.82E-03
SMAD7 Xu et al. 2015 0.44 9.94E-02
WNT2B Li et al. 2013 na na
WNT9B Ragan et al. 2009 na na
5.3.4 Functional enrichment of binding profiles show involvement with cell
growth pathways
Next, we aimed to explore the functional association of miR-1913-3p and miR-324-3p target genes.
Although we have identified lists of differentially enriched target genes from the pulldown data, en-
richment falls along a continuum (See MAplots in Supplementary Figure 5.14), rather than being
specific to a select few gene targets. This broad microRNA targeting lends itself to GSE (Gene Set
Enrichment) approaches, such as GSEA (Gene Set Enrichment Analysis), as they consider the entire
ranked distribution of enrichment values [171].
GSEA analysis of pulldown results is reported in Supplementary Table 5.10. MiR-324-3p yielded
significant (<0.25 FDR qVal as recommended by GSEA) KEGG pathway associations including
‘ErbB Signalling Pathway’ (hsa04012, FDR qVal=0.07) and ‘mTOR signalling pathway’ (hsa04150,
qVal=0.16). It was also flagged in several different KEGG cancer pathways, perhaps due to involve-
ment of these pathways. Circadian clock pathways (e.g. ‘REACT 24941: Circadian Clock’ FDR qVal
0.04) were also reported in Reactome. Reported pathways and terms were similar for miR-1913-3p,
but were not statistically significant.
These associations are consistent with a role in cell growth and differentiation, which we investigated
further through expression changes in SH-SY5Y differentiation - where cells form neurites and stop
proliferating. Mature miR-1913-3p showed an increase in expression during induced differentiation
of SH-SY5Y cells (Figure 5.5), which is consistent with what has been documented for miR-324-3p
in other cell lines in the literature [197, 198]. However, an increase in miR-324-3p expression itself
was not statistically significant (Figure 5.5).
To compare the targeting and effects of miR-324-3p or miR-1913-3p on the transcriptome we con-
structed a set of 158 genes (the ‘SH-SY5Y Differentiation’ geneset) differentially expressed during
the process of ATRA and BDNF induced differentiation of SH-SY5Y cells from experimental data
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from [215].
GSEA analyses of the miR-324-3p and miR-1913-3p pulldown results yielded no significant associa-
tion with the SH-SY5Y differentiation set. However the pulldown assays are a measure of biochemi-
cal binding affinity, which while useful for identification of potential targets for pathway associations,
does not necessarily proportionally reflect the degree of regulation. So to complement the pulldown
assay, we also measured the effect of exogenous over-expression of miR-324-3p and miR-1913-3p
(via transfection) on the whole transcriptome with RNA-seq.
The cells’ transcriptome was not profoundly altered by over-expression of either microRNA, with
no genes differentially expressed on an individual basis (Supplementary Figure 5.14, Supplemen-
tary Figure 5.13b). However, when we considered the entirety of gene expression changes with a
GSEA analysis, there was an enrichment of the most down-regulated genes in the genes altered dur-
ing SH-SY5Y differentiation (Table 5.3). This is consistent with these microRNAs being capable of
a systemic but subtle downregulation across multiple genes during differentiation.
Figure 5.5: Relative expression of miR-324-3p and miR-1913-3p in SH-SY5Y cells differentiated with ATRA
and BDNF, versus undifferentiated cells. Error bars reflect 95% confidence interval. P-values calculated with
two-tailed t-test.
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Table 5.3: A summary of GSEA (Gene Set Enrichment Analysis) [171] looking at the signal of transfection
experiments against genes differentially expressed during induced differentiation of SH-SY5Y cells. The dataset
of SH-SY5Y differentiation is from analysis of arrays in [215]. GSEA input was a ‘pre-ranked’ list of all tested
genes sorted by DEseq2 log2FC values (enrichment/upregulation was high, depletion/downregulation low) with
‘weighed’ scoring. Normalised Enrichment score and Nominal p-value are described in the GSEA documen-
tation. The leading edge geneset (genes contributing to the maximal score) are listed highest-contributing first
(most downregulated for negative enrichments).
Normalised
Enrichment
Score
NOM p-val Leading Edge Genelist
miR-324-3p
Transfection
-1.6983414 0 KLF6 ADD3 FIGN CHGB BTBD11 RNF152 AAK1
CASD1 PRSS12 ANO5 PI15 DLG2 HGF BAZ2B
BACH2 MYH15 PRKRIR FGF14 NSDHL CDCA7L
CLSTN2 AGTPBP1 FAM13A LYN MAP1B CHST11
TSHZ2 SOCS6 RGS4 DOCK9 XPR1 SEMA6D
CHRM3 SLC16A9 CHPT1 HMGCR EXPH5 NAA50
PCDH9 RGS7 RGS13 SEPT6 NAV2 LYRM2 SCG2
VCAN
miR-1913
Transfection
-1.494319 0.002320186 FIGN NSDHL KLF6 CHGB BTBD11 ADD3 CBLN4
HGF DUSP6 CLSTN2 ANO5 AAK1 PI15 TSHZ2
RGS4 PRSS12 CDH2 LYN NAA50 MPPED2 MYH15
NCAM2 SYN2 SCG2 CHRM3 CHST11 SDC2 MAP1B
TEX15 ASTN2 RNF152 FAM72A RGS13 DLG2
MEIS1 RAC1 BAZ2B PRKRIR LYRM2 CDCA7L
CSRNP3 TMEM100 HMGCR DPYSL3 EXPH5
FAM72B RPL22 HMGCS1 CASD1 FGF14 NAV2
SEMA6D
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5.3.5 Lack of support for hypothesised role in L1CAM regulation
We had hypothesised a role for microRNAs miR-1913-3p and miR-324-3p in pathways related to L1
cellular adhesion molecule L1CAM due via their predicted targeting of L1CAM, NFASC (another
L1 protein) and potential protein-interactors of L1CAM; RPS6KA2 (also the host gene of miR-1913
[231]), and NUMB (predicted target of miR-1913-3p only). While the potential for the miR-1913-
3p interaction with L1CAM itself was confirmed in the luciferase assay (Figure 5.6), and in the pilot
pulldown RT-qPCR (Figure 5.13a) ,it was not reproduced in the full pulldown assay. Furthermore, the
overall profile of the enrichment in the pulldown assay was not supportive of this hypothesis either;
although Reactome pathway ‘Interaction between L1 and ankyrins’ was reported for miR-1913-3p it
was not statistically significant (Table 5.10). Without clear support for this hypothesis, analysis has
instead focussed on statistically significant functional associations.
Figure 5.6: Luciferase results for miR-1913-3p and L1CAM target site. The green bars represent treatment
with the test microRNA miR-1913-3p, whereas as the grey bars represent the two controls; cel-miR-67 and
no microRNA. The reduced ratio seen in the miR-1913-3p tests versus the two controls in the positive control
(miR1913 PC) and L1CAM test site (L1CAM site 1) indicate microRNA activity. Significant differences between
miR-1913-3p and both controls are indicated with * (p-values < 0.01 calculated via t-test) . Ratios are between
average luminescence of Renilla luciferase (averaged over 18-22 seconds) versus the firefly control luciferase
(averaged over 4-9 seconds) for the positive control miR-1913-3p, unaltered psiCHECK2 and L1CAM site 1
plasmids. Error bars show standard error, there were 6 replicates for each condition.
5.3.6 Functional evaluation of targeting networks yields a miR-1913-specific
association with proteasome
The broad targeting profiles of miR-324-3p and miR-1913-3p are similar, but not identical, and we
were interested in the biological relevance of these differences. We examined differences between
relative enrichment of miR-324-3p or miR-1913-3p targeted genes at mRNA co-expression modules
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during neural development [86], and protein-protein interactions (PPI) communities at the broad and
local levels, summarised in Figure 5.7, which may indicate differing biological roles.
Because microRNAs act on the transcriptome, and to focus on the neural context, we considered
targets enrichment within co-expression networks generated and characterised by Parikshak et al.
from the BrainSpan human neurodevelopmental transcriptome resource [86, 132].
The strongest enrichment was seen for miR-324-3p targets in Module M2 (p=6.01×10−9), which had
been described as enriched for ‘zinc ion binding’ as the top GO associations, but also terms ‘regulation
of transcription’, ‘DNA binding’, ‘histone modification’ and ‘transcriptional cofactor activity’. Tar-
gets of miR-1913-3p were most enriched in module 14 (p=1.28×10−6), associated with ‘translational
elongation’. Notably this association appears specific to miR-1913-3p targets, as the smaller subset of
miR-1913-3p-specific targets actually has more significance in the module (p=4.55×10−7), whereas
the shared genes are only marginally significant (p=4.65×10−2). MiR-1913-3p targets also had lesser
degrees of enrichment with M9 (regulation of cellular amino acid metabolic process, p=4.32×10−3),
which includes enrichment for ubiquitination-related terms ‘negative regulation of ubiquitin-protein
ligase activity involved in mitotic cell cycle’ and ‘positive regulation of ubiquitin-protein ligase activ-
ity involved in mitotic cell cycle’, and M4 (no GO associations reported, p=1.75×10−3).
To find communities of genes related at the protein interaction level, we created a merged miR-324-
3p and miR-1913-3p network (the ‘merged network’) from all genes significantly enriched in the
pulldown experiments, 2544 genes in total.
A clustering analysis of the protein-protein interactions formed by these genesets yielded 25 commu-
nities, sized between 2 and 496 genes.
GO enrichments of these communities are listed in Supplementary Table 5.7. Significant enrichment
of miR-324-3p and miR-1913-3p in these communities is shown in Figure 5.8, with calculations in
Table 5.5. Note that statistical power of the enrichment calculations in this network is limited, as the
background is the merged target network itself. These enrichment calculations (for the broad com-
munities only) are not corrected for multiple hypothesises, and thus cannot be regarded as overall
indicators of enrichment, rather they are interpreted as the relative targeting biases of these two mi-
croRNA. These biases of the two microRNAs to different communities also tentatively support some
potential differences. MiR-1913-3p’s targets, and the common miR-1913-3p and miR-324-3p targets,
are enriched in community c5, which is associated with ribosome and translational processes (Table
5.11). The miR-1913-3p-only set was the only test enriched in c2, associated with protein ubiquitina-
tion, mirroring the miR-1913-3p-specific association of M9 in the Parikshak co-expression networks
(Table 5.4). Likewise, targets of miR-324-3p are more enriched in c4 (along with the shared targets
but not miR-1913-3p), which is associated with terms concerning transcription and chromatin, and
c10, which is associated with terms relating to chromatin and histone modification, again similar to
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its enrichment in Parikshak M2.
In an effort to identify co-targeting amongst small sets of interrelated proteins (such as a protein com-
plex), we used CFinder tool over the same ‘merged target’ network. The community set generated
with k=8 (CFinder generated communities for k=3-14) was chosen, as it gave 5 communities (CFC0
to CFC4) sized between 10 and 41 genes. The relative enrichment of these communities from both
miR-1913-3p and miR-324-3p is listed in Table 5.6. There was only one significant enrichment; genes
that were targeted only by miR-1913-3p in the CFC1 community, (p=7.71×10−3). This community
contains proteins that form the proteasome complex; using ClueGO [141] (GO BP, CC and MF anno-
tations, term merging enabled) the top significant terms included GO:0000502 ‘proteasome complex’
and GO:0022624 ‘proteasome accessory complex’. However, this association was exclusive to miR-
1913-3p, suggesting a functional difference between these microRNAs.
Figure 5.7: A visual summary of the communities with skewed enrichment to miR-1913-3p (blue) or miR-324-3p
(red) pulldown targets, and their GO associations. Details of the individual associations from the three levels
described in main text. Dotted lines represent weaker associations.
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Figure 5.8: Communities of miR-1913-3p and miR-324-3p target genes. Communities were created from the protein-protein interaction network of all significantly
enriched genes in the miR-324-3p and miR-1913-3p pulldowns, using the cluster fast greedy method implemented in the igraph package [216]. Only communities
with more than 15 members are displayed, and node sizes are log-scaled according to community membership. Edge thickness indicates cluster edge betweenness
calculated in igraph [216], and only edges with at least 10 connections shown. Enrichment of microRNA targets in communities is described in Table 5.5, with red/blue
stars representing significant enrichment (uncorrected p < 0.05) in miR-324-3p or miR-1913-3p targets respectively. Hollow stars indicate enrichment in the uniquely
miR-324-3p or miR-1913-3p targeted subsets, and green the shared genes targeted by both.
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(a) MiR-1913-3p and miR-324-3p Proteasome PPI cluster
(b) KEGG Proteasome
Figure 5.9: MiR-1913-3p targets members of the proteasome complex. (a) This graph shows the ‘c1’ commu-
nity generated by CFinder on the merged miR-324-3p and miR-1913-3p targets PPI network, it only includes
genes enriched in at least one of the pulldown. Node colours represent the fold enrichment on a gradual scale,
redder colours indicate miR-324-3p targeting, and bluer colours represent miR-1913-3p enrichment, overlap-
ping genes are in purple. (b) The KEGG proteasome pathway is shown here genes enriched in miR-1913-3p
pulldown in red. Redness is proportional to logFC enrichment. Image generated from KEGG data [172] with
pathview R package [232].
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Table 5.4: Enrichment of miR-324-3p and miR-1913-3p target genes within coexpressed gene modules identified in [86]. Parikshak et al. constructed and
characterised a set of co-expressed gene modules across within a human neurodevelopmental context, using data from BrainSpan. [86, 132]. The enrichment of
miR-324-3p and miR-1913-3p total, specific and shared (both) genesets was calculated in the PPI communities generated from their shared targeting genelist. P
values are a 1-tailed test using hypergeometric distribution, against a background of genes measured in both pulldown assays and present in the Parikshak 2013
analysis (n=10590), and corrected with BH method [154]. Module numbers and top GO terms are as reported in [86].
Module Module
Size
miR-324-3p Pval miR-1913-3p Pval miR-324-3p
Only
Pval miR-1913-3p
Only
Pval Both Pval
M1
428 41 1.00E+00 67 1.00E+00 4 1.00E+00 18 1.00E+00 22 1.00E+00
M2 GO:0008270 zinc ion binding
572 116 6.01E-09 108 5.58E-01 21 1.48E-01 18 1.00E+00 57 4.73E-05
M3 GO:0090304 nucleic acid metabolic process
721 93 5.50E-01 140 2.98E-01 20 6.64E-01 35 8.83E-01 40 1.00E+00
M4
296 37 7.50E-01 75 1.75E-03 5 9.28E-01 24 9.27E-03 25 4.65E-02
M5
604 79 5.50E-01 93 1.00E+00 22 1.48E-01 21 1.00E+00 31 1.00E+00
M6
233 29 7.50E-01 31 1.00E+00 10 1.48E-01 5 1.00E+00 9 1.00E+00
M8 GO:0045665 negative regulation of neuron differentiation
125 15 8.19E-01 15 1.00E+00 2 9.22E-01 3 1.00E+00 6 1.00E+00
M9 GO:0006521 regulation of cellular amino acid metabolic process
181 24 7.17E-01 48 4.32E-03 3 9.26E-01 15 3.02E-02 18 3.88E-02
M10
0 0 1.00E+00 0 1.00E+00 0 1.00E+00 0 1.00E+00 0 1.00E+00
M11 GO:0007049 cell cycle
367 35 1.00E+00 46 1.00E+00 8 9.22E-01 13 1.00E+00 12 1.00E+00
M12
235 18 1.00E+00 39 1.00E+00 2 1.00E+00 11 1.00E+00 9 1.00E+00
M13 GO:0007268 synaptic transmission
305 25 1.00E+00 44 1.00E+00 5 9.28E-01 13 1.00E+00 9 1.00E+00
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Module Module
Size
miR-324-3p Pval miR-1913-3p Pval miR-324-3p
Only
Pval miR-1913-3p
Only
Pval Both Pval
M14 GO:0006414 translational elongation
428 65 8.61E-02 117 1.28E-06 16 1.48E-01 44 4.55E-07 34 4.65E-02
M15 GO:0009615 response to virus
60 6 1.00E+00 6 1.00E+00 2 6.20E-01 2 1.00E+00 0 1.00E+00
M16 GO:0019829 cation-transporting ATPase activity
369 36 1.00E+00 58 1.00E+00 9 8.28E-01 11 1.00E+00 12 1.00E+00
M17 GO:0007268 synaptic transmission
473 48 1.00E+00 76 1.00E+00 13 6.64E-01 19 1.00E+00 23 1.00E+00
M18 GO:0006952 defense response
216 22 1.00E+00 25 1.00E+00 5 8.28E-01 3 1.00E+00 10 1.00E+00
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Table 5.5: Enrichment of miR-324-3p and miR-1913-3p target genes within communities. The enrichment of miR-324-3p and miR-1913-3p total, specific and shared (both)
genesets was calculated in the PPI communities generated from their shared targeting genelist. P values are a 1-tailed test using hypergeometric distribution. This whole
network was the background. P-values were not corrected, as calculations were against the limited network background (n=2192), already targeted by these microRNAs, and
should be regarded as a guide.
comm comm
size
miR324 miR324
Pval
miR1913 miR1913
Pval
miR324
Only
miR324
Only Pval
miR1913
Only
miR1913
Only Pval
both both Pval
c1 455 216 8.47E-01 348 1.69E-01 47 4.94E-01 71 9.86E-01 109 5.61E-01
c2 450 207 9.57E-01 337 4.71E-01 52 1.68E-01 101 2.36E-02 94 9.70E-01
c3 85 42 5.50E-01 58 9.32E-01 8 6.54E-01 18 3.45E-01 15 9.44E-01
c4 496 276 1.09E-03 356 9.57E-01 46 8.08E-01 82 9.54E-01 136 3.06E-02
c5 455 228 4.05E-01 354 4.50E-02 44 6.95E-01 99 5.58E-02 127 2.09E-02
c6 52 21 9.30E-01 37 7.75E-01 5 6.27E-01 14 1.02E-01 6 9.93E-01
c7 38 15 9.21E-01 29 4.91E-01 5 3.47E-01 8 4.39E-01 6 9.26E-01
c8 49 22 7.87E-01 42 4.51E-02 3 8.92E-01 8 7.42E-01 15 1.82E-01
c9 37 19 4.75E-01 27 6.73E-01 4 5.33E-01 6 7.34E-01 9 5.53E-01
c10 15 6 8.41E-01 11 6.75E-01 4 5.87E-02 1 9.58E-01 2 9.09E-01
c11 6 6 1.46E-02 2 9.95E-01 0 1.00E+00 0 1.00E+00 2 4.45E-01
c12 7 3 7.65E-01 5 7.49E-01 2 1.55E-01 2 3.96E-01 1 8.56E-01
c13 5 3 4.91E-01 3 8.93E-01 1 4.17E-01 0 1.00E+00 1 7.49E-01
c14 5 1 9.67E-01 4 6.25E-01 0 1.00E+00 3 5.05E-02 0 1.00E+00
c15 5 3 4.91E-01 2 9.84E-01 1 4.17E-01 0 1.00E+00 0 1.00E+00
c16 7 3 7.65E-01 6 4.36E-01 0 1.00E+00 1 7.72E-01 2 5.33E-01
c17 3 2 4.92E-01 2 8.40E-01 0 1.00E+00 0 1.00E+00 1 5.64E-01
c18 4 4 5.99E-02 2 9.47E-01 0 1.00E+00 0 1.00E+00 2 2.47E-01
c19 3 3 1.21E-01 0 1.00E+00 1 2.76E-01 0 1.00E+00 0 1.00E+00
c20 3 0 1.00E+00 3 4.16E-01 0 1.00E+00 0 1.00E+00 0 1.00E+00
c21 2 2 2.45E-01 1 9.36E-01 0 1.00E+00 0 1.00E+00 1 4.25E-01
c22 4 2 6.80E-01 2 9.47E-01 1 3.50E-01 0 1.00E+00 0 1.00E+00
c23 2 1 7.45E-01 1 9.36E-01 0 1.00E+00 1 3.44E-01 0 1.00E+00
c24 2 0 1.00E+00 2 5.57E-01 0 1.00E+00 2 3.61E-02 0 1.00E+00
c25 2 0 1.00E+00 2 5.57E-01 0 1.00E+00 0 1.00E+00 0 1.00E+00
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Table 5.6: Enrichment of miR-324-3p or miR-1913-3p pulldown enriched genes within small protein clusters.
Protein clusters made using CFinder [219] on the PPI network of the merged miR-324-3p and miR-1913-3p
pulldown enriched genes. Enrichment calculated as hypergeometric distribution against the background of
2544 merged pulldown network genes, and corrected in R with BH method.
Comm Geneset Hits Comm Size Geneset Size pval padj
cfc0 miR1913 8 11 1636 7.04E-01 9.18E-01
miR1913 only 0 11 417 1.00E+00 1.00E+00
miR324 8 11 1085 1.06E-01 2.66E-01
miR324 only 0 11 224 1.00E+00 1.00E+00
cfc1 miR1913 17 23 1636 6.39E-01 9.18E-01
miR1913 only 11 23 417 1.54E-03 7.71E-03
miR324 8 23 1085 9.49E-01 9.49E-01
miR324 only 1 23 224 9.17E-01 1.00E+00
cfc2 miR1913 6 10 1636 9.18E-01 9.18E-01
miR1913 only 1 10 417 8.79E-01 1.00E+00
miR324 8 10 1085 5.09E-02 2.54E-01
miR324 only 2 10 224 2.72E-01 9.74E-01
cfc3 miR1913 29 41 1636 7.80E-01 9.18E-01
miR1913 only 11 41 417 1.40E-01 3.50E-01
miR324 18 41 1085 8.11E-01 9.49E-01
miR324 only 4 41 224 6.17E-01 1.00E+00
cfc4 miR1913 9 13 1636 7.85E-01 9.18E-01
miR1913 only 2 13 417 7.40E-01 1.00E+00
miR324 7 13 1085 4.85E-01 8.09E-01
miR324 only 2 13 224 3.90E-01 9.74E-01
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5.4 Discussion
This work aimed to explore the relationship between seed-sharing microRNAs miR-324-3p and miR-
1913-3p in terms of their sequence similarity and consequential targeting similarity, the biological
relevance of any differences, and to explore a role in neuronal function and proliferation. It appears
that despite significant overlap in their transcriptome-wide binding profiles, the difference in the ma-
ture sequences of these two microRNAs may account for divergent biological function.
Sets of microRNAs with identical seeds are not uncommon, particularly among more recently dis-
covered examples with lesser evolutionary conservation [193]. MiR-324 is well conserved among
mammals whereas miR-1913 is primate-specific, miR-1913 is one of the many lineage-specific mi-
croRNAs that are less studied than their highly conserved counterparts [193]. It appears that miR-
1913 and miR-324 are not homologous, and that their similarity could be the result of convergent
evolution. MiR-1913 occurs only within the RPS6KA2 gene, which itself is conserved without in-
tronic microRNA outside of primates suggesting that it is unlikely to be a simple duplication of the
miR-324 gene. This is further supported by the lack of similarity in the hairpin sequences outside of
the mature microRNA (Figure 5.3b). Rather, the origin of miR-1913 might be more consistent with
having arisen from within the RPS6KA2 intron via mechanisms described in [233].The presence or
absence of a miR-1913 gene in a primate species did not appear correlated with the conservation of
its predicted target sites (Figure 5.2) - which could be an indicator of convergent evolution to existing
target sequences, but further work is needed to support this.
With identical seed regions, the binding profiles of miR-324-3p and miR-1913-3p have consider-
able overlap (Figure 5.4a). But seed matches are only one component of microRNA specificity [31].
Because the pulldown assay used exogenous tagged mature microRNA duplexes, the differences be-
tween miR-324-3p and miR-1913-3p binding reported (Figure: 5.4b) may be ascribed to differences
in the mature sequence outside of the seed region, rather than local genomic expression or hairpin
structure factors.
In the literature, miR-324-3p is described with an anti-proliferative/pro-differentiation role, with in-
creased expression upon differentiation (and thus reduced proliferation) in several cell lines [197,
198, 234] and decreased expression within several cancer conditions [197, 229, 230, 235, 236]. The
functional annotations of our pulldown results support these observations. The miR-324-3p binding
profile had significant association with several cancer pathways directly described in KEGG (Supple-
mentary Table 5.10), and more generally ‘ErbB Signalling Pathway’ and ‘mTOR signalling pathway’;
pathways with underlying relevance to cell growth and cancer [237, 238]. In contrast to reports for
the 5’ arm of miR-324, the pulldown results suggest that miR-324-3p might not target the Hedgehog
signalling pathway. The hedgehog pathway is absent from the functional associations of miR-324-
3p (nor significant for miR-1913-3p) (Supplementary Table 5.10), and the SMO gene targeted by
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miR-324-5p [197] was not enriched in the pulldown assays.
These potential associations with cell-cycle pathways drove an interest in the involvement of miR-
1913-3p and miR-324-3p during induced differentiation of SH-SY5Y neuroblastoma cell line. We
observed an increase in miR-1913-3p expression levels during induced SH-SY5Y differentiation,
though results for miR-324-3p were not statistically significant (Figure 5.5). It is interesting to note
that this common expression pattern occurs despite the two genes being on different chromosomes in
different genomic contexts. Furthermore, a set of genes having altered expression during SH-SY5Y
differentiation [215] was subtly down-regulated with the exogenous over-expression of these microR-
NAs (Table 5.3). This is consistent with a model of higher miR-324-3p and miR-1913-3p having a
broad but subtle down-regulation of targets in differentiated, non-proliferating cells. However, it
should be noted the same SH-SY5Y differentiation geneset was not significantly enriched in the pull-
down assay results. It may simply be that a subtle signal within the confines of cellular homoeostasis
was lost in the blunter biochemical measure of binding affinity of the pulldown assay.
While miR-324-3p and miR-1913-3p do share a large proportion of targeting, we aimed to identify
differences between them by looking at biases in enrichments of three distinct clustered subsets of
genes, which capture functional units of genes at different biological scales. We used information at
the mRNA level from modules generated by Parikshak et al. [86] from their co-expression analysis of
neurodevelopmental brain tissues. Our two sets of PPI communities were generated from the merged
set of miR-324-3p and miR-1913-3p pulldown targets; using the ‘cluster fast greedy algorithm’ in
igraph [216] and k-clique clustering by CFinder [219] to form communities at the medium-large
‘broad’ level and smaller complex-focused levels respectively. Analysis of enrichment within these
modules revealed some functional associations specific to miR-1913-3p (Figure 5.7).
MiR-1913-3p appears to be involved in regulation of genes involved in the proteasome and ubiqui-
tination pathways. It has a significant enrichment to a small PPI community of genes enriched for
proteasome complex (Table 5.6), many of which form part of the 19S and 20S proteasome complex
particles (Figure 5.9). This enrichment is not seen in hsa-miR-324-3p (Figure 5.9a). The proteasome
degrades proteins marked by ubiquitination, and miR-1913-3p is seen enriched in ubiquitination re-
lated PPI community C2 (GO terms include: ‘GO:0070647 Protein modification by small protein
conjugation or removal’, ‘GO:0004842 ubiquitin-protein transferase activity’), and the mRNA coex-
pression module M9, which includes enrichment by terms ‘negative regulation of ubiquitin-protein
ligase activity involved in mitotic cell cycle’ and ‘positive regulation of ubiquitin-protein ligase activ-
ity involved in mitotic cell cycle’.
Conversely, miR-1913-3p also appears to be involved in regulation of protein translational machinery.
There’s a strong enrichment in Parikshak et al. (2013) modules 14, (which actually increases amongst
the miR-1913-only subset; Table 5.4), and a lesser indication of bias in the broad PPI community C5,
both of which have GO association pertaining to translational processes. Furthermore, miR-1913
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is hosted with RPS6KA2, which encodes a ribosomal kinase, capable of phosphorylating ribosomal
protein R6, which in turn is involved in translational initiation [239, 240]. Our pulldown results also
indicated that RPS6KA2 was significantly enriched in the miR-1913-3p pulldown (but not miR-324-
3p), indicating a possible microRNA to host gene negative feedback loop.
An involvement for miR-1913-3p in regulation of both protein synthesis and degradation makes bio-
logical sense, as maintaining an appropriate balance between these two processes has been shown to
be important in neuronal functions such as long-term potentiation [241], and object memory [242].
A subtle regulatory influence from miR-1913-3p co-expressed with RPS6KA2 could contribute to
maintaining such a balance.
MicroRNAs in general are an important class of regulators in the brain [191, 195], and both miR-324-
3p and miR-1913-3p appear to be present in a neuronal context. MiR-324-3p is expressed across many
tissues, but most highly in the brain [226], and is located very close to synaptic gene DLG4. Though
miR-1913-3p has only been seen at low-levels of expression in the brain [103, 194, 212], it may simply
be active at low levels, or at certain spatio-temporal contexts. Certainly its potential co-expression
with RPS6KA2 does point to a neural context. In mice, RPS6KA2 is expressed relatively higher
during early neural development [243], and in humans, the existence of a brain-specific isoform of
RPS6KA2, even though both encapsulate the miR-1913 gene, would suggest that either of RPS6KA2
itself and/or miR-1913 play some neural function, perhaps in certain spatio-temporal contexts.
Understanding the binding capabilities of a microRNA is an important step in understanding its func-
tion, but it is difficult due to the sheer number of variables involved microRNA binding. MiR-324-3p
and miR-1913-3p share a seed region, and we have used a microRNA:mRNA pulldown assay com-
bined with RNAseq and subsequent systems-based approaches to tease out the similarities and differ-
ences in the binding profiles and functional associations between these two microRNAs. These results
lend further support for an anti-proliferative/pro-differentiation role of the miR-324 gene discussed
in the literature. This work is also the first attempt at characterising the miR-1913 gene, and points
towards a role in the regulation of protein synthesis and degradation pathways - it has been suggested
that dysregulation of this balance may contribute to neuropsychiatric disorders, such as autism [244].
These results also underline the potential for quite similar microRNAs, even quite novel microRNAs
not broadly conserved, to occupy different regulatory niches.
145
5.5 Supplementary Results
5.5.1 Analysis of microRNA:mRNA pulldown sequencing experiments
Because to date there have been no detailed examples of analysis of pulldown sequencing experiments
(rather than microarrays) in the literature, several properties of the data that may be particular to
pulldown analysis have been described here.
Although the pulldown data has been analysed using a typical RNAseq differential expression work-
flow, there is a key difference. While typical RNAseq experiments might examine the difference
effect of a treatment on cells, the microRNA pulldown assay quantifies the effect of a biochemical
assay between pairs of samples and their microRNA-captured lysate. We expect that the mRNA
composition within a lysate would be less constrained than that within living cells. This is supported
by the greater spread of fold-change values seen in the microRNA pulldown contrasts, particularly
compared with the transfection contrasts (Figure 5.14).
In fact there was no significant differential expression detected across either of the microRNA trans-
fection conditions, despite the relatively high levels of transfected microRNA. This can be clearly
seen in the PCA analysis, which shows that transfected samples group with untransfected samples,
but the miR-324-3p and miR-1913-3p pulldown samples are form two distinct clusters (Supplemen-
tary Figure 5.10b). Despite the lack of separation, having the transfected controls as recommended
in [82] enables a paired analysis contrasting each pulldown to its source cells, increasing statistical
power to detect enrichment.
Note that a slight batch effect was detected in the first principal component, however because the
experimental design is paired and balanced it is not a major factor in the analysis (Supplementary
Figure 5.10a).
We tested for bias of enrichment to gene length, and did not see any problematic correlation (Supple-
mentary Figure 5.15).
146
(a) PC1 vs PC2 (b) PC1 vs PC3
Figure 5.10: Principal component analysis (PCA) plots of all sequenced samples, with first 3 principal compo-
nents (PC) Replicates are represented by shape.
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5.6 Supplementary Figures
Figure 5.11: MicroRNA miR-324 expression contrasted across different tissues. Data is normalised copy num-
ber estimations from a broad study of microRNA expression in different tissue types, by Liang et al. [226].
Average reflects average copy number estimates for all microRNAs in each tissue.
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(a) miR-324-3p (b) miR-1913-3p
(c) cel-miR-67 (d) Mock-transfected
Figure 5.12: Staining shows small distinct clusters of streptavidin-594 staining in SH-SY5Y cells transfected
with biotinylated synthetic microRNAs miR-324-3p, miR-1913-3p, cel-miR-67, but no such signal is seen in
mock-transfected control cells. Images were made by merging light images, with DAPI (blue) channel and
Alexa Flour 594 Streptavidin (red). Images were coloured in FIJI imageJ and of the red channel was increased
consistently across all images via Adobe Photoshop levels tool.
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(a) Pulldown
(b) Transfection
Figure 5.13: RT-qPCR results for a) pulldown and b) transfection (exogenous overexpression) of microRNAs
miR-324-3p, miR-1913-3p and control cel-miR-67. Error bars reflect 95% confidence interval. Significance
tested with students t-test, paired in (a), and unpaired in (b), * indicates significance (p-value <0.05), and +
indicates marginal significance (p-value <0.1). Relative expression is 2-CT.
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Figure 5.14: MA plots for differential expression and enrichment contrasts. Genes that are significantly en-
riched are marked in red. Plots created with in R with DEseq2
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(a) miR-324-3p Pulldown (b) miR-1913-3p Pulldown
Figure 5.15: Correlations of log2FC enrichment versus the median mRNA transcript length of test genes. Line
fitted with loess method in R.
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5.7 Supplementary Tables
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Table 5.7: Biotinylated microRNA duplexes used in experiments. These are based on the hairpin predictions annotated by miRBase, with minor modifications (Added 3’
G on miR-1913-5p, removed 3’ U on miR-324-5p) to bring overhangs closer to recommendations in [82].
miRNA 3 Biotinylated strand Sequence 3’ Non-biotinylated strand Sequence 5’
hsa-miR-1913 mir1913-3p UCUGCCCCCUCCGCUGCUGCCA mir1913-5p CCGGCAGAGGAGGCUGCAGAGG
hsa-miR-324 miR324-3p ACUGCCCCAGGUGCUGCUGG miR324-5p CGCAUCCCCUAGGGCAUUGGUG
cel-miR-67 celmir67-3p UCACAACCUCCUAGAAAGAGUAGA celmir67-5p CGCUCAUUCUGCCGGUUGUUAUG
Table 5.8: Primer sequences used in RT-qPCR of predicted miR-324-3p and miR-1913-3p target genes
Target Class Target Size Forward primer Forward Sequence Reverse Primer Reverse Sequence
EMC7 control 108 EMC7-F1 CAGTTGTTCCAGGGGTGAAG EMC7-R1 GAACCACAAAACTCCCATCTG
HPRT1 control 119 HPRT1-F1 TGCTGAGGATTTGGAAAGG HPRT1-R1 GCACACAGAGGGCTACAATG
PSMB4 control 120 PSBM4-F1 GTGGACATGCTTGGTGTAGC PSBM4-R1 CTCGGTCTGGCTTAGCACTG
DLGAP2 Test 86 DLGAP2-F1 CTGAGGCCGTGCCACTAC DLGAP2-R1 CTGCAGGGAATCTCCTCATC
DPYSL2 Test 83 DPYSL2-F1 GTGAGTGGCATAAGGGCATC DPYSL2-R1 AGCCATGTACACGAGGAAGG
L1CAM Test 117 L1CAM-F1 GAGGTTCCAGGGCATCTACC L1CAM-R1 GGCTTCACTGTCTCCTTTGG
NUMB Test 113 NUMB-F1 TCATTCCGTGTCACAACAGC NUMB-R1 GCAACTGATGAACCAACGAC
RPS6KA2 Test 108 RPS6KA2-F1 AGATCGAGGTGGAGCCTATG RPS6KA2-R1 CCTTCACGACGCCTTCTTC
RPS6KA2 Test 92 RPS6KA2-F2 CGTGCGCAGGTTCTTCTC RPS6KA2-R1 CCTTCACGACGCCTTCTTC
SZT2 Test 113 SZT2-F1 GAGTGCCTGGATCTTGCATC SZT2-R1 CAAGAGGCAGCCCTGTACC
TTYH1 Test 90 TTYH1-F1 CACCTGGAGCTGCATTGTC TTYH1-R1 GACACCCCATCACTGGTCTC
Table 5.9: Primer sequences used in cloning and running of miR-1913-3p luciferase assay
Oligo Sequence
hsa-miR-1913 Mimic UCUGCCCCCUCCGCUGCUGCCA
cel-miR-67 Negative Control Mimic UCACAACCUCCUAGAAAGAGUAGA
hsa-miR-1913 Exact match Positive control Fwd CAGTGACTCTCGAGCAGTGGCAGCAGCGGAGGGGGCAGAGACGCGGCCGCCAGTGACT
hsa-miR-1913 Exact match Positive control Rev AGTCACTGGCGGCCGCGTCTCTGCCCCCTCCGCTGCTGCCACTGCTCGAGAGTCACTG
hsa-miR-1913 L1CAM target site Fwd CAGTGACTCTCGAGCAGCATGGGAGGCTGGAGTTGGGGCAGAGACGCGGCCGCCAGTGACT
hsa-miR-1913 L1CAM target site Rev AGTCACTGGCGGCCGCGTCTCTGCCCCAACTCCAGCCTCCCATGCTGCTCGAGAGTCACTG
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Table 5.10: Pulldown GSEA vs public databases. A summary of GSEA (Gene Set Enrichment Analysis) [171] looking at the global expression or enrichment
changes in pulldown and transfection experiments against several public databases; Reactome [142], KEGG [189], Gene Ontology (GO) Biological Process (BP)
and GO Cellular component (CC) . GSEA input was a ‘pre-ranked’ list of all tested genes sorted by DESEQ2 log2FC values (where higher values mean greater
enrichment) with ‘weighted’ scoring. Normalised Enrichment score and Nominal p-value are described in the GSEA documentation.
MicroRNA Database Annotation Size Normalised En-
richment Score
Nominal pVal FDR qVal
miR-324-3p GO CARBOHYDRATE BIOSYNTHETIC PROCESS 33 1.87 0.00E+00 0.44
miR-324-3p GO STRIATED MUSCLE DEVELOPMENT 25 1.86 7.21E-03 0.23
miR-324-3p GO TRANSCRIPTION FACTOR COMPLEX 78 1.84 0.00E+00 0.19
miR-324-3p GO POSITIVE REGULATION OF TRANSCRIPTION 110 1.73 0.00E+00 0.42
miR-324-3p GO PROTEIN TYROSINE PHOSPHATASE ACTIVITY 35 1.7 6.99E-03 0.44
miR-324-3p GO POSITIVE REGULATION OF NUCLEOBASENUCLEOSIDENUCLEOTIDE AND
NUCLEIC ACID METABOLIC PROCESS
115 1.67 1.60E-03 0.49
miR-324-3p GO HISTONE DEACETYLASE COMPLEX 19 1.67 7.23E-03 0.43
miR-324-3p GO POSITIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II
PROMOTER
50 1.66 1.81E-03 0.4
miR-324-3p GO TRANSCRIPTION FACTOR ACTIVITY 222 1.62 0.00E+00 0.52
miR-324-3p GO GENERATION OF A SIGNAL INVOLVED IN CELL CELL SIGNALING 15 1.61 1.58E-02 0.5
miR-324-3p GO CARBOHYDRATE BINDING 20 1.6 2.35E-02 0.48
miR-324-3p GO RESPONSE TO HYPOXIA 21 1.6 2.42E-02 0.47
miR-324-3p GO ENZYME LINKED RECEPTOR PROTEIN SIGNALING PATHWAY 90 1.6 3.29E-03 0.44
miR-324-3p GO ORGAN DEVELOPMENT 257 1.59 0.00E+00 0.42
miR-324-3p GO TRANSMEMBRANE RECEPTOR PROTEIN TYROSINE KINASE SIGNALING
PATHWAY
52 1.59 1.95E-02 0.41
miR-324-3p GO POSITIVE REGULATION OF METABOLIC PROCESS 154 1.57 4.82E-03 0.44
miR-324-3p GO TRANSCRIPTION COACTIVATOR ACTIVITY 99 1.57 8.12E-03 0.42
miR-324-3p GO POSITIVE REGULATION OF CELLULAR METABOLIC PROCESS 150 1.57 1.66E-03 0.39
miR-324-3p GO TRANSCRIPTION ACTIVATOR ACTIVITY 134 1.56 1.61E-03 0.39
miR-324-3p GO POSITIVE REGULATION OF TRANSCRIPTIONDNA DEPENDENT 91 1.56 6.71E-03 0.37
miR-324-3p kegg KEGG ERBB SIGNALING PATHWAY 68 1.87 0.00E+00 0.07
miR-324-3p kegg KEGG ACUTE MYELOID LEUKEMIA 47 1.7 1.84E-03 0.23
miR-324-3p kegg KEGG CHRONIC MYELOID LEUKEMIA 63 1.67 1.73E-03 0.2
miR-324-3p kegg KEGG PHOSPHATIDYLINOSITOL SIGNALING SYSTEM 56 1.67 0.00E+00 0.15
miR-324-3p kegg KEGG MELANOGENESIS 58 1.62 6.79E-03 0.19
miR-324-3p kegg KEGG PANCREATIC CANCER 58 1.6 1.03E-02 0.17
miR-324-3p kegg KEGG NON SMALL CELL LUNG CANCER 43 1.59 6.91E-03 0.16
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MicroRNA Database Annotation Size Normalised En-
richment Score
Nominal pVal FDR qVal
miR-324-3p kegg KEGG GAP JUNCTION 58 1.58 8.80E-03 0.16
miR-324-3p kegg KEGG GNRH SIGNALING PATHWAY 68 1.57 8.43E-03 0.15
miR-324-3p kegg KEGG GLIOMA 48 1.55 1.83E-02 0.16
miR-324-3p kegg KEGG ENDOMETRIAL CANCER 45 1.54 1.89E-02 0.15
miR-324-3p kegg KEGG INSULIN SIGNALING PATHWAY 109 1.54 4.95E-03 0.14
miR-324-3p kegg KEGG GLYCOSAMINOGLYCAN BIOSYNTHESIS CHONDROITIN SULFATE 16 1.54 2.52E-02 0.14
miR-324-3p kegg KEGG RENAL CELL CARCINOMA 61 1.53 1.68E-02 0.13
miR-324-3p kegg KEGG FC EPSILON RI SIGNALING PATHWAY 45 1.5 2.74E-02 0.16
miR-324-3p kegg KEGG MTOR SIGNALING PATHWAY 45 1.49 2.64E-02 0.16
miR-324-3p kegg KEGG NATURAL KILLER CELL MEDIATED CYTOTOXICITY 50 1.43 3.79E-02 0.23
miR-324-3p kegg KEGG CYTOSOLIC DNA SENSING PATHWAY 25 1.39 7.55E-02 0.28
miR-324-3p kegg KEGG CHEMOKINE SIGNALING PATHWAY 101 1.38 3.41E-02 0.28
miR-324-3p kegg KEGG MELANOMA 40 1.37 8.13E-02 0.29
miR-324-3p reactome REACTOME PLC BETA MEDIATED EVENTS 31 1.99 1.77E-03 0.04
miR-324-3p reactome REACTOME CIRCADIAN CLOCK 43 1.94 0.00E+00 0.04
miR-324-3p reactome REACTOME NOTCH1 INTRACELLULAR DOMAIN REGULATES TRAN-
SCRIPTION
38 1.93 0.00E+00 0.04
miR-324-3p reactome REACTOME CIRCADIAN REPRESSION OF EXPRESSION BY REV ERBA 19 1.89 1.90E-03 0.04
miR-324-3p reactome REACTOME RORA ACTIVATES CIRCADIAN EXPRESSION 21 1.83 3.51E-03 0.07
miR-324-3p reactome REACTOME CA DEPENDENT EVENTS 21 1.82 7.41E-03 0.06
miR-324-3p reactome REACTOME TRANSCRIPTIONAL REGULATION OF WHITE ADIPOCYTE
DIFFERENTIATION
52 1.8 0.00E+00 0.07
miR-324-3p reactome REACTOME BMAL1 CLOCK NPAS2 ACTIVATES CIRCADIAN EXPRESSION 28 1.8 0.00E+00 0.07
miR-324-3p reactome REACTOME PPARA ACTIVATES GENE EXPRESSION 79 1.79 0.00E+00 0.06
miR-324-3p reactome REACTOME REGULATION OF HYPOXIA INDUCIBLE FACTOR HIF BY OXY-
GEN
21 1.77 1.98E-03 0.07
miR-324-3p reactome REACTOME PHOSPHOLIPASE C MEDIATED CASCADE 28 1.72 3.72E-03 0.1
miR-324-3p reactome REACTOME DAG AND IP3 SIGNALING 24 1.69 1.26E-02 0.12
miR-324-3p reactome REACTOME ANTIGEN ACTIVATES B CELL RECEPTOR LEADING TO GEN-
ERATION OF SECOND MESSENGERS
20 1.69 3.64E-03 0.11
miR-324-3p reactome REACTOME YAP1 AND WWTR1 TAZ STIMULATED GENE EXPRESSION 17 1.68 1.28E-02 0.11
miR-324-3p reactome REACTOME G PROTEIN ACTIVATION 18 1.6 3.11E-02 0.2
miR-324-3p reactome REACTOME SIGNAL AMPLIFICATION 20 1.6 2.19E-02 0.19
miR-324-3p reactome REACTOME INTERACTIONS OF VPR WITH HOST CELLULAR PROTEINS 31 1.57 1.36E-02 0.23
miR-324-3p reactome REACTOME ADP SIGNALLING THROUGH P2RY12 15 1.54 5.75E-02 0.28
miR-324-3p reactome REACTOME AQUAPORIN MEDIATED TRANSPORT 28 1.54 3.25E-02 0.26
miR-324-3p reactome REACTOME ACTIVATED TAK1 MEDIATES P38 MAPK ACTIVATION 15 1.53 6.10E-02 0.27
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MicroRNA Database Annotation Size Normalised En-
richment Score
Nominal pVal FDR qVal
miR-1913 GO STRESS ACTIVATED PROTEIN KINASE SIGNALING PATHWAY 38 1.69 1.01E-02 1
miR-1913 GO SPECIFIC RNA POLYMERASE II TRANSCRIPTION FACTOR ACTIVITY 25 1.69 8.91E-03 1
miR-1913 GO ORGAN MORPHOGENESIS 72 1.68 2.07E-03 1
miR-1913 GO CELL CORTEX 27 1.67 1.13E-02 0.85
miR-1913 GO NUCLEAR EXPORT 31 1.66 6.24E-03 0.75
miR-1913 GO ECTODERM DEVELOPMENT 24 1.63 1.04E-02 0.8
miR-1913 GO HISTONE DEACETYLASE COMPLEX 19 1.62 1.58E-02 0.71
miR-1913 GO JNK CASCADE 36 1.62 1.27E-02 0.63
miR-1913 GO SMALL NUCLEAR RIBONUCLEOPROTEIN COMPLEX 22 1.61 2.11E-02 0.61
miR-1913 GO NEGATIVE REGULATION OF BIOSYNTHETIC PROCESS 16 1.61 2.00E-02 0.56
miR-1913 GO NEGATIVE REGULATION OF CELLULAR BIOSYNTHETIC PROCESS 16 1.6 2.49E-02 0.53
miR-1913 GO CARBOHYDRATE BIOSYNTHETIC PROCESS 33 1.59 1.00E-02 0.54
miR-1913 GO ATP DEPENDENT RNA HELICASE ACTIVITY 16 1.58 2.36E-02 0.54
miR-1913 GO N ACYLTRANSFERASE ACTIVITY 19 1.55 3.97E-02 0.63
miR-1913 GO REGULATION OF TRANSLATION 52 1.54 1.41E-02 0.63
miR-1913 GO REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT 16 1.54 2.80E-02 0.61
miR-1913 GO REGULATION OF G PROTEIN COUPLED RECEPTOR PROTEIN SIGNALING
PATHWAY
19 1.54 4.12E-02 0.57
miR-1913 GO RIBONUCLEOPROTEIN COMPLEX 137 1.54 2.14E-03 0.54
miR-1913 GO RNA DEPENDENT ATPASE ACTIVITY 17 1.53 4.60E-02 0.52
miR-1913 GO TRANSCRIPTION FACTOR COMPLEX 79 1.51 4.42E-03 0.59
miR-1913 kegg KEGG ERBB SIGNALING PATHWAY 70 1.58 1.06E-02 1
miR-1913 kegg KEGG INSULIN SIGNALING PATHWAY 111 1.55 2.00E-03 0.7
miR-1913 kegg KEGG CHEMOKINE SIGNALING PATHWAY 102 1.52 8.73E-03 0.57
miR-1913 kegg KEGG OLFACTORY TRANSDUCTION 15 1.47 6.60E-02 0.63
miR-1913 kegg KEGG GLYCOLYSIS GLUCONEOGENESIS 37 1.41 6.50E-02 0.75
miR-1913 kegg KEGG NEUROTROPHIN SIGNALING PATHWAY 107 1.41 3.14E-02 0.64
miR-1913 kegg KEGG ENDOMETRIAL CANCER 45 1.37 7.66E-02 0.71
miR-1913 kegg KEGG CHRONIC MYELOID LEUKEMIA 65 1.36 5.42E-02 0.63
miR-1913 kegg KEGG TGF BETA SIGNALING PATHWAY 56 1.36 7.24E-02 0.58
miR-1913 kegg KEGG DRUG METABOLISM OTHER ENZYMES 17 1.33 1.06E-01 0.6
miR-1913 kegg KEGG SYSTEMIC LUPUS ERYTHEMATOSUS 30 1.32 1.09E-01 0.59
miR-1913 kegg KEGG GNRH SIGNALING PATHWAY 70 1.32 7.10E-02 0.55
miR-1913 kegg KEGG MELANOGENESIS 59 1.31 1.08E-01 0.52
miR-1913 kegg KEGG BASE EXCISION REPAIR 33 1.31 1.13E-01 0.49
miR-1913 kegg KEGG PYRIMIDINE METABOLISM 81 1.26 1.08E-01 0.6
miR-1913 kegg KEGG PROSTATE CANCER 71 1.26 1.05E-01 0.58
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MicroRNA Database Annotation Size Normalised En-
richment Score
Nominal pVal FDR qVal
miR-1913 kegg KEGG GLIOMA 49 1.25 1.38E-01 0.57
miR-1913 kegg KEGG GLYCOSAMINOGLYCAN BIOSYNTHESIS CHONDROITIN SULFATE 16 1.22 2.01E-01 0.62
miR-1913 kegg KEGG HEDGEHOG SIGNALING PATHWAY 25 1.2 2.14E-01 0.68
miR-1913 kegg KEGG NOTCH SIGNALING PATHWAY 37 1.18 2.18E-01 0.71
miR-1913 reactome REACTOME NOTCH1 INTRACELLULAR DOMAIN REGULATES TRAN-
SCRIPTION
39 1.78 2.04E-03 0.69
miR-1913 reactome REACTOME INTERACTION BETWEEN L1 AND ANKYRINS 15 1.7 1.74E-02 0.7
miR-1913 reactome REACTOME ANTIGEN ACTIVATES B CELL RECEPTOR LEADING TO GEN-
ERATION OF SECOND MESSENGERS
20 1.69 1.01E-02 0.53
miR-1913 reactome REACTOME G ALPHA Z SIGNALLING EVENTS 31 1.67 9.78E-03 0.47
miR-1913 reactome REACTOME RORA ACTIVATES CIRCADIAN EXPRESSION 22 1.66 1.43E-02 0.42
miR-1913 reactome REACTOME GLUCAGON SIGNALING IN METABOLIC REGULATION 24 1.63 1.62E-02 0.42
miR-1913 reactome REACTOME CIRCADIAN REPRESSION OF EXPRESSION BY REV ERBA 20 1.63 1.72E-02 0.36
miR-1913 reactome REACTOME BMAL1 CLOCK NPAS2 ACTIVATES CIRCADIAN EXPRESSION 29 1.61 2.92E-02 0.38
miR-1913 reactome REACTOME PHOSPHOLIPASE C MEDIATED CASCADE 29 1.6 2.33E-02 0.36
miR-1913 reactome REACTOME BASE EXCISION REPAIR 18 1.59 2.32E-02 0.35
miR-1913 reactome REACTOME CA DEPENDENT EVENTS 21 1.57 2.43E-02 0.36
miR-1913 reactome REACTOME RNA POL III TRANSCRIPTION INITIATION FROM TYPE 3 PRO-
MOTER
25 1.57 3.85E-02 0.35
miR-1913 reactome REACTOME REGULATION OF WATER BALANCE BY RENAL AQUAPORINS 28 1.56 2.91E-02 0.35
miR-1913 reactome REACTOME AQUAPORIN MEDIATED TRANSPORT 28 1.54 3.31E-02 0.35
miR-1913 reactome REACTOME RNA POL III TRANSCRIPTION INITIATION FROM TYPE 2 PRO-
MOTER
22 1.53 2.58E-02 0.36
miR-1913 reactome REACTOME REGULATION OF HYPOXIA INDUCIBLE FACTOR HIF BY OXY-
GEN
21 1.53 3.76E-02 0.35
miR-1913 reactome REACTOME RNA POL III TRANSCRIPTION 32 1.52 4.59E-02 0.34
miR-1913 reactome REACTOME GABA B RECEPTOR ACTIVATION 20 1.52 4.62E-02 0.32
miR-1913 reactome REACTOME DAG AND IP3 SIGNALING 24 1.52 4.04E-02 0.31
miR-1913 reactome REACTOME POST NMDA RECEPTOR ACTIVATION EVENTS 26 1.51 3.91E-02 0.31
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Table 5.11: GO enrichment for miR-324-3p and miR-1913-3p target gene protein-protein (PPI) communities. P-values calculated with fisher exact test via TopGO
R package [218], and corrected with BH method. Background was defined as genes assayed in both miR-324-3p and miR-1913-3p pulldowns, and within PPI
network. Top 5 significant (adjusted p < 0.05.) GO terms shown for each GO ontology.
Comm GO
Ontology
GOTerm Description Hits Expected Comm Size GO size P value Adj P value
c1 BP GO:0016192 vesicle-mediated transport 75 35.26 455 861 1.5E-10 9.2565E-07
c1 BP GO:0031047 gene silencing by RNA 15 2.01 455 49 5.2E-10 1.37819E-06
c1 BP GO:0007010 cytoskeleton organization 66 30.1 455 735 6.7E-10 1.37819E-06
c1 BP GO:0050789 regulation of biological process 307 252.4 455 6164 1.9E-09 2.93123E-06
c1 BP GO:0065007 biological regulation 315 262.88 455 6420 4.6E-09 5.67732E-06
c1 CC GO:0044463 cell projection part 57 21.12 455 512 4E-12 2.9536E-09
c1 CC GO:0042995 cell projection 88 42.03 455 1019 7.1E-12 2.9536E-09
c1 CC GO:0005856 cytoskeleton 105 55.47 455 1345 2.1E-11 5.824E-09
c1 CC GO:0005829 cytosol 143 92.22 455 2236 4.3E-09 8.944E-07
c1 CC GO:0097458 neuron part 58 26.52 455 643 0.00000001 1.30743E-06
c1 MF GO:0005515 protein binding 375 292.05 455 6889 8E-23 9.88E-20
c1 MF GO:0008092 cytoskeletal protein binding 51 24.04 455 567 0.00000022 0.00013585
c1 MF GO:0032403 protein complex binding 51 24.84 455 586 0.00000061 0.000251117
c1 MF GO:0005488 binding 400 373.96 455 8821 0.0000037 0.001142375
c1 MF GO:0017048 Rho GTPase binding 12 2.54 455 60 0.0000063 0.0015561
c2 BP GO:0070647 protein modification by small protein co... 84 28.13 450 672 1.5E-20 9.2565E-17
c2 BP GO:0016567 protein ubiquitination 73 23.24 450 555 4.2E-19 1.29591E-15
c2 BP GO:0032446 protein modification by small protein co... 74 24.74 450 591 4E-18 7.86803E-15
c2 BP GO:0051603 proteolysis involved in cellular protein... 66 20.35 450 486 5.1E-18 7.86803E-15
c2 BP GO:0044257 cellular protein catabolic process 67 21.06 450 503 7.8E-18 9.62676E-15
c2 CC GO:0005737 cytoplasm 361 286.24 450 7040 4E-18 3.328E-15
c2 CC GO:0000502 proteasome complex 23 2.4 450 59 2.1E-17 8.736E-15
c2 CC GO:0005829 cytosol 164 90.91 450 2236 1E-16 2.77333E-14
c2 CC GO:0031988 membrane-bounded vesicle 134 86.6 450 2130 0.000000019 0.000003952
c2 CC GO:0044444 cytoplasmic part 270 216.51 450 5325 0.000000045 5.29455E-06
c2 MF GO:0004842 ubiquitin-protein transferase activity 40 10.67 450 254 2.8E-13 2.964E-10
c2 MF GO:0019787 ubiquitin-like protein transferase activ... 41 11.34 450 270 4.8E-13 2.964E-10
c2 MF GO:0016874 ligase activity 43 14.53 450 346 1.2E-10 4.94E-08
c2 MF GO:0030234 enzyme regulator activity 53 23.01 450 548 7.9E-09 2.43913E-06
c2 MF GO:0043130 ubiquitin binding 16 3.23 450 77 0.000000091 0.000022477
c3 BP GO:0006002 fructose 6-phosphate metabolic process 3 0.04 85 5 0.0000039 0.0240669
c3 MF GO:0008443 phosphofructokinase activity 3 0.05 85 6 0.0000082 0.010127
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Comm GO
Ontology
GOTerm Description Hits Expected Comm Size GO size P value Adj P value
c4 BP GO:0009892 negative regulation of metabolic process 172 73.23 496 1539 1.6E-30 9.7584E-27
c4 BP GO:0016569 covalent chromatin modification 71 15.61 496 328 2E-28 4.066E-25
c4 BP GO:0044238 primary metabolic process 411 310.11 496 6517 2.8E-28 4.2693E-25
c4 BP GO:0016570 histone modification 70 15.47 496 325 6.8E-28 8.29464E-25
c4 CC GO:0005667 transcription factor complex 56 9.04 496 198 9.9E-30 8.1576E-27
c4 CC GO:0005694 chromosome 95 28.11 496 616 2.8E-27 1.1536E-24
c4 CC GO:0043231 intracellular membrane-bounded organelle 430 340.78 496 7468 3.7E-26 1.01627E-23
c4 CC GO:0043234 protein complex 232 128.27 496 2811 1.6E-25 3.296E-23
c4 CC GO:0000785 chromatin 62 13.55 496 297 6.8E-25 1.12064E-22
c4 MF GO:0000976 transcription regulatory region sequence... 67 13.25 496 274 9.2E-30 1.12424E-26
c4 MF GO:0003676 nucleic acid binding 252 141.04 496 2917 1.3E-27 7.943E-25
c4 MF GO:0001012 RNA polymerase II regulatory region DNA
...
56 11.12 496 230 7.7E-25 3.13647E-22
c4 MF GO:0000977 RNA polymerase II regulatory region
sequ...
55 11.07 496 229 4.3E-24 1.31365E-21
c4 MF GO:0003713 transcription coactivator activity 54 11.27 496 233 7.2E-23 1.75968E-20
c5 BP GO:0016071 mRNA metabolic process 87 23.62 455 552 8.3E-28 5.12193E-24
c5 BP GO:0006412 translation 81 21.14 455 494 4.9E-27 1.5119E-23
c5 BP GO:0006414 translational elongation 47 8.13 455 190 1.5E-23 2.62268E-20
c5 BP GO:0006413 translational initiation 53 10.48 455 245 1.7E-23 2.62268E-20
c5 BP GO:0008380 RNA splicing 61 14.25 455 333 6.4E-23 7.89888E-20
c5 CC GO:0005743 mitochondrial inner membrane 71 16.21 455 384 3.3E-27 2.7423E-24
c5 CC GO:0032991 macromolecular complex 246 141.9 455 3361 7.1E-26 2.95005E-23
c5 CC GO:0019866 organelle inner membrane 72 17.69 455 419 1.5E-25 4.155E-23
c5 CC GO:0005840 ribosome 49 8.15 455 193 2.6E-25 4.8198E-23
c5 CC GO:0031966 mitochondrial membrane 80 21.83 455 517 2.9E-25 4.8198E-23
c5 MF GO:0003735 structural constituent of ribosome 40 5.99 455 140 1.1E-22 1.3563E-19
c5 MF GO:0005198 structural molecule activity 56 15.79 455 369 4.1E-17 2.52765E-14
c5 MF GO:0003676 nucleic acid binding 191 124.84 455 2917 2.7E-12 1.1097E-09
c5 MF GO:1901363 heterocyclic compound binding 246 178.13 455 4162 9E-12 2.77425E-09
c5 MF GO:0097159 organic cyclic compound binding 246 179.2 455 4187 1.9E-11 4.6854E-09
c8 BP GO:0006102 isocitrate metabolic process 3 0.02 49 5 0.00000084 0.00518364
c8 CC GO:0016469 proton-transporting two-sector ATPase
co...
4 0.17 49 39 0.000022 0.018304
c8 MF GO:0004448 isocitrate dehydrogenase activity 3 0.02 49 5 0.00000093 0.00114855
c8 MF GO:0036442 hydrogen-exporting ATPase activity 3 0.1 49 21 0.00012 0.03705
c9 CC GO:0016021 integral component of membrane 20 8.22 37 2408 0.000019 0.009568
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Ontology
GOTerm Description Hits Expected Comm Size GO size P value Adj P value
c9 CC GO:0031224 intrinsic component of membrane 20 8.34 37 2443 0.000023 0.009568
c9 CC GO:0031090 organelle membrane 17 7.24 37 2121 0.00021 0.036845714
c9 CC GO:0098588 bounding membrane of organelle 14 5.22 37 1529 0.00027 0.036845714
c9 CC GO:0044456 synapse part 6 0.94 37 274 0.00029 0.036845714
c9 MF GO:0015450 P-P-bond-hydrolysis-driven protein trans... 3 0.02 37 7 0.0000011 0.0013585
c9 MF GO:0008320 protein transmembrane transporter activi... 3 0.04 37 13 0.0000086 0.004528333
c9 MF GO:0022884 macromolecule transmembrane transporter
...
3 0.05 37 14 0.000011 0.004528333
c9 MF GO:0008565 protein transporter activity 4 0.24 37 74 0.000088 0.02717
c10 BP GO:0008334 histone mRNA metabolic process 3 0.03 15 24 0.0000028 0.0172788
c10 BP GO:0006398 histone mRNA 3’-end processing 2 0.01 15 5 0.000014 0.043197
c10 BP GO:0006369 termination of RNA polymerase II tran-
scr...
3 0.06 15 46 0.000021 0.043197
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6.1 Discussion
This thesis has taken a systems perspective to transcriptome-wide binding patterns of specific mi-
croRNAs in order to evaluate their contribution to neurodevelopmental processes, with a particular
focus on the contribution of microRNA-disrupting variants in autism. In order to draw hypotheses
about the biological role and phenotypic relevance of specific microRNAs we need to know what
these molecules are capable of targeting. Then, if there is a mutation or variation within a microRNA
- we would like to be able to measure potential implications to binding affinity and dysregulation of
target genes. In complex and multigenic disorders like autism it is vital to consider these potential
disruptions in the wider context of an individual’s complement of DNA variations. This information
can then be applied in combination with functional gene targeting assays to improve our understand-
ing of the genetic risk and functional mechanisms associated with these disorders, which in turn will
help drive development of diagnostic tools and therapeutic advances for treatment.
This thesis has investigated the binding profiles and potential regulatory roles of several putative
autism associated microRNAs though a combination of binding site predictions, computational analy-
ses, and microRNA:mRNA pulldown experiments. Firstly, a database of microRNA target predictions
was created and helped identify distinct microRNA-specific spatial trends of sites found in the 3’UTRs
(untranslated regions) of gene transcripts. Then microRNAs of interest were selected by two different
approaches: A putative loss-of-function variant of miR-873-5p from exome sequencing of an Aus-
tralian autism cohort, while miR-324-3p and miR-1913-3p were identified from a ‘pathway-first’ top-
down approach from biological processes thought to be involved in autism risk. The patient-derived
rare variant in miR-873-5p was considered in the context of other DNA variants in that individual,
and functionally analysed with biotinylated microRNA:mRNA pulldown transcriptome experiments
to examine changes to binding affinity of the mutant miR-873-5p. In contrast, computational pre-
dictions identified microRNAs miR-324-3p and miR-1913-3p as having potentially enriched target
interactions associated with ASD risk genes involving the L1 family of adhesion proteins. While this
was not supported by pulldown results, we did observe differences in binding profiles and functional
associations of these two microRNAs, despite them sharing a conserved seed sequence.
6.1.1 MicroRNA binding profiles from predictions and pulldowns
Despite their inherent noisiness, microRNA target site predictions are a useful starting point for
analysing microRNAs involved in mental health disorders. While target site predictions can differ
quite substantially when using different prediction tools [66], this can be mitigated by focussing on
an overlapping prediction set. We therefore used an intersection of RNAhybrid [71] and miRanda
[92] to select a congruent set of target site interactions. Importantly, to avoid possible bias associated
with highly conserved microRNAs that could result in missing the contribution of recently evolved
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microRNAs to mental health disorders, (which are quite common [193]), we deliberately selected
tools that do not take into account evolutionary conservation.
To address the limitations of microRNA target site predictions, we used biotinylated microRNA:mRNA
(pulldown) assays for several microRNAs of interest, with the method most similar to the protocols
described in [82], as well as [80, 81, 83]. Not only does this provide in vitro evidence of binding, but
by using SH-SY5Y neuroblastoma cell line, we were able to focus on the neuronal environment of
interest in neurodevelopmental disorders.
The microRNA:mRNA pulldown method differs from some other assays used for transcriptome-wide
microRNA target identification like HITS-CLIP [76] or PAR-CLIP [77] in that it does not include
an Argonaut immunoprecipitation step. Broadly speaking, the Argonaut immunoprecipitation step in
these methods focusses results onto the canonical Argonaut mediated interactions, and the desirability
of putative Argonaut-independent interactions (which were wanted in this work) should be a factor
in assay selection. Importantly, like TAP-tar (a two-step method that involves Argonaut immunopre-
cipitation followed by tagged microRNA purification) [79], the microRNA:mRNA pulldown method
used inherently focuses on a specific biotinylated microRNA of interest.
We chose to contrast pulldown results against a whole-transcriptome control, as suggested in [82],
rather than a pulldown from an unrelated microRNA control (typically from C. elegans) as described
in [81]. Both methods have biases; either to the off-target binding of the microRNA control or the
overall capture of the transcripts. Using the whole-transcriptome control allowed for the extra statis-
tical power of paired analyses (contrasting pre- and post- pulldown from the same cell lysate sample),
and the opportunity to include a few extra untreated samples in order to measure exogenous overex-
pression from the microRNA transfection. Although the exogenous overexpression contrasts showed
no differentially expressed genes for any of our microRNAs, the inverse correlation seen between pull-
down and overexpression fold changes does suggest the capture of a subtle regulatory signal which
increases confidence in the results of the pulldown assay. Certainly, it is also possible that other mi-
croRNAs might trigger expression changes, even if miR-1913-3p, miR-324-3p and miR-873-5p do
not. We are also mindful that the pulldown assay does not represent physiologically relevant levels
(particularly in the case of microRNAs like miR-1913-3p with low expression), but is rather indicative
of their potential real-world molecular interactions.
Considering the above, the pulldown protocol provides a practical, simple experiment to get a pic-
ture of global binding interactions of specific microRNAs at the gene level. Other assays such as
CLASH [29], or the RNase digestions described in [81] allow for identification down to the spe-
cific microRNA target sites in use - and these technologies might drive some exciting progress in
understanding of microRNA targeting mechanisms. Notably, they have enabled some promising de-
velopments in computational microRNA target site prediction, with the emergence of tools that apply
feature-based modelling and machine learning approaches to transcriptome-wide targeting informa-
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tion [74, 75], which may improve reliability of predictions in future work.
6.1.2 Functional hypotheses from microRNA binding profiles
Computational microRNA target site predictions enable analyses across all microRNAs that are as yet
not feasible in molecular approaches. Focussing on genome-wide analyses trends can identify emerg-
ing properties above the noise of individual site-level predictions; such as the distinct, microRNA-
specific spikes in predicted target site density offset at the 3’ end of 3’UTRs which were explored
in chapter 2. Although this analysis is yet to elucidate the significance of these peaks, closer exami-
nation of these trends could provide a window into the function of affected microRNAs, particularly
in cases when there is motif similarity with other binding elements such as SOX9 or PITX1. Albeit,
none of the microRNAs followed up during this analysis exhibited these peaks. Future work may look
into this phenomenon from a evolutionary point of view - a systemic analysis might reveal if certain
microRNAs have evolved to co-target motifs that have spatial significance and selective constraint.
The pulldown assays provide more concrete clues into biological roles of a microRNA by identifying
target gene interactions which can be validated for functional significance. However, the line between
significant and non-significant genes in the pulldown results is somewhat blurred, especially when
considering the large number of enriched genes identified (Figures 4.1 and 5.14). This makes it diffi-
cult to evaluate genuine enrichment with statistical tests like Fisher’s exact test which are dependent
on sampling sizes [245]. Gene set enrichment approaches, like the GSEA tool used in this thesis [171]
are one way to address this issue, as they make use of the ranked full set of data from most to least
enrichment [171, 245].
An obvious advantage of a transcriptome-wide assay is that it allows an unbiased picture of the bind-
ing affinity of microRNAs. In contrast to testing target genes using luciferase reporter gene assays
(single target site interactions), it avoids the need to limit the scope at to a set of known genes during
study design - potentially allowing for unexpected insights. This is evident through the results of
the three microRNAs examined in this thesis. There is a significant body of work exploring the role
of miR-324 in cancers due to its anti-proliferative and pro-differentiation functions [197, 198, 198],
which was further supported by our results. In contrast, microRNA miR-873 has been fairly well
studied in diverse contexts; with the miR-873-5p arm examined largely in cancers [156–159], but
also in the immune system [160, 161] and pregnancy [162–164]. These studies are generally based
on microRNA expression changes and or focussed on particular interactions in a system of interest to
address specific biological questions. By using a transcriptome-wide approach, we were able to detect
previously undescribed association with voltage-gated potassium channel genes (described in chapter
4) and key synaptic molecules including SHANK3 and NRXN2 (described in chapter 3). Conversely,
miR-1913-3p had almost no functional characterisation after being initially reported [200], and the
pulldown assay was able to propose a role in protein synthesis and degradation.
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It is worth noting that, on the basis of microRNA target site predictions and genomic context, we
have hypothesised a role for miR-1913-3p and miR-324-3p in regulation of the L1 family of cellular
adhesion molecules and their interactions. However, our pulldown results did not support this, but
provided enough information to redirect our research into a more promising direction based on their
overall functional association.
In chapter 5 we examined seed-sharing microRNAs miR-324-3p and miR-1913-3p, and the pulldown
assay not only indicated a difference in binding profiles - but also subtle differences in their functional
characterisation. The anti-proliferative function seen in the conserved miR-324-3p was somewhat
present in miR-1913-3p, but the primate-specific miR-1913-3p may have acquired a role in regulation
of protein synthesis, ubiquitination and degradation. This underlines the importance of considering
members of microRNA gene families separately. Such ‘seed paralogs’ are not uncommon, especially
in primates, and are often tissue specific [193], and thus they could occupy different regulatory niches
- perhaps including those active during brain development.
6.1.3 A workflow for evaluating microRNA gene variants
Once a mature microRNA-altering SNP is identified in a sequencing study it poses two pressing
questions; (1) How might the variant affect the microRNAs binding specificity? (2) What are the
potential functional implications? There are databases focussed on the known microRNA or target
site SNPs [167, 246], but these are limited by known variants and the accuracy of computational
predictions. However, de novo variants contribute prominently to autism [9, 11, 12, 18], necessitating
case by case analyses. While luciferase based assays are a robust ‘gold-standard’ to measure the
effects of DNA variation on binding, this is a low-throughput approach.
In this work we have quantified the effect of a potentially autism-association patient-derived mutation
in miR-873-5p with transcriptome-wide pulldown assays, demonstrating an end-to-end workflow to
take from sequence variant to quantification of altered genome-wide binding patterns measured in
vitro. Additionally, because we were investigating a hypothesis of an additive effect of the miR-
873-5p variant, we were then able to look at these binding changes in the context of other coding
and non-coding mutations seen in the same individual. This is particularly important in complex
disorders such as autism, as an accumulation of small-effect variants may contribute to risk in a
liability threshold model [5, 9–11, 16].
Indeed, in the individual family from which this variant was derived, the paternally inherited variant
results in a loss in binding of NRXN2, which combines with a maternally inherited variant in NRXN1.
This information about in vitro targeting has facilitated the design of downstream assays to further
explore the effect of this mutation. Experiments are currently underway to explore the effect of miR-
873-5p on neurite outgrowth, and behavioural phenotype of a mouse knockout model.
166
The ability to evaluate microRNA variants found in individual cases presents tantalising possibilities
for application in personalised medicine. For example, one of the potassium channel genes targeted
by miR-873-5p is KCNH2. KCNH2 encodes a brain-expressed potassium channel protein (Kv11.1)
which has been linked to efficacy of risperidone action in schizophrenia [187] - a drug that is also
sometimes used in the treatment of autism [247].
6.1.4 Utility of microRNA binding profiles in neurodevelopmental disorders
While the approaches described in this thesis are applicable to other complex disorders, they are of
particular use in neurodevelopmental disorders like autism.
Human microRNAs are particularly well represented in brain tissue [248], and their broad config-
urable regulatory capacity likely underpins delicate regulatory control that is required for neuronal
differentiation and development. In a study by Ziats et al (2013), the importance of differentially
expressed micoRNAs in brain development was illustrated by the observed associations with target
genes involved in neurodevelopmental, but not neurodegenerative disorders [88], and naturally, there
has been significant interest in microRNAs potentially involved in neurodevelopmental disorders (Re-
viewed in [249, 250]).
The past few years have seen an explosion in the amount of autism sequencing studies [9–12, 14,
16]. Although the primary purpose of these studies has been the identification of protein-coding
mutations, even exome studies capture significant areas of microRNA gene and target site regions.
These regulatory regions are an untapped resource, which will benefit from more concerted analyses
in recent and future studies. With the advent of genome scale resources such as BrainSpan [103] and
ENCODE [85], once a putative regulatory variant is identified they can be automatically prioritised
(via regulation-aware tools such as CADD [110]).
Then, these resources allow the biologist to make an informed judgement on the potential relevance
of a variant, and the need for follow up experiments. The pulldown assay as described in this thesis
can be used to directly evaluate the potential implications of a given variant on transcriptome-wide
binding affinity. Furthermore, these assays and results could be readily translated into experiments
within patient-derived iPSC cells; an exciting method that can place variants in the context of other
variants in an individual, which is particularly important in the multiple-hit autism liability threshold
considered in this work [251, 252]. This also paves the way for personalised medicine approaches
with potential applications in drug development [253].
167
6.1.5 Conclusions
This study also provides first insights into the role of miR-873-5p, miR-324-3p and miR-1913-3p
in different aspects of neuronal function; synaptic genes and potassium channels, cell differentia-
tion, as well as protein translation and degradation pathways associated with ASD. The diversity of
these results parallels the phenotypic diversity in these disorders and emphasises the importance of
considering each microRNA in its own right.
Ongoing improvements in target site prediction and binding assays should improve the feasibility and
accuracy of systems based microRNA analyses - in complement to highly focussed single microRNA
to specific targets in a pathway. This should also improve the utility of non-coding variant analysis
in exome or whole genome sequencing cohorts - which is rapidly becoming a standard part of any
modern cohort study [15, 17].
Overall the work of this thesis in studying the transcriptome-wide binding profiles of microRNAs in
consideration with their wider regulatory context may provide more information about their functional
roles, and their contribution to complex disorders such as autism.
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Conclusions
Overall, this thesis contributes to our understanding of the role of microRNAs in neurodevelopmental
processes and disorders such as autism, via a number of conclusions outlined below.
This work established a database of microRNA target site predictions across all human 3’UTRs, a
resource used throughout this thesis. Within this, there are peaks of predicted microRNA target site
density relative to the 3’ end of the 3’UTR, offset at distances specific to individual microRNAs. This
may be due to binding site similarity to other sequence motifs - future work may be able to mine
biological insights from microRNAs exhibiting these trends.
We implemented a workflow to take a list of variants (from an exome sequencing study) and identify
and prioritise ‘regulatory mutations’ within putative microRNA or transcription factor binding sites.
We showed that among a cohort of autistic individuals, these variants were significantly more common
in autism-association genes, than for a control cohort.
We have hypothesised that a paternally inherited miR-873-5p variant could contribute to an autis-
tic phenotype in conjunction with other coding and non-coding variants. A biotinylated-microRNA
mRNA-pulldown assay was used to characterise the effect of this variant on binding affinity, and
found a loss-of-binding effect on NRXN2, (in conjunction with targeting of several other synaptic
genes). Additionally, miR-873-5p’s full binding profile suggests a potential role in potassium chan-
nel regulation. Combined with a maternally inherited coding variant in NRXN1 these findings are
consistent with a contribution to polygenic risk.
Despite their shared seed, microRNAs miR-324-3p and miR-1913-3p may occupy different regula-
tory niches. MiR-1913-3p appears to have some involvement in regulating translational and protein
degradation pathways, which is not seen in the more conserved miR-324-3p, which has a binding pro-
file consistent with its established anti-proliferative pro-differentiation role. This work also represents
the first functional characterisation of miR-1913-3p.
This thesis has explored the role of microRNAs in autism and neurodevelopmental processes through
functional analysis of their target binding affinity, focussing on microRNAs miR-873-5p, miR-324-3p
and miR-1913-3p. These results underline the possible contribution of microRNA variants to autism
risk, particularly as an additive factor in conjunction with other variants. The functional roles of
individual microRNAs are clearly diverse; characterisation of their binding networks provides valu-
able clues to their overall function, and aids design of targeted biological functional assays. These
approaches may prove valuable in the evaluation of other putative autism-associated variants, partic-
ularly in the case of rare or de novo variants.
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